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General Introduction

General Introduction
/nfroducf/on
Blood flows through the vascular system as a carrier of nutrients, oxygen,
metabolites and waste products as well as a transporter of proteins and hormones.
When a blood vessel wall is damaged, leakage of nutrients and metabolites into the
interstitium occurs, that lead to a loss of resources and to inflammatory responses. In
order to prevent leakage at the wounded site, physiological mechanisms are
available that turn the liquid blood into a solid mass that covers the injured part. The
vessel wall also contracts, causing a reduction in blood flow that prevents excessive
blood loss. The process of staying fluid and when necessary turning into a solid
phase is regulated by many proteins in the blood and vessel wall. This process is
called hemostasis. Preservation of the fluidity of blood is of great importance, since
obstruction of a significant artery (e.g. coronary artery) by thrombi may be life
threatening.
Under resting conditions the reactions of hemostasis are slowly ongoing, but
once coagulation is initiated, the hemostatic system is rapidly activated. Although the
various procoagulant and anticoagulant reactions are usually described in a stepwise
manner, in reality many of these reactions occur parallel, with different reactions
taking place simultaneously.
7.7 S/oocf coagu/af/on
The coagulation cascade consists of many proteolytic reactions in which
inactive zymogens are converted into active enzymes. For most zymogens to
become active in coagulation (FVII, FIX, FX and prothrombin, Protein S and C),
specific glutamic acid (Glu) residues need to be carboxylated into y-carboxyglutamic
acid (Gla) residues by the vitamin K dependent y-glutamyl carboxylase. Gla residues
are necessary for calcium-mediated binding of coagulation factors to membrane
surfaces. Calcium binding leads to conformational changes that promote the binding
of coagulation factors to negatively charged phospholipid surfaces '. Inhibition of y-
carboxylation, e.g. by vitamin K antagonists, results in defective calcium binding and
loss of interaction with phospholipids. This phenomenon forms the basis of
anticoagulant treatment with warfarin and coumarin in patients suffering thrombotic
events.
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Historically two pathways of coagulation have been recognized: the intrinsic
and extrinsic pathway (Fig 1.1). The extrinsic pathway that is triggered by tissue
factor is regarded as the principal physiologic pathway. The intrinsic pathway of
coagulation is initiated when blood is exposed to arteficial negatively charged
surfaces (e.g. glass or kaolin). On these surfaces kallikrein activates FXII that,
together with the cofactor high molecular weight kininogen (HMWK), subsequently
activates FXI. The physiological role of this so-called contact activating system of
hemostasis is likely associated with immunological reactions, since the
immunological complement pathway and the contact activating system share the
same inhibitors *.
T/ie primary p/ug
The extrinsic coagulation pathway is activated after injury of the vessel wall.
Under normal conditions the vessel wall is covered with a thin layer of endothelial
cells. These cells secrete or expose several substances that regulate the vessel wall
motility (e.g. Nitric Oxide), and the activation of platelets (prostacyclin (PGI2), von
Willebrand factor (vWF)) as well as the hemostatic system (tissue factor pathway
inhibitor (TFPI), thrombomodulin (TM), tissue type plasminogen activator (tPA),
plasminogen activator inhibitor-1 (PAI-1)). However, when endothelial cells are
damaged or lost, collagen and fibronectin that are present in the sub-endothelium,
become exposed. Platelets adhere to these proteins (via surface receptor GPIa/lla,
GPVI and GPIb/IX/V *) and become activated to form the primary plug. Activated
platelets release a number of compounds contributing to platelet aggregation and to
the activation of the coagulation system (e.g. FV, vWF, TXA2). After activation
platelets expose negatively charged phospholipids (phosphatidylserine) on their cell
surface, which serve as a template at which coagulation factors efficiently interact *,
thereby ensuring optimal rates of coagulation factor activation.
Procoagu/anf reacf/ons
Damaged or pathologic endothelial cells expose tissue factor on their surface
*• ®. Tissue factor (TF) is a transmembrane cell surface receptor that binds activated
FVII. The TF-FVIIa complex initiates the so-called extrinsic pathway of coagulation
(Fig 1.1). The complex of TF-FVIIa will activate FX and FIX '• ®. The comples of
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activated FIX (FIXa), together with its cofactor FVMIa, negatively charged
phospholipids and calcium ions produces more FXa. This Xa-forming complex of
FIXa, FVIIIa, phospholipids and calcium ions is called the fenase comp/ex. In turn,
FXa cleaves prothrombin (PT) to thrombin (Flla). The conversion of prothrombin to
thrombin by FXa is enhanced several orders of magnitude by its cofactor FVa,
negatively charged phospholipids and calcium ions '. This complex of FXa, FVa,
phospholipids and calcium ions is called the profhromö/nase comp/ex. In both
complexes the cofactors FVIIIa and FVa, two proteins that share 80% amino acid
homology, are essential for efficient substrate activation. The subsequently formed
thrombin is a key enzyme in haemostasis, which activates coagulation factors FVIII
and FV, but also FXI * ™ and FXIII and most important, thrombin converts fibrinogen
into fibrin. Fibrinogen is cleaved to form fibrin monomers, which are cross-linked into
a fibrin network by FXIIIa. The fibrin clot stimulates the repair of the vessel wall,
which takes 5 to 10 days. During this time the clot is very slowly lysed by plasmin
(generated from plasminogen by tissue plasminogen activator (tPA)).
Extrinsic Pathway
Intrinsic Pathway
Contact Activation
FXIaJ
(^Fibrinolysi«
Clot
Figure 1.1 Initiation and continuation of coagulation. The activation of many
proteolytic enzymes and cofactors (indicated with roman numbers)
eventually leads to the formation of thrombin that cleaves fibrinogen to fibrin.
Fibrin threads, together with platelets form a clot. Platelets are not in this
figure, however, it is assumed that procoagulant surfaces (""') stem from
platelet origin. F= factor, PT=prothrombin, TAFI=thrombin activatable
fibrinolysis inhibitor, FDP=fribrin degradation products.
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Thrombin-activated FXI, which can activate more FIX, plays an important role
in maintaining and amplifying thrombin formation and fibrin deposition. The additional
supply of thrombin formed via FXIa also ensures that enough thrombin is formed to
convert a protein called TAFI (thrombin activatable fibrinolysis inhibitor) " " into an
active carboxypeptidase that releases carboxyterminal lysines from fibrin. This
renders the fibrin less susceptible to fibrinolytic proteins like plasmin.
The reactions of coagulation and plug formation at the site of injury are very
rapid and prevent loss of blood from the circulation, however coagulation should not
be too effective and obstruct the whole vessel. Thus thrombus formation should be
restricted to the site of the injured part of the vessel wall. This proces is regulated by
the anticoagulant and fibrinolytic systems.
Extrinsic Pathway
—„
Tissue Factor
Intrinsic Pathway
Contact Activation
FXIaU
Clot
Figure 1.2 Inhibitors of activated coagulation factors
represented in the black boxes. TFPI=tissue factor pathway
inhibitor, AT=antithrombin, APC=activated protein C
/nh/b/f/on of coagu/at/on
Blood contains several specific inhibitors that exert a one-to-one action with
coagulation factors at each level of the coagulation pathway. The enzym-inhibitor
complexes are no longer active and are rapidly cleared from the circulation. Important
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inhibitors are antithrombin (AT), tissue factor pathway inhibitor (TFPI ") , a2-
macroglobulin (a2-M), a1-antitrypsin (a1-AT) and heparin cofactor II (Fig 1.2).
Tissue factor pathway inhibitor is exposed by the endothelium and rapidly
binds the TF-FVMa(-FXa) complex " , leading to the formation of an inactive
quarternary complex, thus inhibiting the formed FXa and preventing further activation
of FX. Antithrombin inhibits several enzymes of the coagulation cascade such as Xa,
IXa and thrombin. Heparin or heparin-like molecules stimulate the activity of
antithrombin, increasing the rate of inhibition. Furthermore, thrombin is inhibited by
a2-M, a1-AT and heparin cofactor II.
77ie profe/n C pafhway
Besides the protease inhibitors, there is an anticoagulant pathway, the protein
C pathway that puts a stop to thrombin formation (Fig 1.3). Thrombin bound to
thrombomodulin (TM), a protein that is anchored in the membrane of endothelial
cells^, efficiently converts protein C into activated protein C (APC) ^ " which can
inactivate FV(a) and FVIIIa " .
Activation of protein C by
thrombin is facilitated by the
endothelial cell protein C
receptor (EPCFT *>). The EPCR
brings protein C in close range
of TM to which thrombin is
bound. Inactivation of FV(a) and
FVIIIa by APC is accelerated by
Thrombomodulin
^——
Thrombin
Figure 1.3 The anticoagulant Protein C-Protein S
pathway. APC = activated protein C.
negatively Charged
phospholipids and by an
additional cofactor, protein S *\
Protein S is reported to increase the affinity of APC for phospholipid surfaces, where
the Va and Villa are located " .
The inactivation of factor V(a) by APC involves three cleavage sites (Arg306,
Arg506 and Arg679). Cleavage at Arg506 occurs rapidly and results in a FV molecule
with approximately 40% cofactor activity in the prothrombinase complex". Total loss
of cofactor activity occurs after cleavage at Arg306. The cleavage of Arg679 is
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reported to have no major role in the inactivation of FVa^. Inactivation of FVa is
inhibited by FXa, since FXa protects the cleavage at the Arg506 position. This effect
is, however, overcome by the presence of protein S, which stimulates the cleavage at
Arg306 about 20-fold, resulting in full inactivation of FV(a) *\ The proteolytically
cleaved FV(a) no longer binds to prothrombin and FXa". FV is also directly cleaved
and inactivated by APC, resulting in a loss of procoagulant activity. Inactivation of
FVIII does not occur, as it is protected through binding to vWF. Upon activation,
however, FVIIIa dissociates from vWF and the FVIIIa-inactivation occurs in a similar
manner as in FV(a) inactivation with cleavages located at Arg336, Arg562 and
Arg740. The first two cleavages are considered important in inactivation by APC.
Free protein S enhances cleavage at Arg562 two-fold.
Prote/n S
Protein S circulates through plasma both in a free form (40%) and in 1:1
complex with C4b binding protein (C4bBP) (60%), a protein of the acute phase
classical complement system, /n wVo, all C4bBP binds to protein S thus the free
protein S is determined by the molar excess of protein S in plasma *\ Protein S has
anticoagulant properties by hampering thrombin formation but it is also a cofactor of
APC in the inactivation of FV(a) and FVIIIa (see above). It is reported that free protein
S and thrombin-cleaved protein S can bind FVa and independently of APC inhibit
prothrombin activation """. Furthermore free protein S and protein S bound to
C4bBP, but not thrombin-cleaved protein S, can bind and inhibit FXa in
prothrombinase. In the tenase complex C4bBP-protein S inhibits FX activation by
binding to FVIIIa '° " . Thus, protein S can exert an APC-independent inhibitory effect
on coagulation through interaction with FVIIIa, FVa, FXa and phospholipids " .
Furthermore, only the free protein S is reported to have APC cofactor activity.
It can be concluded from these paragraphs that thrombin exerts a dual action
in hemostasis: It acts as a potent procoagulant enzyme by activating many other pro-
coagulant enzymes and it is a key regulator of the anticoagulant pathway by
activating the protein C-protein S pathway and by modulating fibrinolysis via TAFI.
General Introduction
f. 2 77)rombos/s
Most people may be familiar with the classical bleeding disorder hemophilia (A
or B), resulting in extreme low levels of factors VIII or IX. Bleeding problems may,
nonetheless, also result from rare cases of other deficiencies in clotting factors (factor
V, VII, X, XIII, or prothrombin deficiency). However, in this thesis I will focus on
(coagulation) disorders that lead to venous thrombosis.
When normal hemostasis is disturbed e.g. the balance between pro- and
anticoagulant reactions is pushed towards the procoagulant side, thrombosis may
occur. The triad of Virchow (1859) represents three factors involved in thrombosis:
changes in the vessel wall, reduction in blood flow and changes in blood composition.
A distinction between arterial and venous thrombosis can be made based upon the
blood vessel in which the thrombus arises. Arterial thrombosis occurs in arteries e.g.
cerebrovascular accident (CVA) or myocardial infarction (Ml). Venous thrombosis
occurs in the veins (pulmonary embolism, sinus thrombosis and deep venous
thrombosis). Due to differences in "initiation" mechanisms and variation in fibrin
content of the plug arterial and venous thrombosis are quite different processes that
lead to different types of thrombi.
In arteries the shear force and flow are high and platelets are easily activated.
Also activated platelets secrete and bind to von Willebrand Factor (vWF) multimers
under high shear " . In these larger arteries, the formation of a thrombus is often the
result of a rupture in the vessel wall. This is most pronounced in arteriosclerotic
lesions ^ where tissue factor containing macrophages and monocytes" are present
and the subendothelium is packed with collagen. After damage of the vessel wall,
activated platelets easily adher and fibrin deposition occurs^, resulting in a thrombus
that is rich in platelets and fibrin.
In veins a different process is thought to occur. Under normal conditions a low
level of coagulation factor activation probably occurs continuously. However,
inhibitors of coagulation and the protein C pathway are capable of counterbalancing
this. In patients with so-called prothrombotic states, this /n wVo activation presumably
is increased and is in disbalance with the anticoagulant capacity. Decreased blood
flow or stasis in veins leads to local accumulation of activation products of the
coagulation system and fibrinolysis, which can induce endothelial damage that in turn
leads to further activation of the hemostatic system. Locally this may result in
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concentrations of activated clotting factors that rise above a certain threshold at
which anticoagulant proteins are no longer able to withhold the procoagulant force.
Accordingly, venous thrombosis can be regarded as the clinical symptom of
hypercoagulable blood.
R/s/c factors for venous fhrombos/s
A subdivision can be made in two major classes of risk factors for venous
thrombosis, hereditary and acquired risk factors (Table 1.1). Hereditary factors that
lead to the development of venous thrombosis are often associated with mutations in
proteins that are involved in the down-regulation of coagulation. Such mutations can
lead to deficiencies in anticoagulant proteins like protein S (PS), antithrombin (AT) or
protein C (PC), which result in impaired down-regulation of the clotting system. In 8%
of VTE patients these genetic alterations are the probable cause of venous
thrombosis. These mutations follow an autosomal dominant trait and thrombosis
develops at a relatively young age (below 50 years). In general there are two types of
deficiencies in AT, PC and PS, type I and type II deficiency. In type I deficiency both
antigen and activity are reduced, a quantitative deficiency. In type II deficiency, a
qualitative deficiency, functional defects lead to a reduced activity, while the antigen
level of the protein is normal. For AT and PC several subtypes of deficiency type II
are recognized, depending on the site of the mutation. For protein S deficiency an
additional type III is recognized in which only the free protein S antigen and activity is
reduced and total protein S antigen and activity is normal. More recently, mutations in
pro-coagulant coagulation factors have been reported as a probable cause of venous
thrombosis. These mutations lead to proteins that are either insensitive to inactivation
(FvYeiden) or are over-expressed (PT20210,"). Moreover, elevated levels of several
other clotting factors have been identified as risk factors for venous thrombosis
(factors VHP", IX**, Xl'° and TAFI"). These latter defects are found in approximately
60% of patients that develop venous thrombosis.
Acquired factors that lead to an increased risk for thrombosis are generally
transient states of hypercoagulability that occur during surgery, immobilization, use of
oral contraceptives and hormone replacement therapy or underlying diseases.
Pregnancy and the post-partum period are also periods during which women are at
high risk for the development of venous thrombosis (Table 1.1).
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Table 1.1 Risk factors for venous thrombosis
Heredrtary r/sfc factors Acquired risk factors
Antithrombin deficiency Immobilisation
Protein C deficiency Surgery / Trauma
Protein S deficiency Pregnancy / post-partum
FV-Leiden (FV R506Q) Oral contraceptive use
PT20210 (G20210A, Lupus anticoagulans (ACA, anti-I^GPI)
high levels of prothrombin) Cancer
Preso/nab/y Hered/fary
High levels of Factor VIII
High levels of Factor IX
High levels of Factor XI
High levels of TAFI
APC resistance (without FV-Leiden)
It is well accepted that venous thrombosis is a multifactorial disease** " and
the so-called second hit hypothesis states that more risk factors have to be present to
cause a thrombotic event. 73% of the patients with co-segregation of FV|_eiden and
protein C deficiency suffered from venous thrombosis, compared to 31% and 13%
resp. in the patients with either protein C deficiency or FV|_eiden ""• This indicates that
co-existence of two or more mutations may increase the risk for venous thrombosis
several-fold. The interaction of environmental factors and genetic status might also
predispose individuals to an increased risk for thrombosis **. Additionally, more
polymorphisms and mutations are being identified that may render a person more
vulnerable to thrombosis (e.g. TFPI-polymorphism **, R2-Factor V **\ protein C "').
7.3 APC res/stance
The discovery of mutations and polymorphisms in the human genome has
contributed a great deal to understanding the molecular basis of many diseases. Until
1993 the genetic causes for thrombophilia were inherited deficiencies of protein S,
protein C or antithrombin, although these only accounted for 8% of VTE cases. In
1993, Dahlbäck and coworkers were the first to report that in a population of patients
with venous thrombosis, the clotting time was poorly prolonged after the addition of
APC *". These patients were called APC resistant. One year later, APC resistance
was reported to result from a single point mutation in the FV-molecule at a
predominant cleavage site of APC (the G to A base substitution at position 1691
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leading to an Arg to Gin mutation at position 506) *'"". This mutation renders the FV-
molecule less susceptible for cleavage and inactivation by APC " " . Moreover,
FVLekJen, or FV*^*° as it is called, is reported to have full procoagulant activity but a
reduced cofactor activity in the inactivation of factor FVIIIa by APC*\ As a result of
this, down-regulation of thrombin formation is impaired. This defect may lead to a
higher level of ongoing thrombin formation, which could induce venous thrombosis in
these patients. Furthermore, the increased thrombin formation may result in higher
levels of activated TAFI, impairing fibrinolysis in these subjects. The FV|_eiden mutation
appears to be present in 20-40% of the patients with deep-venous thrombosis and its
prevalence is 5% in the Caucasian population " .
The discovery of this important risk factor for venous thrombosis led to the
development of various clotting assays to quantitate APC resistance. Most of these
are based on quantitation of the effect of activated protein C, either exogenously
added APC or by activating the protein C present in plasma, on clotting times initiated
via the intrinsic pathway. An alternative approach which is used throughout this thesis
concerns assessment of the efficacy by which APC downregulates the generation of
thrombin in tissue factor initiated coagulation. In this approach the total amount of
thrombin formed is assessed by measurement of the amount of thrombin that
becomes trapped in the a2M-thrombin complex in the absence and presence of
exogeneously added APC." "
Ora/ contraceptives and APC-res/sfance
Ever since their use, oral contraceptives (OC) are associated with an
increased risk for venous thromboembolism. However the relative small increase in
risk associated with the low dose estrogen containing second generation pills was
generally considered acceptable as the benefits outweighed the disadvantages. With
the marketing of so-called third generation OC (low dose estrogen with desogestrel
or gestodene) it was expected that this risk would be decreased even further.
However in 1995 several epidemilogical findings indicated that women using third
generation OC (desogestrel or gestodene as progestagen) had a 2-3 fold higher risk
for venous thrombosis compared to older oral contraceptive preparations containing
second generation progestagens (levonorgestrelf"". These data were highly
disputed not in the least for want of a biological explanation. In the same year two
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other reports appeared that mentioned the occurrence of a mild APC resistant
phenotype in plasma of oral contraceptives users in an aPTT-based clotting assay "
'*. Moreover, in 1997, using the assay developed in Maastricht it was reported that
plasma of women who were using OC, was found to exhibit an APC resistant
phenotype similar to that observed for FV|_eiden carriers ^. The results obtained with
the thrombin generation-based APC resistance assay showed similar trends as the
risks observed by epidemiologists for different OC preparations and FV|_eiden carriers.
Thus it was proposed that OC-induced APC resistance might explain the risk
increase reported for OC users * (Table 1.2). '
Table 1.2 Relative risk for venous thrombosis and results from tissue factor-based assay
Women no FVYeiden
no OC
2"" generation OC
3'" generation OC
Heterozygous FV,_eiden
no OC
using OC
Homozygous FV|_e,<ien
Relative risk
1
3460-62
6-8°'
7*'
30-50*"*
>50"
APC resistance value*'
1.22
1.81
2.59
3.10
5.41
4.75
>*/7T? of f/i/s f/ies/s
The work presented in this thesis was initiated to follow up the original
observations published in 1997 ^. The first part of this thesis is devoted to the details
of the tissue factor-based or thrombin generation-based APC resistance assay. Both
pre-analytical and analytical variables that can affect the outcome of the assay are
described in Chapter 2. We have investigated the effects of different molar
concentrations of citrate, the time of processing of blood, different centrifugation
steps, storage temperature and thawing on APC resistance in normal individuals, FV-
Leiden carriers and OC users. Also the effects of analytical variables, such as the
concentrations of tissue factor, calcium and APC are described. In chapter 3 the
classical clotting test and the tissue factor-based assay are compared. Both tests are
able to determine with reasonable specificity the FVLeiden mutation, but a difference
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is observed between the two assays in screening for acquired APC resistance
developed during OC use. Furthermore Chapter 4 describes how the results obtained
with the tissue-factor based test are influenced by the presence of hereditary and
acquired risk factors for venous thrombosis.
The second part concerns the mechanism(s) underlying oral contraceptive-
induced APC resistance. Since the original pill study " concerned a non-cycle
controlled, cross-sectional set-up, a second study was performed in a cycle-
controlled randomized clinical setting, in which the effect of OC use on a large
number of hemostatic parameters were measured (Chapter 5). Additionally, in vitro
fertilization treatment was used to determine the effects of changes in endogenous
estrogen and progesterone on APC resistance (Chapter 6). The final chapter
(Chapter 7) comprises a study that evaluates the effects of second and third
generation oral contraceptives in non-carriers and carriers of the FVLeiden mutation
using combined preparations, as well as progestagen-only preparations.
Chapter 8 contains a summary and general discussion of the results
presented in this thesis, on hereditary and acquired APC resistance measured in the
tissue factor based assay.
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PARTI
Measurement of APC resistance
Laboratory teste for APC res/sfance
The discovery of APC resistance as a risk factor for venous thrombosis has
led to the development of an enormous amount of assays to detect APC resistance.
At first, efforts were aimed at developing assays with the highest specificity assays to
detect FV|_eiden mutation. The most well known might be DNA-analysis of the Mnl
restriction site in the B-domain of FV, that is lost in carriers of the FV|.e,den mutation.
This assay is 100% specific and sensitive to the mutation. Functional assays for APC
resistance in diluted plasma also give a near 100% specificity and sensitivity to the
FV|_eiden mutation. By diluting in V-deficient plasma, the assay becomes fully sensitive
to factor V^  without being influenced by individual variations in other plasma
components (e.g. protein S )^. Another advantage is that these assays are not
influenced by anticoagulant therapy/* Functional analysis has the advantage over
DNA analysis that is also provides insight to the thrombophilic mechanism and the ;n
wVo phenotype (e.g. pseudo-homozygosity" or APC resistance combined with FV-
deficiency^).
For a certain period it was thought that the panel of assays available (DNA
analysis and functional dilution assays) provided sufficient insight in (pro)thrombotic
status of an individual. However, in order to appraoch more closely the /n wVo
situation, measurements in undiluted plasma or even in whole blood become
inevitable. Such measurements may have the disadvantage that they are less
specific for the FV|_eiden mutation and show more individual variation. The consensus,
however, is emerging that this is precisely the additional information needed in order
to be able to assess whether a certain individual is at risk for the development of
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thrombosis or not. With regard to APC resistance measurements this means that it is
now recognised that a person may not only be at risk as a result of the defect in
FVLeiden but that it is the overall response to the anticoagulant action of APC
(inlcuding acquired APC resistance states such as occurring during OC-use and
pregnancy) that is important. This is reflected in the fact that APC resistance as such
even in the absence of FVLeiden has been established to be associated with the
occurrence of venous thrombosis.®"®
Thus measurements in undiluted plasma have been firmly reestablished in the
panel of laboratory testing for APC resistance. These tests can differ in trigger (e.g.
kaolin (aPTT), tissue factor (PT and ETP), factor V or X activating russels viper
venom (RVV-V and RW-X respectively)) and they may be performed by either
adding activated protein C or by activating the protein C in plasma (by a purified
snake venom from the /\g/«sfr"odon concorf/x concort/x). The assay that we chose to
develop further is based on measurement of thrombin formation.^ Rather than the
more limited measurement of clotting times. The total amount of thrombin that is
formed (the so-called endogenous thrombin potential or ETP) appears to be a good
indicator for the pro-coagulant condition of a plasma sampled °^ The total amount of
thrombin formed after initiation with tissue factor, is directly proportional to the
endlevel of a2-macroglobulin-thrombin (a2-M-lla) complex after 20 minutes^ both in
the absence and presence of APC.^ Thus, rather than determining the full course of
thrombin formation both in the absence and presence of APC, APC resistance can
simply be determined by quantifying the effect of APC on the endlevel of a2-M-lla
complexes formed in a certain plasma^ (for reviews see ^ ™). The specifics of this
assay will be discussed in the next chapters.
Chapter 2
Analytic and
pre-analytic variables
Based on:
Effecfs of (pre-Jana/yf/ca/ vanab/es on activated prote/n C res/stence detenu/ned wa fhe endogenous
f/)romii/n pofenf/a/. Joyce Curvers, M Chrisfe//a LG.D Thomassen, Hans de Ronde, Rog/er M.
Sert/na, Fri/s R. Rosendaa/, Gu/do Tans and Jan Ros/ng. Submitted
28 I PART I Measurement of APC resistance
Summary
The normalized activated protein C sensitivity ratio (nAPC-sr) determined with
an assay that quantifies the effect of APC on thrombin formation initiated via the
extrinsic coagulation pathway identifies hereditary and acquired defects of the protein
C system. We investigated the influence of assay conditions (analytical variables)
and plasma handling (pre-analytical variables) on nAPCsr obtained with this APC
resistance test.
The effect of the analytical variables (CaCb, phospholipid and APC
concentrations and the concentration and source of tissue factor) was determined in
pooled normal plasma. Inhibition of thrombin formation by APC was dependent on
the APC concentration and was also affected by the tissue factor, Ca^* and
phospholipid concentrations. Thus, strict standardization of reactant concentrations is
required to obtain reproducible nAPCsr.
Three different tissue factor preparations were compared by determining
nAPCsr in plasma samples obtained from 90 healthy individuals. nAPC-sr were
similar for all three tissue factor preparations although, compared with the non-
commercially available tissue factor used in earlier studies, values determined with
commercial tissue factor preparations showed larger variation.
Pre-analytical variables, investigated in plasma of nine volunteers (3 normal
individuals and 6 individuals with an APC-resistant phenotype) were: concentration of
anticoagulant (3.2% vs. 3.8% trisodiumcitrate), time before processing of blood (0, 4
and 24 hours), centrifugation speed, storage temperature of plasma (-20 °C vs. -80
°C) and sample thawing. Multiple linear regression analysis showed that only the
citrate concentration affected the nAPC-sr, which was higher in samples collected in
3.2% trisodiumcitrate than in samples collected in 3.8%. trisodiumcitrate.
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/nfroducf/on . -
The identification of the A1691G mutation in the factor V gene,^'^ resulting in
a mutated FV molecule (FVi_eiden, FV*^*°), has led to a higher number of patients
with an identifiable prothrombotic disorder. Arg506 represents a predominant target
for proteolytic inactivation of FVa by activated protein C (APC) and as a result of the
Arg506-Gln mutation FVaLeiden is more resistant to APC.^ ^ ' ^ Moreover, it appears
that the mutation in FV[_eiden also results in a substantial loss of the cofactor activity of
FV in APC-dependent down-regulation of FVIII(a).^ "
APC-resistance, which is found in 20% of patients with venous thrombosis** ^
also occurs in individuals without FV|_eiden and recently, it was shown that APC
resistance in the absence of the FV|_eiden mutation is a risk factor for venous
thrombosis.^ ' ^ APC resistance without factor VLeiden can be attributed to other
hereditary defects of the protein C pathway or to acquired coagulation abnormalities
occuring during oral contraceptive (OC) use or pregnancy.^"^°
In 1997 we developed an assay^ ^ in which the anticoagulant effect of APC in
plasma is quantified by measuring the effect of APC on the time integral of thrombin
formation (the endogenous thrombin potential, ETP^) initiated via the extrinsic
coagulation pathway. This assay not only allows detetection of the FV|_eiden mutation,
but is also sensitive for acquired APC resistance occurring during OC use.^ ^ ^ In
contrast, the classical aPTT-based APC resistance test is much less affected by OC
use.**
Since APC sensitivity ratios (APCsr) determined with the ETP-based assay
change parallel with the thrombotic risks reported in epidemiological studies,^ this
assay may gain the interest of other research or coagulation laboratories. In this
paper we report how the quantitation of APC-resistance with the ETP-based assay is
affected by analytical variables i.e. the APC, Ca^* ions and phospholipid
concentrations, and the source and concentration of tissue factor and by pre-
analytical variables i.e. blood collection and handling and storage of plasma.
Afafer/a/s and mefhocfs
Mafer/a/s Tris (Tris (hydroxymethyl amino-methane), Hepes (N-(2-
Hydroxyethyl) piperazine-N'-(2-ethanesulfonic acid), NaCI, EDTA (Ethylendinitrilo-
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tetraacetic acid), BSA (bovine serum albumin) and ovalbumin were purchased from
Sigma, St. Louis, USA. The chromogenic substrates D-Phe-(pipecolyl)-Arg-pNA
(S2238) and L-pyroGlu-Pro-Arg-pNA (S2366) were supplied by Chromogenix,
Mölndal, Sweden. Ancrod, obtained from the WHO International Laboratory for
Biological Standards (Hertfortshire, England) was dissolved in distilled water (50
U/ml) and frozen in portions at -20 °C.
1,2-Dioleoyl-sn-glycero-3-phosphoserine (DOPS), 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE) were obtained from Avanti Polar Lipids, Alabaster, Alabama, USA. Small
unilamellar phospholipid vesicles composed of DOPS/DOPE/DOPC (20/20/60,
M/M/M) were prepared by mixing appropriate quantities of phospholipid dissolved in
CHCI3/CH3OH (9/1 v/v) in a glass tube. The phospholipids were dried under a mild
flow of N2 and stored at -20 °C. Before use the dryed phospholipids were brought to
room temperature, suspended in 25mM Hepes (pH 7.5), 175mM NaCI by rigorous
vortexing for at least 1 minute and subsequently sonicated for 10 minutes at 4 °C
with a MSE Soniprep 150 ultrasonic disintegrator set at 7.5 (.im peak to peak
amplitude. Phospholipid concentrations were determined by phosphate analysis.^
Purified human APC was from Enzyme Research Laboratories (ERL) and
supplied Dy Kordia Laboratory Supplies, Leiden, The Netherlands. APC was diluted
in 25 mM Hepes (pH 7.5 at 37 °C), 175 mM NaCI, 5 mg/ml BSA and frozen in small
portions at -80°C. APC concentrations were determined with S2366 using kinetic
parameters reported by Sala et al.^
Recomboplastin S without additives was a kind gift of Dr H. Pelzer (Dade,
USA). Relipidated recombinant tissue factor Dade Innovin® was purchased from
Behring. RecombiPlasTin® (Ortho) was from Instrumentation Laboratories. Tissue
factor preparations were reconstituted according to the instructions of the
manufacturer and stored at -80 °C. Tissue factor concentrations were determined
with an antigen assay (American Diagnostics).
P/asma preparation for ;nvesf;gaf;ng fhe effecf of ana/yf/ca/ var/ab/es on
fhe nAPCsr. Blood was obtained by clean venapuncture in the forearm, without
pressure and discarding the first 2 ml of blood. Nine parts of blood were collected in
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one part of 0.13 M (3.8%) trisodium citrate (pH 7.8) and the blood was centrifuged for
15 min at 3000xg at room temperature, followed by centrifugation for 30 min at
20000xg at 4°C.^ ^ The cell free plasma was stored at -80°C until analysis. A
pooled normal plasma was prepared from plasma of healthy volunteers not on
medication, not using OC and non-pregnant (21 females and 44 males, mean age 35
years). The individuals who donated blood for normal pooled plasma were not
screened for FVLeiden or other hereditary coagulation abnormalities.
P/asma preparaf/on for /nvesf/gaf/ng f/je effect of pre-ana/yf/ca/ var/ab/es
on f/ie n^PCsr. Blood was collected from nine volunteers: three factor V|_eiden
negative individuals (2 men, 47 and 55 year; 1 woman, 51 yr), three heterozygous
factor V|_eiden carriers (1 man, 30 yr; 1 woman, 41 yr and a 32 yr old woman who was
1 month pregnant) and three women (<30 years of age) using a monophasic oral
contraceptive (OC) preparation containing 30 ug ethinyl estradiol and 150 pg
desogestrel. The presence of the factor VLeiden mutation was established by DNA
analysis.^
The handling of the blood samples and the preparation and handling of plasma
samples from the volunteers is schematically presented in Fig. 1. Nine parts of blood
were collected in one part of 3.2% (0.109 M) or 3.8% (0.130 M) trisodium citrate and
divided into three equal portions, one part of which was immediately further
processed and the others were left 4 or 24 hours at room temperature before
processing. Platelet poor plasma was obtained by centrifuging either 15 minutes at
2000xg at room temperature or 15 minutes at 3000xg at room temperature followed
by 30 minutes at 20.000xg at 4°C. Samples were frozen in small aliquots and stored
at either -20°C or -80 °C until analysis. For each variable one aliquot was thawed
once and refrozen again. Taken together this resulted in 432 samples (9 individuals x
48 combinations) available for analysis. The nAPC-sr in six samples was not
determined because the plasma was clotted upon thawing and 27 samples were left
out of analysis because in these measurements residual thrombin formation
determined in the presence of APC in normal plasma fell outside the range 6-16%
(see also results section).
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>*PC-res/sfance assay and determ/naf/on of fhe nAPCsr. Plasmas were
thawed and defibrinated with ancrod (1 U/ml final concentration) for 10 min at 37 °C
after which the clot was removed with a plastic spatula (Sarstedt). Defibrinated
plasma was used within 3 hours after defibrination. The nAPC-sr was routinely
determined essentially as described before.^ ^ Briefly, 80 ul defibrinated plasma
was incubated at 37°C and thrombin formation was initiated with 45 ul starting
solution (prewarmed at 37 °C) containing tissue factor, CaCb, phospholipid vesicles
with or without APC in 25 mM Hepes (pH 7.5 at 37 °C), 175 mM NaCI, 5 mg/ml BSA.
This resulted in final concentrations in plasma of 0.4 ng/ml tissue factor
(corresponding to a final 940-fold dilution of stock solution of reconstituted tissue
factor preparations), 16 mM added CaCb, 15 nM phospholipid vesicles
(DOPS/DOPC/DOPE, 20/60/20, M/M/M) and if present, 5 nM APC. It should be
noted that in earlier publications^ ^ ^ the tissue factor concentration was abusively
given as 0.1 ng/ml. When quantified with an antigen assay (American Diagnostics)
the tissue factor concentration used in the previous studies was 0.4 ng/ml.
After 20 min an aliquot from the plasma mixture was diluted 50-fold in a 50 mM
Tris buffer (pH 7.5 at 37°C) containing 175 mM NaCI, 20 mM EDTA and 0.5 mg/ml
ovalbumin. The amount of o^M-thrombin complex present in the diluted plasma
mixture, which is a measure for the ETP (see below), was quantified by adding an
appropriate aliquot from the diluted plasma to the well of a microtiterplate containing
buffer with S2238. The well finally contained 250 (.il 50 mM Tris (pH 7.5 at 37°C), 175
mM NaCI, 0.5 mg/ml ovalbumin, 20 mM EDTA and 235 (.iM S2238. The rate of
change in absorbance was determined at 405 minus 492 nm at 37°C in a 340 ATTC
microtiterplate reader (SLT Labinstruments, Salzburg, Austria) set in the kinetic
mode. The amidolytic activity was corrected by blank values measured in plasma
samples (80 ul) to which 45 nl 25 mM Hepes (pH 7.5 at 37 °C), 175 mM NaCI, 5
mg/ml BSA with or without APC was added and which were subjected to the same
incubation and dilution procedure as described above.
In routine nAPC-sr determinations 21 subject plasmas together with 3 samples of
pooled normal plasma (first, middle and last sample) were determined in duplicate to
yield a total of 96 amidolytic measurements on a single microtiterplate (48 with and
48 without APC).
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anticoagulant time before centrifugation storage sample
concentration processing procedure temp thawing
0.11 M
Individual sample
0.13 M
Figure 2.1 Schematic diagram of different procedures of plasma preparation and storage
Ca/cu/af/on of nAPCsr. Since the final level of a2-macroglobulin-thrombin (012M-
lla) complexes is proportional to the ETP, the effect of APC on the ETP can be
quantified by measuring the amidolytic activity of the oc2M-lla complex generated in
plasma with and without APC.^ ^ From the o^M-lla amidolytic activities (+/- APC)
thus obtained in subject plasma and in pooled normal plasma determined in the
same microtiterplate the nAPC-sr was calculated as:
nAPC-Sr=(a2M-lla+APC/a2M-lla.APC)plasmasample/(a2M-lla+APC/a2lv1-lla.APC)poolednonnalptasma
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Determination of f/»e efifecf of variation of the ana/yticai variab/es. The
effect of variation of analytical variables (i.e. the APC, tissue factor, phospholipid and
Ca^* concentrations) on the efficacy by which APC inhibits thrombin formation was
determined by varying the amount present in the assay mixture while keeping the
others constant at the concentration at which the standard assay is performed (0.4
ng/ml tissue factor, 16 mM added CaCb, 15 (.iM phospholipid vesicles and 5 nM
APC). The effect of the use of different tissue factor preparations in the assay was
analyzed by determining the nAPC-sr in 90 normal healthy volunteers who donated
blood for the normal plasma pool.
Sfaf/sf/cs. The influence of pre-analytic variables on the nAPCsr of the
plasma samples of the nine individual volunteers was assessed in a multiple linear
regression model with nAPC-sr as dependent variable using indicator variables for
the nine individuals. In the comparison different tissue factor preparations differences
of means and 95% confidence intervals were calculated in the standard fashion.
Resu/fs
The ETP-Jbased /»PC resistance tesf. The ETP-based APC resistance test
presented in earlier reports is based on determination of the effect of APC on the
time integral of thrombin generation, the ETP, initiated in plasma via the extrinsic
coagulation pathway. To quantify the effect of APC on thrombin generation an APC
sensitivity ratio (APCsr) was defined^ that is equal to the ratio of the endogenous
thrombin potentials determined in the presence and absence of APC. In order to
improve day to day reproducibility the APCsr was normalized by division through the
same ratio determined in pooled normal plasma (eq. 1).
nAPC-Sr = (ETP+APC/ETP_APC)plasmasample/(ETP+Apc/ETP_APC)pooled "°™al Plasma(eq.
which reduces to eq. 2 when the residual ETP determined in the presence of APC is
expressed as percentage of the ETP determined without APC.
nAPC-sr = Residual ETP (%)piasma sampie/Residual ETP (%)pooied normal plasma (eq. 2)
For quantification of the effect of APC on the ETP it is not necessary to measure
complete time courses of thrombin generation. Thrombin generation curves typically
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reach a residual level of amidolytic activity that can be attributed to the oi2M-lla
complex ^ "°. The a2M-lla level remains constant in time and is a direct indicator for
the ETP in plasmas with the same c^M levels ^ ^ . Since this is particularly the case
when the same plasma is tested with and without an effector of thrombin generation,
the effect of APC on the ETP can be simply quantified on the basis of single
amidolytic assays of the end levels of oi2M-lla present in plasma in which thrombin
was generated in the absence and presence of APC.
Effecfs of f/ssue factor, CaC/2 and p/jospho/;p/d concenfraf/ons on
fhromto/n generaf/on /n fhe absence and presence of ÄPC. Fig. 2.2 shows the
results of titration experiments in which the concentration of one of the reactants
(tissue factor, CaCb or phospholipid) was varied while the others were kept constant
at their respective optimal concentrations. In the absence of APC (open symbols)
optimal thrombin formation was observed at 0.4 ng/ml tissue factor (Fig. 2.2A), 16
mM added CaCb (Fig. 2.2B) and 2.5 uM phospholipid vesicles in addition to the lipid
present in the relipidated tissue factor preparation (Fig. 2.2C).
In the presence of 5 nM APC thrombin formation was inhibited at all reaction
conditions tested (Figs. 2.2 A-C, closed symbols). However, with 5 nM APC thrombin
formation increased at increasing tissue factor and CaCb concentrations. This
indicates that the efficacy by which APC inhibited thrombin formation gradually
decreased at higher tissue factor (Fig. 2.2A) and CaCb concentrations (Fig. 2.2B). In
the presence of APC, thrombin formation progressively decreased when the amount
of phospholipid in the assay was increased, indicating that the ability of APC to inhibit
thrombin formation was enhanced at higher phospholipid concentrations (Fig. 2.2C,
closed symbols).
Fig. 2.2 D-F summarizes the effect of variation of the tissue factor, CaCb and
phospholipid concentrations on residual thrombin formation in the presence of 5 nM
APC (expressed as percentage of thrombin formation determined in the absence of
APC, cf. Fig. 2.2 A-C). In all cases residual thrombin formation remained a function
of the concentration of reactants and increased when the amounts of tissue factor
(Fig. 2.2D) and CaCb present in the assay mixture were increased (Fig. 2.2E) and
decreased at increasing phospholipid concentrations (Fig. 2.2F).
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Figure 2.2 Effects of varying amounts of tissue factor, Ca ions and phospholipid on thrombin
generation in normal pooled plasma Thrombin formation was initiated in defibrinated normal pooled
plasma with a starting mixture containing varying amounts of tissue factor (Innovin), Ca"-ions and
phospholipid vesicles either with or without APC (A-C). Residual thrombin formation in the presence of
APC, was expressed as percentage of thrombin formation determined in the absence of APC (D-F).
(A, D): 16 mM Ca^' ions, 15 (iM phospholipid and variable amounts of tissue factor. (B. E): 0.4 ng/ml
tissue factor, 15 (iM phospholipid and variable amounts of Ca^* ions. (C, F): 0.4 ng/ml tissue factor, 16
mM Ca'* ions and variable amounts of phospholipid. The amounts of tissue factor, Ca**-ions and
phospholipid vesicles represent final concentrations in the assay mixture. Plotted is thrombin
formation in the absence (O) or presence (•) of 5nM APC expressed in arbitrary units (final levels of
012M- I la complex present in plasma after 20 min). Y-error bars indicate the 95% confidence interval (n
= 4)
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Effecfs of APC on f/iromb/n formaf/on /n norma/ p/as/na and /n F\/(.e/den
p/asma. The data presented in Fig. 2.2 form the basis for the reaction conditions at
which the ETP-based APC resistance is performed (15j.iM phospholipid, 0.4 ng/ml
tissue factor and 16 mM CaCb). Assay conditions were chosen such that thrombin
formation in the absence of APC was near optimal, i.e. insensitive to small variations
in concentrations of phospholipid, tissue factor or CaCb. The amount of phospholipid
present in the assay mixture (15 nM) is higher than the concentration required for
optimal thrombin formation in the absence of APC (<5 (.iM, Fig. 2.2C). The use of a
high phospholipid concentration makes the assay insensitive to small amounts of
phospholpid present in plasma. Moreover, the amount of APC required to inhibit
thrombin formation is less at high phospholipid concentration (Fig 2.2F), which
reduces the contribution of APC to the amidolytic activity determined to calculate the
nAPCsr. The experiment presented in Fig. 2.3 shows the effect of increasing APC
concentrations on thrombin generation in pooled normal plasma and in plasmas from
a normal healthy male volunteer and from a male heterozygous carrier factor VLeiden-
In all plasmas residual thrombin formation gradually decreased at increasing APC
concentrations. However, thrombin formation in the plasma from the heterozygous
carrier of factor VLeiden was less sensitive to APC than that in plasma from the
wildtype volunteer. At all APC concentrations tested the latter plasma showed a
sensitivity towards APC similar to that of pooled normal plasma.
Figure 2.3 Effects of varying amounts APC
on APCsr of normal pooled plasma, plasma
from a normal healthy individual and factor
VLeiden plasma. Thrombin formation was
initiated in defibrinated plasma with a
mixture of tissue factor (Innovin), Ca^'-ions
and phospholipid vesicles containing
varying amounts of APC. The final
concentrations of reactants present in the
assay mixture were 0.4 ng/ml tissue factor,
16 mM Ca^* ions, 15 nM phospholipid and
concentrations of APC indicated in the
figure. Residual thrombin formation in the
presence of APC, expressed as percentage
of thrombin formation determined in the
absence of APC in normal pooled plasma
(O), plasma of a normal healthy volunteer
(A) and plasma of a heterozygous carrier of
factor VLe,den (•)• Y-error bars indicate the
95% confidence interval (n=4).
50%
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Quanf/f/caf/on of tfie effect of ÄPC on fhromo/n generaf/on. In APC
resistance tests the sensitivity of a particular plasma for APC is commonly
determined on the basis of an APC sensitivity ratio (APCsr) which is defined as the
ratio of the test result with and without APC. In the case of the ETP-based APC
resistance test this yields:
>APCsr = E7P+WE7P.XPC = KeS/dua/ E7P (%Jp,asmasamp/e/700
in which residual ETP (%)piasma sample is the ETP determined in the presence of APC
expressed as percentage of that determined without APC. To enable comparison
with normalized APC sensitivity ratios (nAPCsr, see below) the APCsr is multiplied
by 10/.e.:
APC-Sr = ReS/dua/ ETP (%,)p/asmasamp/e/70
To minimize the effect of day-to-day variation the so-called nAPCsr was introduced'"
in which the APCsr of a plasma sample is divided by the APCsr of pooled normal
plasma determined in the same experiment ;.e.
A1/APC-Sr = ReS/dua/ E7P (%Jp,asma sampte/ReS/dua/ ETP (%Jpoo/edno™a/p/asma
During the development of the ETP-based APC resistance test the concentration of
APC added to plasma was chosen such that the residual ETP in the presence of
APC was 10%.^ This resulted in a large window for the APCsr (0-10) and in a good
discrimination between normal and APC resistant individuals.^ ^ ^ However, due to
small variations in reaction conditions, the day to-day values of residual thrombin
formation in normal pooled plasma may deviate from 10%. This has different effects
on the APCsr and the nAPCsr of a particular plasma sample. Fig. 2.4 compares the
APCsr and the nAPC-sr of plasma from the wild type volunteer (Fig. 2.4A) and from
the heterozygous carrier of factor V|_eiden (Fig. 2.4B) when residual thrombin formation
in pooled normal plasma varied between 1%-18% (data from Fig. 2.3). The APCsr of
the wildtype volunteer showed a 20-fold increase at increasing levels of residual
thrombin formation in pooled normal plasma, while the nAPC-sr remained virtually
constant when residual thrombin formation in the pooled normal plasma varied
between 5% and 18% (Fig. 2.4A). In the plasma from the factor V|_eiden carrier an
opposite trend was observed. The nAPC-sr of factor V|_eiden plasma strongly
depended on the percentage of residual thrombin formation in pooled normal
plasma. When this was less than 5%, the nAPC-sr of the factor V|_eiden plasma
became very high with large error margins (Fig. 2.4B). The APCsr (not-normalized)
Chapter 2 Pre-analytical variables 39
of factor VLeiden plasma was much less affected under these conditions. At levels of
residual thrombin formation in normal plasma above 5% the APCsr and the nAPCsr
showed a similar but opposite variation.
0% 5% 10% 15% 20%
Residual thrombin formation of NP
0% 5% 10% 15% 20%
Residual thrombin formation of NP
Figure 2.4 Deviations in the APC sr calculated by varying methods. APCsr determined in plasma from
the normal healthy volunteer (A) and the carrier of factor VYeiden (B) were calculated from the data
presented in Fig. 2.3 by the three different methods described in the Results section. Plotted are
deviations of the APCsr (expressed as % of the APCsr determined at 10% residual thrombin in normal
pooled plasma) as function of residual thrombin in normal pooled plasma.
(•) nAPCsr = Residual ETP (%)p,as„,asampie/Residual ETP (%)„ormai pooled pias™-
(A) APCsr = Residual ETP (%)plasma sample/10%
Thus, normalization, which was introduced to minimize day-to-day variation of
the APC resistance test may also cause deviations in the nAPCsr, especially in APC
resistant plasmas. However, the data presented in Fig. 2.4 show that, irrespective of
the method of calculation, reproducible (n)APCsr can be obtained when residual
thrombin formation in pooled normal plasma is maintained between 6 % and 15 %.
Under these circumstances normalization of the APCsr is the preferred method since
the coefficients of variation of the nAPCsr were lower than those of the APCsr (see
below).
Table 2.1 summarizes the in between assay variations of the (n)APCsr obtained
by determining the effect of 5 nM APC on thrombin formation in pooled normal
plasma, plasma from a healthy volunteer with an intermediate APCsr and a factor
VLeiden plasma on 18 different days. The coefficient of variation (%CV i.e. SD/mean x
100%) for residual thrombin formation of the pooled normal plasma (mean = 10.1%)
was 20.8%. The in between assay variations of the (n)APCsr determined in plasma
from the healthy normal volunteer were 14.8% (nAPCsr) and 23.1% (APCsr). Also in
40 I PART I Measurement of APC resistance
the case of factor Vi_eiden plasma, the in between assay variation of the nAPCsr
(12.4%) was lower than that of the APCsr (17.5%).
Table 2.1 In between assay variation of the ETP-based APC resistance test.
APCsr In between assay variation
(mean) (%CV)
Hea/fhy /nd/wdua/ w/Y/?ouf FW.e/de/7
APCsr 1.80 23.1%
n-APCsr 1.79 14.8%
Factor Vi«*,,, p/asma
APCsr 2.75 17.5%
n-APCsr 2.76 12.4%
The effect of APC on thrombin formation was determined in normal pooled plasma
and plasma from a heterozygous carrier of factor V,.e,den on 18 different days. Given
are the mean values of the residual ETP measured in the presence of APC
(expressed as percentage of the ETP determined without APC), the APCsr calculated
by the three methods described in the results section and the in between assay
variation (%CV).
APCsr=Residual ETP (%Ws™sampie/10%
n-APCsr=ReSidual ETP (%)piasmasample/Residual ETP (%)normal pooled plasma-
Comparison of d/fferenf r/ssue factor preparations. In earlier studies
concerning the ETP-based APC resistance test^ ^ ^ ^ a tissue factor preparation
was used that is not commercially available. To compare this preparation with
commercial tissue factor preparations, we determined the nAPC-sr of 90 plasmas
from normal healthy individuals (52 men, 38 women) using our earlier preparation
(Recomboplastin S) and two commercially available tissue factors (Dade® Innovin®
and Ortho RecombiPlasTin®) at 0.4 ng/ml tissue factor, 16 mM CaCb and 15 M
added phospholipid vesicles. The results obtained are shown in Fig. 2.5 for men
(open symbols) and women (closed symbols) separately and are summarized in
Table 2.2. APC concentrations needed to attain 10% residual thrombin formation in
pooled normal plasma were 4.8 nM APC for Innovin®, 5.2 nM APC for
RecombiPlasTin® and 5.0 nM APC for our original tissue factor preparation
(Recomboplastin S), which hints at small differences between the preparations
(Table 2.2). Average nAPC-sr obtained were, however, the same for all tissue factors
and with all preparations plasma of women was more resistant to APC than plasma
of men (Fig. 2.5 and Table 2.2). Thus, estimation of population averages was not
influenced by the choice of tissue factor preparation. However, with the commercial
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tissue factor preparations a wider range of nAPC-sr values was observed, especially
towards the lowest nAPC-sr values i.e. for plasmas that are more sensitive to APC
than pooled normal plasma (Fig. 2.5). This was even more clear from the plots
showing the correlation between the nAPCsr determined with different tissue factor
preparations (Fig. 2.6).
Table 2.2 Effect of tissue factor preparations on the nAPC-sr.
Tissue factor
Innovin
RecombiPlasTin
Recomboplastin S
subjects
all
man
women
all
man
women
all
men
women
n
(mean)
90
52
38
90
52
38
90
52
38
nAPC-sr
1.19
0.95
1.51
1.20
1.02
1.44
1.23
1.05
1.46
5-95% Cl
1.14-1.24
0.91-1.01
1.43-1.59
1.15-1.24
0.97-1.07
1.38-1.50
1.19-1.24
1.02-1.08
1.42-1.52
nAPC-sr values were determined using three different tissue factor preparations in
plasmas obtained from 90 healthy individuals. For more details see legend to Fig.
2.6 and Materials and Methods.With all tissue factor preparations a significant
difference between the nAPCsr of men and women was observed (p <0.001).
6
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<
DADE Innovin RecombiPlasTin Recomboplastin S
Figure 2.5 nAPC-sr determined in plasma from normal healthy individuals with three
different tissue factor preparations. The nAPC-sr was determined in plasma from 90
healthy volunteers, 52 men (O) and 38 women (•), at 0.4 ng/ml tissue factor, 16 mM
Ca^* ions. 15 uM phospholipid and 5 nM APC (final concentrations present in the assay
mixture). The following tissue factor preparations were used: Innovin. RecombiPlasTin
and a not commercially available preparation (Recomboplastin S) used in earlier
s t u d i e s . " " - * *
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An excellent correlation was observed between the original non-commercial
recomboplastin S and Innovin® (r = 0.92, Fig. 2.6A) and a somewhat lower
correlation with RecombiPlasTin® (r = 0.79, Fig. 2.6B). However, due to a relative
lack of low nAPC-sr values in the determination with the original Recomboplastin S
preparation, regression lines did not cross the origin. The two commercially available
tissue factor preparations showed a good correlation (r = 0.71) with a regression line
which passes through the origin and which has a slope of 0.94 indicating that nAPC-
sr values showed similar individual variation with these preparations (Fig. 2.6).
y = 0.61x + 0.49
R2 = 0.844
CO
c
6 o-
Si
y = 0.61x + 0.49
R2 = 0.628
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y = 0.93x
R2 = 0.571
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nAPC-sr (Ortho RecombiPlasTin)
Figure 2.7 Correlations of nAPC-sr determined
with different tissue factor preparations.
Correlation plot of the nAPC-sr determined with
(A) Innovin and Recomboplastin S, (B)
RecombiPlasTin and Recomboplastin S and
(C) Innovin and RecombiPlasTin. Data from
Fig. 2.6.
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nAPC-sr (Innovin)
Effecf of p/asma /iand//ng on fhe nAPC-sr of n/ne /nd/V/dua/ p/asmas To
obtain information on the influence of plasma handling (i.e. pre-analytical variables)
on the nAPC-sr, plasmas from nine individual volunteers with a large variation in the
nAPC-sr were collected and subjected to different treatments as described under
Materials and Methods (cf. also Figure 2.1). The pooled normal plasma used for
normalisation of the APCsr was collected according to the standard procedure (nine
parts of blood in one part 3.8% citrate) and processed as described in Materials and
Methods.
Table 2.3
Genotype
Effects
n
of pre-analytical variables
Anticoagulant
3.2 % citrate
nAPC-sr 5-95% Cl
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on the nAPCsr.
3.8 % citrate*
nAPC-sr 5-95% Cl
43
GG 3
AG 2
GG+O 3
AG+pregnancy
1.77
3.22
4.47
1
1.22-2.32
1.81-4.62
3.58-5.37
7.33
0.89
2.52
3.99
0.73-1.04
0.96-4.07
3.33-4.64
6.97
Centrifugation
15 min 2000xg
15min 3000xgRT,
30 min 20.000xg4''C*
Genotype n nAPC-sr 5-95% Cl nAPC-sr 5-95% Cl
GG 3
AG 2
GG+OC 3
AG+pregnancy
1.34
2.80
4.27
1
1.15-1.53
1.27-4.33
3.53-5.02
7.21
1.32
3.00
4.19
0.80-1.84
1.63-4.36
3.35-5.02
7.10
Hours at RT
Ohrs* 4 hrs 24hrs
Genotype n nAPC-sr 5-95% Cl nAPC-sr 5-95% Cl nAPC-sr 5-95% Cl
GG
AG
GG+OC
3
2
3
AG+pregnancy
1.20
2.92
4.15
1
0.73-1.67
1.37-4.47
3.09-5.20
7.14
1.31
2.91
4.07
1.20-1.41
1.67-4.15
3.55-4.58
7.16
1.48
2.82
4.47
1.00-1.97
1.23-4.41
3.67-5.26
7.15
Storage temperature plasma
-20°C -80°C*
Genotype n nAPC-sr 5-95% Cl nAPC-sr 5-95% Cl
GG
AG
GG+OC
3
2
3
AG+pregnancy
1.32
2.69
4.41
1
0.99-1.66
1.56-3.82
3.54-5.28
7.23
1.34
292
4.06
0.96-1.72
1.44-4.41
3.33-4.79
7.08
Thawing
1 x* 2x
Genotype n nAPC-sr 5-95% Cl nAPC-sr 5-95% Cl
GG
AG
GG+OC
3
2
3
AG+pregnancy
1.33
2.90
4.14
1
0.92-1.74
1.47-4.33
3.53-4.74
7.34
1.33
2.88
4.33
1.03-1.63
1.38-4.38
3.34-5.31
6.97
Mean nAPC-sr values and 95% C.I. were calculated for individuals with a similar
genotype/phenotype. GG = normal genotype, AG = factor V^den heterozygous genotype, OC
= oral contraceptives. * Refers to the routinely used plasma preparation procedure
The results are summarized in Table 2.3. Under all circumstances the plasma
sample from the heterozygous carrier of factor VLeiden, who was 1 month pregnant,
had the highest nAPCsr. The nAPC-sr determined for the heterozygous factor VLeiden
carriers showed values comparable to the women who did not carry the factor VLeiden
mutation but who were using oral contraceptives. Values close to normal plasma
were observed for the non-factor VLeiden men and for the non-factor VLeiden woman
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who was not using oral contraceptives (Table 2.3). These nAPCsr are in agreement
with earlier reported values.^ ^
The data obtained for all possible combinations of plasma processing were
analyzed in a multiple regression model which included the nine individuals as
indicator variables (Table 2.4). Thereby, adjustment for individual differences (factor
VLeiden carriers, OC users and pregnant woman) was achieved. The model showed
that the citrate concentration and the 24 hour wait at room temperature before the
blood was processed were variables that clearly influenced the nAPC-sr
measurement (Table 2.4). The largest effect was observed with the anticoagulant
concentration. Samples collected on 3.2% citrate showed an average increase of
0.74 of the APCsr compared to plasma collected on 3.8% citrate. The difference
between the APCsr of plasma collected on 3.2% and 3.8% citrate became less in
samples with higher nAPCsr (Table 2.3). The other pre-analytical variations /.e.
centrifugation procedure, 4 hour wait at room temp before processing of the blood
sample, temperature during 3 month storage as well as additional sample thawing
did not notably influence the nAPC-sr (Table 2.4).
Table 2.4 Regression model for the ETP-based nAPC-sr
Variables ß 95% Cl
3.2% citrate vs 3.8% citrate 0.739 0.647 - 0.831
4 hrs delay vs immediate processing -0.016 -0.130-0.096
24 hrs delay vs immediate processing 0.149 0.037 - 0.261
single vs double centrifugation 0.089 -0.003 -0.181
storage at-20 vs-80 -0.023 -0.117-0.071
thawing twice vs once -0.035 -0.127-0.057
nAPC-sr were obtained in plasmas of nine individuals processed by 48 different methods
and analyzed in a multiple regression model The nine individuals were included as
indicator variables and the effect of a change in preanalytical variable was assessed
against the routine method of plasma preparation (3.8% citrate as anticoagulant,
immediate processing of the blood sample, double centrifugation, storage at -80 and no
extra thawing).
D/scuss/on
The data reported here concern the effects of variations in plasma handling and
assay conditions on nAPCsr values determined in the ETP-based APC resistance
test described in earlier publications.^ ^ ^ It has been reported that the
measurement of the nAPC-sr with this assay, apart allowing detection of the factor
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mutation, is very sensitive for conditions of acquired APC-resistance such as it
occurs during the use of oral contraceptives^' ^ ' ^ and pregnancy."^"^ Part of this
sensitivity is likely due to the decision to use an APC concentration which diminishes
thrombin formation in normal plasma by 90%. This results in a large window for the
nAPC-sr (values between 1-10) of APC resistant samples. However, in order to
obtain results that are comparable from study to study and between different
laboratories the assay conditions need to be standardized. The assay conditions
were chosen such that thrombin formation in the absence of APC is insensitive to
small variations in phospholipid, CaCb or tissue factor concentrations. The amount of
phospholipid present in the assay mixture (15 nM) is higher than the concentration
required for optimal thrombin formation in the absence of APC. The use of a high
phospholipid concentration makes the assay insensitive to small amounts of
phospholipid present in plasma and also limits the amount of APC required to inhibit
thrombin formation. However, measurements obtained in the presence of APC and
thus, the nAPCsr remain sensitive to variations in concentrations of reactants (cf.
Figs. 2.2-2.4) and therefore, rigorous standardization is essential in order to minimize
within- and between laboratory variation.
It is not surprising that the ability of APC to inhibit thrombin formation is
decreased at higher tissue factor and CaCb concentrations and increases when the
amount of phospholipid present in the assay mixture is increased. At high tissue
factor concentrations excessive amounts of factor Xa and factor Va will be formed,
which will result in a condition at which APC is incapable to effectively inactivate
factor Va and inhibit thrombin generation. The observation that in model systems
containing purified proteins APC-catalyzed factor Va inactivation has a sharp Ca**
optimum (3 mM) and is inhibited at high Ca** concentrations,"^ can explain the
increase of residual thrombin formation at increasing amounts of Ca^*. The fact that
APC has a rather low affinity for negatively charged phospholipids"^ can account for
the increased effectivity by which APC down-regulates thrombin formation at higher
phospholipid concentrations.
In order to obtain reliable nAPCsr, it is necessary to ensure that the residual
thrombin formation determined in the presence of APC in normal pooled plasma is
close to 10%. A good day-to-day reproducibility is then achieved, which can be
further improved upon by normalizing against the normal pooled plasma (Fig. 2.4).
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When the level of residual thrombin formation in pooled normal plasma is kept within
a narrow range (6%-16%) the coefficients of variation of the nAPCsr (SD/mean x
100%) were 14.8% and 12.4% for a plasma of normal healthy donor and a factor
VLeiden plasma, respectively (Table 2.1).
When the residual thrombin formation in pooled normal plasma is below 6%,
normalization /'.e. dividing the percentage of residual thrombin formation in the
plasma sample by that determined in pooled normal plasma leads to systematic
overestimation of nAPC-sr in APC resistant samples and the inter- and intra-assay
variability becomes too large (Fig. 2.4). The extent of overestimation of the APCsr is
then reduced by omitting the normalization procedure. There is a second reason why
normalization may affect the actual value of the nAPCsr determined for an individual
plasma sample. This occurs when users of oral contraceptives or carriers of factor
VLeiden are included in the subjects who donate blood for the pooled normal plasma.
Then one obtains a pooled normal plasma that is already resistant to APC.
Normalization with such a pooled normal plasma will result in lower nAPCsr for
individual plasma samples than nAPCsr normalized against a pooled normal plasma
from which users of oral contraceptives and carriers of factor VLeiden are excluded. In
order to allow comparison of nAPCsr values obtained in different studies it is
recommended to use pooled normal plasma containing samples from a large number
of volunteers (to minimize variations in the percentage of carriers of factor VLeiden)
and to exclude women who use oral contraceptives.
nAPCsr obtained with the ETP-based APC resistance test are hardly affected by
the handling of plasma. The major variable to control appears to be the concentration
of anticoagulant (Table 2.3, 2.4). This is not surprising considering the CaCb
dependence of the measurement in the presence of APC (cf. Fig. 2.2) and the fact
that the normal plasma pool was collected at 3.8%. An influence of anticoagulant
concentration has also been reported for APC resistance tests that are based on
measuring the effect of APC on clotting times."' *® Therefore, it is preferable to
normalise APCsr against a pooled normal plasma that is collected on the same
concentration of anticoagulant. The linear regression analysis further indicated a
small influence of the storage time of blood before plasma is prepared and of the
temperature at which plasma is stored (Table 2.4). Other variables appeared to have
little or no influence.
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Summary
In the past years several hereditary and acquired risk factors for venous
thromboembolism (VTE) were defined that are associated with impaired down-
regulation of thrombin formation via the protein C pathway. To identify individuals at
risk, functional tests are needed that estimate the actual risk to develop venous
thrombosis.
We determined the effects of hereditary and acquired risk factors of venous
thrombosis on an activated protein C (APC) resistance test that quantifies the
influence of APC on the time integral of thrombin formation (the endogenous
thrombin potential, ETP) initiated in plasma via the extrinsic coagulation pathway.
APC sensitivity ratios (APCsr) were determined in plasma from carriers of the factor
VLeiden (n=56) or the prothrombin G20210A mutation (n=18), of individuals who were
deficient in antithrombin (n=9), protein C (n=7) or protein S (n=14) and of women
exposed to acquired risk factors such as hormone replacement therapy (n=49), oral
contraceptive use (n=126) or pregnancy (n=35). In addition, we analysed the effect of
combinations of these risk factors (n=60).
The ETP-based APC resistance test was sensitive to the presence of the
factor VLeiden and prothrombin G20210A mutation, to protein S deficiency and to
hormone replacement therapy, oral contraceptive use and pregnancy. The assay
was not influenced by antithrombin- or protein C deficiency. The simultaneous
presence of more than one risk factor of venous thrombosis resulted in more
pronounced APC resistance. The APCsr of individuals with a single or combined risk
factors of VTE correlated well with reported risk increases.
The ETP-based APC resistance test is a useful assay to identify individuals at
risk for the development of venous thrombosis due to acquired risk factors and/or
hereditary thrombophilic disorders that affect the protein C pathway.
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Venous thrombosis is a multifactorial disease which often results from an
interaction between hereditary and acquired risk factors.^ Mutations in genes of
procoagulant proteins (factor V-R506Q also called factor VLeiden^  and prothrombin
G20210A^°), hereditary defects of anticoagulant proteins^ (e.g. deficiencies of
antithrombin, protein C or protein S), and phenotypic abnormalities (APC resistance®'
* and high levels of factor VIM," factor IX" and factor Xl^) predispose individuals to
an increased risk of venous thrombosis.
A poor anticoagulant response to activated protein C (APC resistance) is an
important risk factor for venous thrombosis.^ APC resistance is often associated with
a mutation in factor V (factor V|_eiden),^  which causes the replacement of an amino
acid (Arg506->Gln) at a predominant APC cleavage site in factor Va. This results in
impaired inactivation of factor Va by APC^ and in enhanced thrombin generation,^
phenomena, which can explain the increased risk of venous thrombosis in carriers of
the factor VLeiden mutation.^ *® Later it was recognised that other mutations in factor
V (R2-factor V," factor Vnongkong,^  factor Vcambndge^ ) and acquired coagulation
disorders due to pregnancy or oral contraceptive use^° also cause APC resistance.
Recently, it was reported that APC resistance without factor VLeiden is an independent
risk factor of venous thrombosis.® '
We have developed a functional APC resistance test, which is based on
quantification of the effect of APC on the time integral of thrombin formation (the
endogenous thrombin potential, ETP) initiated in plasma via the extrinsic coagulation
pathway^. This assay not only allowed detection of factor VLeiden, but also disclosed
that the use of oral contraceptives (OC)^ ** is associated with acquired APC
resistance. A good correlation was noted between APC sensitivity ratio's (APCsr)
determined with this test and the risk of venous thrombosis in carriers of factor VLeiden-
and OC users.^ °^ This indicates that APCsr determined with this test may predict
the risk of venous thrombosis, both in the absence and presence of factor VLeiden.
In the present study we evaluated the effect of hereditary and acquired risk
factors of venous thrombosis on the ETP-based APC resistance test and correlated
the APCsr obtained with reported risk increases of thrombosis. This study involved
carriers of factor VLeiden or the prothrombin G20210A mutation, individuals deficient in
protein S, protein C or antithrombin (AT), OC users, women on hormone replacement
52
therapy (HRT) and pregnant women as well as individuals who were exposed to
combinations of these risk factors.
Mafe/7a/s and Methods
Afate/7a/s. The chromogenic substrates D-Phe-(pipecolyl)-Arg-pNA (S2238)
and L-pyroGlu-Pro-Arg-pNA (S2366) were supplied by Chromogenix, Mölndal,
Sweden. Ancrod, used to defibrinate plasma, was purchased from the WHO
International Laboratory for Biological Standards, Hertfordshire, UK. Relipidated
recombinant tissue factors, Recomboplastin S (a preparation not commercially
available) and Innovin were obtained from Dade. Purified human APC (Enzyme
Research Laboratories) was purchased from Kordia Laboratory Supplies, Leiden, the
Netherlands. Phospholipids were from Avanti Polar Lipids, Alabaster, Alabama, USA.
Small unilamellar phospholipid vesicles used in the APC resistance test were
prepared as described earlier^.
Co//ecf/on and Hand//ng of P/asma Samp/es. Nine parts of blood from
consenting volunteers were either collected in one part of 0.105 M trisodium citrate
(pH 7.8) or in one part of 0.13 M trisodium citrate (pH 7.8). Platelet poor plasma from
blood samples collected on 0.105 M trisodium citrate was obtained by centrifuging 10
minutes at 2000xg at room temperature, removal of plasma and a second
centrifugation for 10 minutes at 2000xg at room temperature. Blood samples
collected in one part of 0.13 M trisodium citrate (pH 7.8) were centrifuged for 15 min
at 3000xg at room temperature, followed by centrifugation for 30 min at 20000xg at
4°C. Plasma was frozen in small aliquots and stored at -80°C until analysis.
Sufo/ecfs Plasma samples were obtained from the Sheffield Haemostasis and
Thrombosis Center, Royal Hallamshire Hospital, Sheffield, UK, the Academic
Hospitals of the Universities of Groningen and Maastricht, the Netherlands and from
the laboratory of Biochemistry of the Maastricht University, the Netherlands. Normal
pooled plasma was obtained from 90 healthy volunteers (40 women that were not
pregnant or using OC, 50 men, mean age 35 years).
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Subjects with the factor VLekJen (n=56), the prothrombin G20210A mutation (n=18) or
who were deficient in AT (n=9), protein S (n=14) or protein C (n=7) and individuals
with a combination of these risk factors (n=33) were patients with a previous episode
of venous thrombosis (not on anticoagulant therapy) or their first degree family
members. Controls for this group were healthy age- and sex-matched volunteers (34
men and 62 women, mean age 42 years) who were screened for factor VLeiden but not
for the prothrombin G20210A mutation or AT-, protein S- and protein C-deficiency.
The effect of hormone replacement therapy (HRT) on the APCsr was studied in
plasma from 49 women (37-72 years, mean age 52 years) and 47 age- and sex-
matched controls not on HRT (36-71 years, mean age 51 years). From 44 women
data were available on the HRT preparation used. These were classified as estrogen
only (n=22) or combined estrogen/progestagen preparations (n=22). HRT was
administered orally (n=23) or via transdermal patches (n=21).
To study the influence of pregnancy, APCsr were determined in plasma from 35
healthy pregnant women (mean age 31 years and average gestational age 26
weeks) with uncomplicated pregnancies. Data on the effects of OC on the APCsr are
from an earlier investigation.^ Controls were healthy non-pregnant women without
the factor VLeiden mutation who were not using any hormonal preparation (n=62, age
range 17-41 years, mean age 31 years). Women participating in the study on the
effects of HRT, pregnancy and OC use on the APCsr and the corresponding controls
(cf. Fig. 3.2) were screened for the factor VLeiden mutation (carriers were excluded) but
not for other coagulation abnormalities.
D/agnos/s of coagu/af/on atonorma/rt/es and /IPC res/sfance.
Heterozygosity or homozygosity for the factor VLeiden mutation was determined by
DNA analysis or by determination of the sensitivity of diluted plasma factor Va for
APC.^ Prothrombin G20210 was established by DNA analysis. Protein S (total and
free antigen) was determined by ELISA and protein S deficiency was defined by
antigen levels of free protein S (< 0.64 Ill/ml) or total protein S (<0.71 IU/ml).^
Protein C was determined by ELISA (Diagnostica Stago) or after activation with
Protac (Pentapharm, Basel, Switzerland) by measurement of amidolytic activity
against S2366 (Chromogenix, Mölndal, Sweden). AT was determined by ELISA or by
chromogenic activity (Coamatic antithrombin, supplied by Chromogenix). Subjects
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were considered to be protein C deficient when they had plasma protein C levels
<0.7 lU/ml and AT deficient at plasma AT levels <0.84 lU/ml.
APC sensitivity ratios (APCsr) were determined with the ETP-based APC resistance
t^ under conditions described in a later publication.^*
Sfaf/sf/cs P-values for differences between the groups of individuals with a
single acquired or hereditary risk factor for venous thrombosis were obtained using
Student's t-test. Differences in APCsr between the groups with combined risk factors
were compared using the Mann-Whitney test for independent samples. The
association between the APC-sr and risk of venous thrombosis was determined by
linear regression (for odd's ratios <20) and by Spearman rank correlation.
Resu/fs
Effect of hereditary r/slf factors of venous thrombosis on the APCsr. The
APCsr of individuals with a single hereditary risk factor of venous thrombosis are
summarised in figure 3.1 and table 3.1. Individuals who were either protein C or AT
deficient had APCsr values that did not significantly differ from controls. Carriers of
the prothrombin G20210A mutation exhibited a moderate though significant higher
resistance to APC (APCsr = 1.87, 95%CI 1.53-2.22) than controls (APCsr = 1.31,
95%CI 1.20-1.41). Protein S deficient subjects had APCsr values (APCsr = 3.35,
95%CI 2.77-3.94), which were similar to those observed in heterozygous carriers of
the factor Vi_eiden mutation (APCsr = 3.75, 95%CI 3.52-3.98). The highest APCsr
values were found in homozygous carriers of the factor VLeiden mutation (APCsr =
4.76, 95%CI 4.34-5.18).
Both in controls and in carriers of hereditary coagulation abnormalities, men
(closed symbols, figure 3.1) generally had lower APCsr /.e. were more sensitive to
APC than women (open symbols, figure 3.1).
Effect of acquired r/slc factors of venous f/iromoos/s on fne APCsr. Table
3.1 and figure 3.2 show that women on hormone replacement therapy had
significantly higher APCsr (1.70, 95% Cl 1.55-1. 85) than age-matched controls not
using HRT (APCsr = 1.44, 95% Cl 1.31-1.56). Comparison of estrogen-only
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preparations with preparations containing estrogen and progesterone did not reveal
significant differences. However, a small difference was noted between oral HRT
(APCsr = 1.86, 95% Cl 1.63-2.08) and HRT administered via transdermal patches
(APCsr = 1.59, 95% Cl 1.34-1.84), a trend which reached borderline significance (p =
0.054).
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Figure 3.1 APCsr values of individuals with hereditary risk factors of VTE. APCsr values
in male (•) and female (O) controls, individuals deficient in protein C (PC), antithrombin
(AT) or protein S (PS), heterozygous carriers of the prothrombin G20210A mutation (PT)
and heterozygous or homozygous carriers of factor V,_e,den were determined as described
under Methods. Solid lines indicate the mean APCsr. Further details are given in Table
3.1.
Pregnancy was also associated with APC resistance (Table 3.1, figure 3.2). In the
first trimester (5-13 weeks) the APCsr was significantly elevated (APCsr = 2.46, 95%
Cl 1.78-3.14) and further increased during the second and third trimester (Table 3.1).
There appeared to be a significant correlation (r=0.52 , p=0.001) between gestational
age and the APCsr.
For comparison we have presented in Table 3.1 and figure 3.2 APCsr values of OC
users reported in an earlier publication ^. It appears that APC resistance during
pregnancy, particularly in the second and third trimester, was more pronounced than
during third generation OC use (p<0.001) and that APCsr values of women on HRT
were lower than those of second generation OC users (p<0.001).
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Figure 3.2 APCsr values of women with acquired risk factors of VTE. APCsr values of
controls, women on hormone replacement therapy (HRT), second generation oral
contraceptive users (2nd OC), third generation OC users (3' OC) and pregnant women
(gestational age >5 weeks) were determined as described under Methods. Solid lines
indicate the mean APCsr. Further details are given in Table 3.1.
Table 3.1 APCsr values obtained with the ETP-based APC resistance test in individuals
with hereditary and acquired risk factors of VTE
Risk factor
Hereditary
Controls (62 men/34 women) S
Protein C deficient
Antithrombin deficient
Prothrombin G20210A
Protein S deficient
FV|.e,den heterozygous
FV|_e,den homozygous
Controls HRT
HRT
oral HRT
transdermal HRT
Controls pregnancy/OC
Pregnant women (all)
Pregnant women (5-13 weeks)
Pregnant women (14-26 weeks)
Pregnant women (27-40 weeks)
Second generation OC
Third generation OC
n (m/f)
)6 (62/34)
7 (3/4)
9(7/2)
18 (8/10)
14(4/10)
40 (8/32)
16(6/10)
47
49
23
21
62
35
7
15
13
62
64
mean age mean APCsr
42
31
51
40
47
42
40
51
52
54
51
31
30
32
31
30
29
28
1.31
1.16
1.29
1.87
3.35
3.75
4.76
1.44
1.70
1.86
1.59
1.35
3.87
2.46
4.03
4.45
2.21
2.87
95% CI
1.20-1.41
0.99-1.33
0.88-1.71
1.53-2.22
2.77-3.94
3.52-3.98
4.34-5.18
1.31-1.56
1.55-1.85
1.63-2.08
1.34-1.84
1.23-1.48
3.45-4.30
1.78-3.14
3.56-4.51
3.74-5.15
2.00-2.42
2.68-3.06
Data on OC users are from an earlier publication of Curvers et al.
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Table 3.2 APCsr values obtained with the ETP-based APC resistance test in individuals with more
than one risk factor of VTE
Risk factor n (m/f) age
mean
APCsr 95% Cl
Protein C deficient + AT deficient
AT deficient + Pregnant
Protein C deficient + Pregnant
Prothrombin G20210A + OC
Prothrombin G20210A + pregnant
Heterozygous FV|_e,den + Protein C deficient
Heterozygous FVu>,<jen +Prothrombin G20210A
Heterozygous FV,_eiden + HRT
Heterozygous FV|_e,den + OC
Heterozygous FV|.eKjen + Pregnancy
Heterozygous FVujiden + Protein S deficient
Heterozygous FV i^den + AT deficient + Pregnant
Heterozygous Fvleiden + AT deficient + Protein S deficient
Heterozygous FV,_e,den + ProthrombinG20210A + OC
Homozygous FVi_e,den + Pregnant
Homozygous FV|_e,den + homozygous Prothrombin G20210 1
1
1
1
1
1
4
18
5
12
4
6
1
1
1
1
(1/0)
(0/1)
(0/1)
(0/1)
(0/1)
(3/1)
(6/12)
(0/5)
(0/12)
(0/4)
(3/3)
(0/1)
(1/0)
(0/1)
(0/1)
(1/0)
17
29
32
22
23
42
41
51
27
31
37
36
35
26
30
35
1.58
3.76
2.86
4.04
4.18
3.11
3.77
4.04
6.02
6.50
6.52
4.91
6.11
6.44
7.66
4.16
1.62-4.60
3.23-4.30
3.72-4 35
5.58-6.45
5.58-741
5.86-7 18
AT = antithrombin; OC = oral contraceptive use; HRT = hormone replacement therapy
Effecf of comb/naf/ons of r/s/c factors of venous fnrombos/s on fhe
APCsr. The majority of individuals with more than one risk factor for VTE were
carriers of the factor V[_eiden mutation who were exposed to either another hereditary
thrombophilic disorder (the prothrombin G20210A mutation, protein S or AT
deficiency) or to an acquired risk factor (HRT, OC, pregnancy) for venous
thrombosis. Subjects with more than one risk factor generally exhibited responses to
APC that reflected a combination of the effects of the individual risk factors on the
APCsr (figure 3.3, table 3.2).
In line with the observation that AT deficiency and protein C deficiency were not
associated with APC resistance (cf. Table 3.1, figure 3.1) no further increase of the
APCsr was observed in individuals carrying this risk factor in combination with a risk
factor that did affect the APCsr (figure 3.3, Table 3.2). The presence of the
prothrombin G20210A mutation or HRT had virtually no additional effect on the
APCsr in factor VYeiden carriers (figure 3.3).
Heterozygous carriers of factor Vi_eiden who were also proteins S deficient, using OC
or who were pregnant had APCsr that were significantly higher than those of
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heterozygous carriers of factor V|.eiden without an additional risk factor (p<0.001). The
mean APCsr determined for these groups were even higher than the value
determined for homozygous carriers of factor V|_eiden (p<0.02). The highest APCsr
(7.90) was observed in a heterozygous carrier of factor Vieiden who was also protein S
deficient (figure 3.3).
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Fig 3.3 APCsr values of heterozygous carriers of factor VYeiden mutation with an
additional risk factor of VTE. FV|_e,den = heterozygous carrier of factor V^der; PC =
protein C deficiency; PT = heterozygous for the prothrombin G20210A mutation;
HRT = hormone replacement therapy; PS = protein S deficiency; OC = users of oral
contraceptives. Solid lines indicate the mean APCsr. Further details in Table 3.2.
Assoc/af/on of APC-sr w/f/j reported r/s/fs for venous fhrombos/s. Table
3.3 summarises the APCsr for the various subgroups together with the thrombotic
risks reported in epidemiological studies. Risk factors for which only one plasma
sample was available or for which no odds ratios are known were omitted from this
analysis. With the exception of AT- and protein C-deficiency a general trend was
observed in which increases in risk of venous thromboembolism are reflected by
increased APC-resistance in the ETP-based assay. The strong association between
the APC-sr and the reported risk increases for odds ratios <20 is illustrated in figure
3.4 (r = 0.95, p<0.00001). For odds ratios higher than 20 the curve deviates from
linearity. This can be explained by the fact that the maximum APCsr is 10, a value
obtained in a plasma that is fully (100%) resistant to APC. Spearman rank correlation
(with the inclusion of all risk factors, Table 3.3) still yielded a clear correlation
between the APCsr and the odds ratio (r = 0.893, p < 0.00001).
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Table 3.3 APC sensitivity ratios and previously published risk for venous thromboembolism
Risk factor
Controls
Prothrombin G20210A
Protein S deficient
FVLeiaen heterozygous
FvYeiden homozygous
Acquired
Controls HRT
HRT
Second generation OC
Third generation OC
Pregnant women (all)
Comb/ned
Heterozygous FV|_e,aen +
+ Prothrombin G20210A
+ HRT
+ Protein S deficient
+ OC
+ Pregnancy
n =
18
14
40
16
47
49
62
64
35
18
5
6
12
4
nAPCsr
96
1.87
3.35
3.75
4.76
1.44
1.70
2.21
2.87
4.15
3.77
4.04
6.52
6.02
6.50
95% C.I.
1.31
1.53-2.22
2.77-3.94
3.52-3.98
4.34-5.18
1.31-1.56
1.55-1.85
2.00-2.42
2.68-3.06
3.45-4.30
3.23-4.30
3.72-4.35
5.86-7.18
5.58-6.45
5.58-7.41
relative risk
1.20-1.41
2.8
5.0
6.8
79.4
1
3.6
3.6
7.4
5
58.6
13.3
41.3
34.7
18.3
95% C.I.
1
14-5.6
1.5-16.8
3.6-12.0
22.0-289
1.6-7.8
2.5-5.1
4.2-12.9
22.1-155
4.3-41
12.1-142
7.8-154
2.7-432
Ref
50
62
25
56
63
64
65
64
26
66
a
67
68
Corrected for age 49; 26; 66; a calculated from data of refs 69; 67; 68. In other publications 70-75
relative risk enhancements are reported that fall within the 95% conficence interval presented in this
table
(A
Ü
a
5 10 15
Relative Risk
Figure 3.4 Correlation between APC-sr and relative risks of
VTE. The average APC-sr determined in the various subgroups
in the ETP-based APC-resistance assay were plotted against
odds ratios published in literature. See Table 3.3 for further
details.
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D/scuss/on
In this paper we report the effects of hereditary and acquired risk factors of
venous thrombosis on APCsr determined with the ETP-based APC resistance test. It
is shown that this assay is not only sensitive to the factor Viewer, mutation, but that
individuals with the prothrombin G20210A mutation or with protein S deficiency or
women who are exposed to acquired risk factors for venous thrombosis such as
HRT, OC and pregnancy also exhibited increased resistance to APC. The APCsr of
individuals who were protein C- or AT-deficient fell within the range of normal healthy
individuals, indicating that these coagulation abnormalities do not influence the APC
resistance test.
The moderate increase of the APCsr in carriers of the prothrombin G20210A
mutation is in agreement with a recent report concerning the association of elevated
plasma prothrombin levels with increased APC resistance as determined in the
classical aPTT-based assay.^ The fact that prothrombin can inhibit APC-dependent
factor Va inactivation" may provide a mechanistic explanation for these
observations.
Protein S deficient subjects had APCsr similar to heterozygous carriers of factor
VLeiden- Since protein S is a cofactor of APC in the inactivation of factor Va,^ it is not
surprising that a decrease in plasma protein S results in higher thrombin formation in
the presence of APC and hence in an increased APCsr. It is interesting to note that
the aPTT-based APC resistance test, which probes the effect of APC on the intrinsic
coagulation pathway, is hardly affected by plasma protein S levels.^ This suggests
that the regulation of the extrinsic coagulation pathway by the protein C system is
more sensitive to variation of the plasma protein S level than the intrinsic pathway.
Individuals with protein C or AT deficiency had normal APCsr. In the case of protein
C deficiency this can be explained by the fact that APC resistance tests quantify the
effect of APC added to the plasma, thus by-passing the contribution of plasma
protein C to the down-regulation of thrombin formation. Although it has been reported
that the thrombin formation is increased in AT deficiency® this does not come to
expression in the APC resistance test. This is likely caused by the fact that changes
of the plasma levels of AT similarly influence thrombin formation in the absence and
in the presence of APC, which reduces the effect on the APCsr (i.e. the ratio of
thrombin formation with and without APC).
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We also report increased APC resistance in plasma from pregnant women and from
women on HRT. With respect to HRT, the increase in APCsr is moderate compared
to that observed during OC use. This is likely caused by the fact that women on HRT
are exposed to lower dosages and less potent hormone derivatives than OC users. It
is interesting to note that orally administered hormones induced more pronounced
APC resistance than transdermal therapy. This suggests that APC resistance is
affected by route of administering HRT, a phenomenon that was also observed for
other coagulation parameters/® Pregnancy was associated with a gestation-
dependent increase of the APCsr, which, particularly in the third trimester of
pregnancy, became higher than the APCsr observed in heterozygous carriers of the
factor VYeiden mutation and in women using OC.
The decreased sensitivity to APC observed during HRT, third generation OC use or
pregnancy can, at least partially, be explained by a decrease in protein S
concentration under these conditions.^ The influence of protein S on the APCsr
values may also explain the further increased resistance to APC of carriers of the
FV|_eiden mutation who were also protein S deficient, pregnant or who used OC.
Individuals exposed to a combination of these risks factors had APCsr values that
were in the range of homozygous carriers of the factor V|_e,den mutation. The highest
APCsr was observed for a woman who was a heterozygous carrier of factor V^en
and protein S deficient; APCsr = 7.90 (cf. figure 3.3) indicating that her plasma was
almost fully resistant to APC.
One of the advantages of the ETP-based APC resistance measurement is that the
APCsr obtained with this test correlate remarkably well with the risk of venous
thromboembolism reported in epidemiological studies (cf. figure 3.4). This makes the
assay potentially suitable for a more overall evaluation of individual thrombotic risks.
The large variation of the APCsr within the various sub-groups indicates that a
number of variables that modulate the response to APC in the APC-resistant
phenotype remain to be identified.
In the present study, we did not discriminate between individuals with and without a
history of venous thrombosis. A preliminary analysis of the plasma collection of the
Leiden Thrombophilia Study (LETS) showed, however, that the APCsr determined
with the ETP based APC resistance test predicts the risk of venous thrombosis in
both patients with and without factor VYeiden (G. Tans et al. unpublished observations).
62
Taken together, the observations reported in the present paper indicate that the ETP-
based APC resistance test is a useful assay to assess the risk of venous thrombosis
and to study the pathophysiology of venous thrombosis.
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66 I PART I Measurement of APC resistance
Summary
Resistance to activated protein C (APC) is often associated with a mutation in
factor V (factor VLeiden)- Individuals without factor VLeiden who exhibit a response in
functional APC resistant tests similar to that of carriers of factor VLeiden are considered
to be acquired APC resistant. This phenomenon is particularly observed in women
using oral contraceptives (OC).
In the present study we compared the response to APC in plasma samples from
normal individuals, carriers of factor V|_eiden and women who use OC using functional
tests that either quantify the effect of APC on the endogenous thrombin potential
(ETP) or on the activated partial thromboplastin time (aPTT).
Both tests discriminate equally well between individuals with and without factor VLeiden
who were not using OC. In contrast to the aPTT-based test, the ETP-based assay
yielded significant differences in sensitivity to APC between non-OC users and OC
users and between users of second and third generation OC. Since there is no
correlation between APC-sensitivity determined with both assays in non-carriers of
factor VLeiden and in women who use OC and a rather poor correlation in carriers of
factor VLeiden, we propose that other plasma components differentially modulate the
response to APC in the aPTT- and ETP-based APC-resistance tests and that OC
change the level of plasma protein(s) that modulate the effect of APC on thrombin
formation initiated via the extrinsic coagulation pathway.
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/nfroducf/on
Prolongation of the activated partial thromboplastin time (aPTT) by activated
protein C (APC) was reported to be considerably less in a large group of patients with
venous thrombosis than in a control group of healthy individuals.^ This defect, called
APC resistance, appears to be a common hereditary risk factor for venous
thrombosis,^ ^ ®° ^ which in the majority of the cases is associated with a single
point mutation in factor v^® . This mutation, often referred to as factor \A_eiden, causes
the replacement of an amino acid (Arg506->Gln) at a predominant APC cleavage site
which renders the activated form of factor V, factor Va, less susceptible to proteolysis
^ A p e 19. 20. 82. 83
On the basis of the original observations of Dahlbäck et al.^ several functional
tests were developed for the diagnosis of APC resistance. However, screening
methods that are based on measurement of the effect of APC on the aPTT of
undiluted plasma do not fully discriminate between carriers and non-carriers of the
factor V|_eiden mutation.®* ^  In particular, women who are using oral contraceptives"'^
or who are pregnant^ appear to be less sensitive to the anticoagulant action of APC
and hence are considered to have acquired APC resistance.
Recently, we developed an APC resistance test^ that is based on
measurement of the effect of APC on the endogenous thrombin potential (ETP), i.e.
the time integral of thrombin generated in plasma in which coagulation is initiated via
the extrinsic pathway."" This so-called ETP-based assay not only enabled detection
of an abnormal anticoagulant response of plasma to APC (e.g. the presence of factor
en). but it also appeared that the plasma of women using oral contraceptives
(OC) exhibited considerable resistance to APC when analysed by this procedure.^
The observation that women who were using so-called third-generation oral
contraceptives were more resistant to APC than women using second-generation
oral contraceptives attracted much attention®^ "®® in the discussion about the different
risks for venous thrombosis between second and third generation OC users.^ ^ ®°
However, the impact of our observations for "pill thrombosis" was also questioned^"^
Amongst other things it was argued that the APC resistance test developed in our
laboratory has not yet been clinically validated^"^ and that the different effects of OC
in our APC resistance test might have been affected by the selection of patients or
may be due to an ex-wVo effect.^
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In order to gain more insight in possible differences between the aPTT- and
ETP-based APC resistance tests we present in this article a comparison of APC
sensitivity ratios of a large plasma collection of normal individuals, women who use
OC and carriers of FV|.eiden determined with both tests.
Afater/a/s and Afefftods
Mater/a/s. The aPTT-based APC resistance test (Coatest ® APC™) and D-
Phe-(pipecolyl)-Arg-pNA (S2238) and L-pyroGlu-Pro-Arg-pNA (S2366) were supplied
by Chromogenix, Mölndal, Sweden. Ancrod was purchased from the W.H.O.
International Laboratory for Biological Standards, Hertfordshire, U.K., and Arwin® was
from Knoll, Germany. Relipidated recombinant tissue factor was obtained from Dade,
U.S.A. The APC used in the ETP-based APC resistance test was purified human
APC (a kind gift of Immuno A.G., Vienna, Austria) or human APC (Enzyme Research
Laboratories) purchased from Kordia Laboratory Supplies, Leiden, The Netherlands.
APC was quantitated as described by Sala et al.^ Immuno-depleted factor V-
deficient plasma was obtained from Organon Technika. Phospholipids were from
Avanti Polar Lipids, Alabaster, Alabama, U.S.A. Small unilamellar phospholipid
vesicles, composed of a mixture of 1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPS),
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine (DOPC) (20/20/60, M/M/M), were prepared by mixing
appropriate quantities of phospholipids dissolved in CHCI3/CH3OH (9/1,v/v) in a
glass tube. After drying under a mild flow of N2, the phospholipids were suspended in
2 ml buffer (25 mM Hepes, 175 mM NaCI, pH 7.5) and vigorously vortexed for 1 min.
The phospholipid suspension was subsequently sonicated for 10 min at 0°C using a
MSE Soniprep 150 ultrasonic disintegrator set at 7.5 (.im peak to peak amplitude.
Phospholipid concentrations were determined by phosphate analysis.^
Co//ecf/on and Hand/zng of P/asma Samp/es. This study was performed
according to a protocol approved by our institutional ethics committee. Nine parts of
blood from consenting volunteers were collected in one part of 0.13 M trisodium
citrate (pH 7.8). Platelet-poor plasma was obtained by centrifugation for 25 minutes
Chapter 4 Compared to the classical clotting assay | 69
at 3000 g at room temperature followed by centrifugation for 25 min at 20000 g at
4°C and was snapfrozen in liquid nitrogen in small aliquots and stored at -80°C until
analysis.
Normal pooled plasma from healthy volunteers (40 females not using OC, 50 males,
mean age 35 years) was the same as used before.^
Some of the plasma samples used in this study were also used in an earlier paper in
which we reported the effect of OC use on the ETP-based normalized APC sensitivity
ratio (nAPC-sr)^. Plasmas no longer available for determination of the aPTT-based
nAPCsr were excluded from current analysis. Plasmas of women using triphasic OC,
treated as a separate group earlier,^ were reclassified as second (n=23) or third
generation OC (n=6) depending on the kind of progestagen. When sufficient plasma
was available, the ETP-based nAPC-sr was redetermined and the average of the
original and newly determined value was used. When insufficient plasma was
available to redetermine the ETP-based nAPC-sr, the original value^ was used.
Compared to the earlier study the plasma collection was extended with 101 new
samples from individuals recruited within our own institute.
The final plasma collection contained plasma samples of: male volunteers (n = 46,
18-48 years old, mean age 30 years, new n=21), women not using OC (n = 62, 17-41
years, mean age 31 years, new n=15), women using second-generation
contraceptives containing levonorgestrel or lynestrenol (n=62, 20-41 years, mean
age 29 years, duration OC use 0.3-20 year, average duration OC use 9 years, new
n=14), women using third-generation contraceptives containing desogestrel or
gestodene (n = 64, 18-46 year; mean age 28 year, duration OC use 0.3-20 years,
average duration OC use 6 years, new n=24), men heterozygous for the factor VLeiden
mutation (n =21, 14-78 years, mean age 40 years, new n=13) of which four with
previous venous thrombolic embolism (VTE), 14 were asymptomatic relatives of a
propositus with VTE and three were obtained by random sampling, women
heterozygous for the factor VLeiden mutation not using OC (n =26, 17-80 years, mean
age 42 years, new n=12) of which nine had a histrory of previous VTE, 13
asymptomatic relatives and three obtained by random sampling. Women
heterozygous for the factor VLeiden mutation using second or third generation OC (n
=7, 20-35 years, mean age 29 years, duration OC use 3-15 years, average duration
OC use 10 years, new n=2) of which non with previous VTE, two asymptomatic
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relatives and five obtained by random sampling. Compared to our previous study,^
the group specifics, i.e. range and average of age and duration of OC use, had not
changed significantly.
Women who had ceased OC therapy for >6 months were considered non-
users. The OC user group consisted of women that were using the same OC for at
least 3 months. We further excluded pregnant women and individuals with known
hereditary risk factors for venous thrombosis other than factor V|_eiden, with a previous
episode of venous thrombosis, a chronic or intercurrent acute disease or with
medication known to interfere with blood coagulation.
D/agnos/s of the presence of the factor l/Le/den mufaf/on. The occurrence of
heterozygosity for factor VLekien was established by determination of the sensitivity of
plasma factor Va for APC^ or by DNA analysis^.
Deferm/naffon of n,APCsr w/fh fhe ErP-based and fhe aP7T-based 4PC
res/sfance tesfs. Normalized APC sensitivity ratios (nAPCsr) were determined with
the ETP-based APC resistance as described before^. The normalized APC
sensitivity ratio (nAPCsr) was defined as the ratio of a2M-lla determined in the
presence and absence of APC divided by the ratio determined in the normal plasma
pool(cf."):
nAPCsr = (ct2M-lla+Apc/a2M-lla_Apc)piasma sampie/(a2M-lla+Apc/a2M-lla_/\pc)normai P'«™
The aPTT-based APC resistance test was performed in undiluted plasma as
described by the supplier (Chromogenix, Mölndal, Sweden). Clotting times were
determined on an ACL 300R coagulation analyser (Instrumentation Laboratory,
Milan, Italy). The normalized APC sensitivity ratio (nAPCsr) was defined as the ratio
of the clotting times (aPTT) determined in the presence and absence of APC
normalized by division through the same ratio determined in the normal plasma
pool^:
nAPCsr = (aPTT+Apc/aPTT_Apc)plasma sample/(aPTT+APC/aP"TT-APC)nornial plasma
Sfaf/sf/cs. Statistical analysis was performed after logarithmic transformation
of the data which resulted in normally distributed nAPCsr values. 95% confidence
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intervals of the mean are given in Tables 4.1 and 4.2. P values shown in the figures
were obtained by comparison of the groups using Student's f-test. The association
between both tests (Pearson's correlation and P values) were obtained by regression
analysis using SPSS.
Men/Women Men/Women FVL Men/Women Men/Women FVL
Figure 4.1 Comparison of nAPCsr of carriers and non-carriers of FVuiden determined with the (A)
aPTT- and (B) ETP-based APC resistance tests.APC sensitivity ratios were determined in the same
plasma collection of 109 non-carriers (46 men and 62 women) and 47 carriers of the FVi_eioen mutation
(21 men and 26 women) with the aPTT- and ETP-based APC resistance test as described under
Methods.
Resu/fs
Comparison of >4PC sens/f/V/fy raf/os of no/ma/ /nd/V/dua/s and carriers
of factor We/den '"n fhe aP7T- and ETP-oased ÄPC resistance fesfs. Normalised
APC sensitivity ratios (nAPCsr) of healthy individuals (men and women not using oral
contraceptives) and heterozygous carriers of the factor V|_eiden mutation were
evaluated in the aPTT- and ETP-based APC resistance test in undiluted plasma (Fig
4.1). Due to the calculation procedure, APC resistant plasmas will give a decrease of
the nAPCsr in the aPTT-based (A) and an increase in the ETP-based assay (B). At
cut-off ratio's of 0.76 for the aPTT-based APC resistance test and 2.08 for the ETP-
based APC resistance test (95% specificity) the sensitivity of the tests were 83% and
89%, respectively. Table 4.1 summarizes the data together with the results for men
and women, separately. In both tests women appeared slightly more resistant to APC
than men, confirming earlier reports,^ ^ ^ * but only in the ETP-based assay did
gender difference reach statistical significance (P< 0.05, Table 4.1).
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Table 4.1 nAPCsr of men and women determined in the aPTT- and ETP-based APC resistance tests.
aPTT-based test
median mean 95% Cl
ETP-based test
median mean 95% Cl
Men and women 108 0.94 0.95 0.93-0.98 1.13 1.20 1.10-1.30
Men and women FV-Le,den 47 0.67 0.69 0.65-0.72 2.97 3.09 2.77-3.41
Men 46 0.95 0.97 0.93-1.02 0.98 1.00 0.86-1.13
Men FV-Leiden 21 0.71 0.72 0.68-0.76 2.33 2.67 2.30-3.05
Women
No OC 62
Second geneartion OC 62
Third geneartion OC 64
Women FV-Leiden
NoOC 26 0.64 0.66 0.60-0.71 3.11 3.43 2.98-3.88
Using OC 7 0.56 0.58 0.53-0.62 5.99 5.74 5.14-6.35
0.92 0.94 0.91-0.97
0.86 088 085-0.91
0.86 0.86 0.83-0.89
1.21 1.35 1.23-1.48
1.97 2.21 2.00-2.43
2.75 2.87 2.68-3.07
u
O.
0.37 <0.0001 0 03
p<0 0005
no OC OC2nd OC3rd FVL FVL
• OC
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Figure 4.2 Effect of OC use on nAPCsr determined with (A) aPTT- and (B) ETP based APC
resistance tests APC sensitivity ratios were determined with the aPTT and ETP-based APC resistance
tests as described under Methods in the same plasma collection of women not using OC (n=62),
women using second generation OC (n=62) and women using third generation OC (n=64) who were
not carrying the FV-Leiden mutation and of heterozygousfemale carriers of FV-Leiden not using OC
(n=26) or using OC (n=7)
Effect of OC use on nAPCsr cteferm/ned /n aP7T- and E7P-based
resistance fesfs. Fig 4.2 and Table 4.2 summarize the effects of OC use on nAPCsr
obtained in both tests for plasmas of normal healthy women who do not carry the
factor vielen mutation and of women heterozygous for the factor vielen mutation.
Increased resistance to APC in OC users was observed in both tests, but the
differences between non-users and OC users in the aPTT-based test appeared
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rather small. The effects of OC use on nAPCsr determined in the ETP-based were
much more pronounced and significant differences were observed between non-
users and pill users independent of the kind of OC used (P<0.0001) and between
users of second and third generation OC (P<0.0001). Women who used third
generation OC had nAPCsr in the range of heterozygous female carriers of factor
VVeiden-who were not using OC (Fig 4.2B). The effect of OC and the factor v^ eiden
mutation on the nAPCsr appear to amplify each other, since female heterozygous
carriers of factor vYeiden who used OC were considerably more resistant to APC than
carriers of the mutation who did not use OC (p<0.0001), a phenomenon that was not
observed with the aPTT-based APC resistance test (Fig 4.2A).
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Figure 4.3 Correlation between nAPCsr
determined with the aPTT- and ETP-based
APC resistance tests for (A) men and women
not carrying FVi_e,den not using OC, (B) women
not carrying FVLeiden using second or third
generation OC and (C) heterozygous male and
female carriers of FVLe.oen not using OC.
Correlation coefficients and P values are given
in the figure.
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Corre/af/on between nAPCsr deferm/ned ;n fhe aP7T- and EfP based
APC res/sfanf fesfs. Fig 4.3 shows a correlation plot of nAPCsr determined with the
aPTT-based and ETP-based APC resistance tests. There appears to be a rather
poor correlation between the nAPCsr determined with the two tests in the case of
non-carriers of factor VYeiden (r = -0.37, Fig 4.3A) and in women using oral
74 PART I Measurement of APC resistance
contraceptives (r = -0.12, Fig 4.3B). The correlations were also low (data not shown)
within the populations of men (r = -0.36), women not using OC (r = -0.34), women
using second generation OC (r = -0.13) and women using third generation OC (r =-
0.06).
A slightly higher correlation (r = -0.46) was observed for heterozygous carriers of
factor VLeiden. This means that, despite the fact that both assays have approximately
equal sensitivity and specificity for the diagnosis of factor VLeiden, the correlation
between the nAPCsr obtained in both tests is rather low. These data, taken together
with the fact that OC use shows differential effects in both tests, indicates that the
nAPCsr is subject to differences in modulation by other plasma components in the
two APC-resistance tests. This is illustrated by the experiment in Fig 4.4 which shows
the effect of the factor VLeiden mutation per se on values of the nAPCsr of plasma in
which the levels of other coagulation factors are the same. In this experiment factor
V-deficient plasma was reconstituted with varying amounts of purified factor V and
factor (homozygous) VLeiden at a fixed total factor V concentration (20 nM). In these
plasmas there appeared to be an excellent correlation (r = -0.99) between nAPCsr
determined in the aPTT- and ETP based assays.
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Figure 4.4 Effect of FV-Leiden on nAPCsr determined with
aPTT- and ETP-based APC resistance tests. FV-deficient
plasma was supplemented with varying amounts of purified
normal FV and FV-Leiden at a constant level of 20nM total
factor V. In the ETP-based APC resistance test -50nM was
required to reduce thrombin formation to 10% in FV-deficient
plasma reconstituted with 20 nM normal FV. The nAPCsr of
plasmas with varying amounts of FV and FV-Leiden was
normalized against plasma with 100% normal FV.
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D/scuss/on
An impaired response to APC in functional clotting tests is associated with an
increased risk for venous thrombosis.^ ^ ®° ^  The defect, called APC resistance, is
often caused by a mutation^"™ in factor V (factor VLe,den) at a predominant APC
cleavage site (Arg^->Gln). APC resistance associated with factor VLeiden is a
hereditary defect that increases the risk for venous thrombosis some 7-fold in the
case of heterozygosity^ ^ and 80-fold in the case of homozygosity.^
In contrast to assays performed in factor V-deficient plasma,®'' commercially available
aPTT-based APC-resistance tests on undiluted plasma®*"®® are generally not 100%
specific and 100% sensitive for the diagnosis of the factor VLeiden- Depending on the
test used, there appears to be a variable number of individuals who do not carry the
mutation but who show an impaired response to APC that is comparable to that
observed for heterozygous carriers of factor VLeiden- When no other reason for this
impaired response to APC is known, these individuals are considered to be acquired
APC resistant.
Acquired APC resistance particularly occurs in plasma of women who use oral
contraceptives""^ or who are pregnant^ and is particularly observed in a functional
test in which the ability of APC to down-regulate the coagulation pathway is
quantitated by measuring its effect on thrombin generation initiated in plasma via the
extrinsic pathway.^
Since the effects of oral contraceptives on APC sensitivity ratios determined with
other APC-resistance tests appeared to be marginal,"' ^ ^ it was argued^ that our
earlier observations^ in the ETP-based assay may have been caused by the
selection of OC users or by an ex wVo effect on the plasma collection. The data
presented here, however, show that our plasma collection yields results that are in
agreement with earlier publications in which rather small effects of OC use on the
aPTT-based APCsr were reported." ^ *"
Therefore we propose that the different observations in the two APC resistance tests
are due to the fact that levels of other plasma proteins differentially modulate the
response to APC in the ETP-based test (effect of APC on thrombin generation
initiated via the extrinsic pathway) and in the aPTT-based test (effect of APC on
clotting times after initiation of the intrinsic pathway).
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Differences in modulation of the nAPCsr determined in the two tests by other plasma
proteins becomes evident after correlation of nAPCsr determined with the aPTT- and
ETP-based assays in a population of heterozygous carriers of the factor V|_eiden
mutation. Although the effect of the mutation per se (variation of relative amounts of
normal factor V and factor V|_eiden in a single plasma) shows an excellent correlation
between nAPCsr determined with the two assays (Fig 4.4), the correlation between
the nAPCsr of a population of heterozygous carriers of the factor Vi_eiden mutation
appears to be considerably less (Fig 4.3C). In our opinion these observations support
the hypothesis that the actual value of the nAPCsr of an individual, especially in OC-
users, is subject to differential modulation by other plasma proteins in the ETP- and
aPTT-based APC resistance tests.
With respect to the different effects of oral contraceptives on nAPCsr determined in
the aPTT- and ETP-based assays, this would imply that OC change the level plasma
protein(s) that particularly affect the response to APC probed by measuring its effect
on thrombin generation initiated via the extrinsic coagulation pathway. At present we
have no information about possible proteins that might be responsible for such a
phenomenon.
Another major question is the clinical significance of acquired APC resistance. There
are as yet no reports that directly associate acquired APC resistance with an
increased risk for venous thrombosis. To investigate this possibility we are presently
comparing nAPCsr of populations of patients with a previous unexplained venous
thrombosis and proper controls.
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PART II
APC resistance during hormonal changes:
sex steroids and APC resistance
/nfroducf/on*
Risk factors for venous thrombosis include transient states of high hormonal
levels as oral contraceptive (OC) use, pregnancy and the use of so-called hormone
replacement therapy (HRT) in postmenopausal women. Female sex hormones
(estrogens) have always been associated with a risk for venous thrombosis. The triad
of Virchow (1859) represents three factors involved in thrombosis: changes in the
vessel wall, reduction in blood flow and changes in blood composition. Since the
latter component plays a predominant role in thrombus formation in the veins, venous
thrombosis can be regarded as the clinical symptom of hypercoagulable plasma.
Many investigators have therefore, put effort in studying changes of haemostatic
parameters in individuals at risk of venous thrombosis in an attempt to understand
and explain the causes of this disease.
In numerous studies the effects of oral contraceptive use, pregnancy and
hormone replacement therapy on haemostatic variables have been investigated. In
the next sections of this introduction an overview will be given on the thrombotic risks
and changes of the haemostatic variables associated with the use of oral
contraceptives, with pregnancy and with hormone replacement therapy.
Ora/ confracepf/Ves
Soon after the marketing of oral contraceptive (OC) preparations in the early
60's it was reported that women who use OC are exposed to an increased risk of
' This introduction is based on: J.Curvers, G.Tans and J. Rosing. Sex steroids and blood coagulation
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venous thromboembolism. The incidence of venous thrombosis decreased when the
estrogen dose in oral contraceptive pills was lowered to 50ug ethinylestradiol or
less\ In the mid-eighties so-called third generation OC pills were introduced which
instead of levonorgestrel, lynestrenol or norethisterone contained a less androgenic
progestagen (desogestrel or gestodene). These third generation oral contraceptives
were developed to reduce the risk of cardiovascular disease. However, in 1995 it was
reported that the risk of venous thrombosis in third generation OC users was
increased 2- to 3-fold compared to users of the older second generation preparations
containing levonorgestrel." Until the present day, reports are appearing in literature
that either deny or confirm this risk difference.® *
The effects of oral contraceptives on the haemostatic system have been
studied extensively during the past years (for reviews see references®"™). In women
who use oral contraceptives the plasma level of almost every protein that participates
in blood coagulation changes. The concentration of many coagulation factors
(prothrombin, VII, VIII, IX, X, XI) is increased. Together with the decrease of the
anticoagulant proteins antithrombin and protein S this is indicative for a net
prothrombotic effect. It has been argued, however, that these procoagulant changes
may be counterbalanced by antithrombotic effects of the pill, such as elevated levels
of protein C, a,-antitrypsin, plasminogen, a decrease of plasminogen activator
inhibitor-1 (PAI-1) and by an increased fibrinolytic activity.
Recently, a cross-over study was published, of which part will be presented in
Chapter 6^ ^, in which a direct comparison was made between a second generation
OC (containing 30ug ethinylestradiol and 150ug levonorgestrel) and a third
generation OC (containing 30ug ethinylestradiol and 150ug desogestrel).
The OC-induced changes of the plasma levels of proteins involved in the
procoagulant, anticoagulant and fibrinolytic pathways are moderate and in most OC
users the values of the haemostatic parameters stay within the normal range.
However, nowadays it is known that even relatively small increases in levels of
coagulation factors are associated with an increased risk of venous thrombosis""^.
This suggests that the modest changes of plasma levels of coagulation factors and
the differential effects of second and third generation OC thereon cannot be ignored
in the discussion about the thrombotic effects of OC.
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In 1997 observations were published that are indicative for another
prothrombotic effect of OC. It was reported that plasma of users of OC is resistant to
APC and that there was a significant difference in APC resistance between users of
second and third generation OC.^ The criticism on the design of this study was taken
away in the randomised cross-over study mentioned above which established that
women who use OC pills with desogestrel are more resistant to APC than users of
levonorgestrel-containing OC." It is interesting to note that women who were using
OC and who were also heterozygous carriers of factor Vielen had a degree of APC
resistance that is normally observed for homozygous carriers of the factor Vleiden
mutation (Chapter 4 and ™). The amplifying effects of OC use and factor vYeiden in the
APC resistance test may explain the high risk of venous thrombosis of women with
factor V|_eiden who use OC*
Pregnancy
It is generally accepted that there is a state of hypercoagulability during
pregnancy and puerperium. This hypercoagulable state may prevent excessive blood
loss during delivery,^ but it also accounts for thrombotic complications that may
occur during pregnancy. During pregnancy the incidence of venous
thromboembolism is 0.3-1.0 per 1000 pregnant-women years^° ^ of which 75%
occurs antepartum.^ " Thus, the risk of venous thrombosis during pregnancy rises
some three- to sevenfold. However, the post-partum period can be regarded as the
most dangerous period, since the majority of cases of pulmonary embolism, occur
post-partum^. Correction of the epidemiological data for the shorter duration of the
post-partum period yields a twenty fold risk increase during the puerperium.^ ^ "
Although a number of additional factors can be designated as risk factor for post-
partum thrombosis (>35 years of age, multiparity, caesarean section, hereditary
thrombophilia), it is likely that changes in the haemostatic system also play a major
role in the thrombotic risk during this period.
A detailed report on the effect of normal pregnancy on coagulation parameters
was published in 1984 by Stirling et al.^ They showed that the plasma levels of a
number of coagulation factors consistently rise during pregnancy: factor VII (to
170%), factor VIII (to 200%, an increase that sustained after delivery), factor X (to
130%) and fibrinogen (to 4.2 g/L). Prothrombin and factor V initially also increased,
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but after 20-30 weeks decreased again, a phenomenon that may be due to
haemodilution. The levels of the protease inhibitors ai-antitrypsin and c*2-
macroglobulin, which probably do not play an important role in the /n wVo regulation
of coagulation, considerably increased during pregnancy. However, the plasma level
of the major physiological inhibitor antithrombin hardly changed. Furthermore, the clot
lysis time decreased during pregnancy but increased enormously after delivery
indicating a vast drop in fibrinolytic capacity in the post partum period. On the basis of
these observations Stirling and co-workers^ concluded that the initial increase of the
level of coagulation factors and fibrinogen was mediated by estradiol and that this
was a mechanism to ensure integrity of the endometrium and placenta.
With respect to markers of coagulation van Wersch et a l . " showed significant
positive correlations between gestational age and thrombin-antithrombin (TAT)
complexes and fibrin monomers. In several other studies increased levels of TAT
complexes,^" soluble fibrin monomers** ^ and F1+2^"^ were observed. F1+2 is
formed when prothrombin is converted to thrombin by factor Xa and like TAT
complexes and fibrin monomers is a marker for ;n v/Vo thrombin formation. F1+2
formation increases with gestational age (correlation = 0.69), especially after 20
weeks of pregnancy."" ^ ** Since increased plasma levels of TAT complexes, F1+2
and D-dimer are indicative for thrombin formation and for fibrinolytic activity, it
appears that in pregnant women both the coagulation and fibrinolytic system are in
an activated state.
Protein S, the cofactor of APC in the anticoagulant protein C pathway,
circulates in plasma in a free form and in complex with C4B binding protein. The total
plasma protein S levels decrease during pregnancy to 70% of normal.^ Later it was
shown that not only total protein S decreases, but that free protein S is also
decreased.^' •"• ^ * Low levels of free protein S are already observed after 10
weeks of gestation"" and in some cases free protein S dropped to 40% of normal.
This low level sustains until after delivery (even until 8 weeks postpartum). In
contrast, changes of protein C during pregnancy are much less pronounced or
absent.^ ® ^ Since free protein S acts as a cofactor of APC in the down regulation of
coagulation, the impairment of the protein C pathway due to low levels of free protein
S may contribute to the increased risk of venous thrombosis during pregnancy.
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Soon after the discovery of APC resistance and factor V|_eiden it was reported
that pregnant women who do not carry the factor V|.eiden mutation become resistant to
^PQ 34, 37-40 g phenomenon that was called acquired APC resistance. Since
increased resistance to APC was measured with an APC resistance assay that is
based on a clotting test and clotting times are influenced by factor VIII and protein S
levels, it is possible that increased APC resistance is due to the high levels of FVIII
and/or the low levels of protein S during pregnancy. Although a number of studies
suggested that the changes in APC resistance correlated with the changes in factor
VIlF ^ ^ and protein S,^ Kjellberg and co-workers^ did not find such correlations.
This indicates that other plasma components may also contribute to APC resistance.
Although significant, the extent of APC resistance determined with classical
APC resistant assays is in general less pronounced than that of carriers of the factor
VLeiden mutation. In 1997 we described an APC resistance test that is based on
measurement of the effect of APC on thrombin formation in full plasma.'" We found
that this assay is strongly affected by pregnancy and we have shown that APC
resistance determined with this test increases with gestational age (Chaper 4 and **).
Using a similar assay, Sugimura et al.** reported an enormous increase in APC
resistance in one woman who developed thrombosis during delivery demonstrating
that APC resistance that develops during pregnancy may contribute to the risk for
venous thrombosis.
Hormone Rep/acemenf Therapy
Although early epidemiological studies did not show that HRT is associated
with an increased risk for VTE,**^ recent case-control studies established that
compared to non-users, current users of hormone replacement therapy have some 3-
fold higher risk of VTE/" *®
With respect to the effect of HRT on haemostatic variables there are many
conflicting reports. This is likely caused by the fact that the changes of coagulation
parameters during HRT are less pronounced than those occurring during OC use or
pregnancy. Also the amount and source of estrogen, the route of administration (oral
or transdermal) and the absence or presence of opposing progestagens may have
different impacts on the coagulation system. Orally administered preparations seem
to have a more pronounced effect than transdermally applied preparations.
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Only limited information is available on the effect of HRT on the coagulation
factors II, V, VIII, IX, X and XI. Several studies focussed on the effects of HRT on
factor VII and fibrinogen. The interest in these coagulation factors, which substantially
increase during OC use and pregnancy, is presumably caused by the fact that they
have been implicated with an increased risk of arterial thrombosis^ *°. Oral estrogen-
only therapy appears to be associated with increased levels of factor V l l ^ ' " ,
whereas combined HRT or transdermal estrogens have no effect or even lower the
plasma level of factor VII.""^ In contrast to oral contraceptives and pregnancy, HRT
with both estrogen-only and combined preparations causes a reduction of
fibrinogen.^ ~^®° Since high factor VII and fibrinogen levels are associated with an
increased risk of cardiovascular disease""^  °^ the lowering of the plasma levels of
these proteins during HRT may have a beneficial effect on the risk. These beneficial
effects may, however, be counteracted by decreases of the plasma levels of the
anticoagulant proteins antithrombin,^ ^"^ protein C^ and protein s .^® We would
like to mention, however, that there are also studies in which increases of protein C^
^ ^ and protein S™ were reported. Like OC users and pregnant women, users of
HRT develop acquired APC resistance (Chapter 4 and **• ^ ) , the extent of which is,
however, much less pronounced than during OC use and pregnancy.
Markers of ongoing coagulation such as F1+2,^ ^ " fibrinopeptide A^ and
soluble fibrin" are increased during HRT. Despite modest effects of HRT on the
levels of individual coagulation factors this is indicative for activation of the
coagulation system. Increased D-dimer^ and plasmin-antiplasmin^* levels show that
not only the coagulation system but that fibrinolysis is also enhanced during HRT.
However, there are also studies in which no changes of F1+2,^* TAT-complexes^
and D-dimer^ were observed. In the cases in which increased coagulant and
fibrinolytic activities were observed there appeared to be no correlation between the
elevation of markers of coagulation and fibrinolysis." ™ This suggests that the
potentiation of fibrinolysis during HRT is not a response to enhanced activation of
coagulation.
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Acquired APC resistance
during OC use
Based on:
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Summary
The use of oral contraceptives (OC) causes disturbances of the procoagulant,
anticoagulant and fibrinolytic pathways of blood coagulation which may contribute to the
increased risk for venous thrombosis associated with OC therapy. We have reported
previously that, compared with use of second generation oral contraceptives, the use of third
generation OC is associated with increased resistance to the anticoagulant action of
activated protein C (APC). Owing to the cross-sectional design of that study, these
obsevations may have been subject to unknown bias or uncontrolled effects of the menstrual
cycle. We aimed to overcome these sources of bias by doing a cycle-controlled randomised
cvross-over trial. A number of anticoagulant parameters and the response to APC in plasma
was assessed in 33 women, who were randomly prescribed either a second generation (150
ng levonorgestrel/30 |jg ethinylestradiol) or a third generation OC (150 jug desogestrel/30 ug
ethinylestradiol) and who switched preparations after two pill-free cycles. The anticoagulant
parameters determined were: antithrombin (AT), a2-macroglobulin (ci2-M), cti-antitrypsin,
protein C inhibitor (PCI), protein C, total and free protein S and activated protein C sensitivity
ratios (APC-sr) measured with two functional APC resistance tests which quantify the effect
of APC on either the activated partial thromboplastin time (aPTT) or on the endogenous
thrombin potential (ETP). Of the 33 women, five were excluded because not all required
plasma samples were available. During the use of desogestrel-containing OC the plasma
levels of (i2-M, a,-antitrypsin, PCI and protein C significantly increased, whereas AT and
protein S significantly decreased. Similar trends were observed with levonorgestrel-
containing OC, although on this kind of OC the changes in AT, PCI and protein S (which was
even slightly increased) did not reach significance. Compared with levonorgestrel,
desogestrel-containing OC caused a significant decrease of total (p<0.005) as well as free
protein S (p<0.0001) and more pronounced APC resistance in the aPTT-based APC
resistance tests (p=0.02). The additional increase (0.51, 95% Cl 0.37-0.66) in APCsr in the
ETP-based APC resistance tests was highly singificant (p<0.0001). Normalised APC
sensitivity ratios during OC treatment correlated with values before OC use.
These observations indicate that the activity of the anticoagulant pathways in plasma from
users of desogestrel-containing OC is more extensively impaired than in plasma from users
of levonorgestrel-containing OC.
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/nfrocfucf/on
Since the early 1960s, the use of oral contraceptives has been associated with
an increased risk of venous thromboembolism. After the introduction of low-dose pills
containing 50ug ethinyl estradiol or less the thrombotic risk gradually decreased";
thus the oestrogen component of oral contraceptives was generally accepted as
being the cause of the increased risk for venous thromboembolism (VTE). However
recent epidemiological reports suggest that the type of progestagen in oral
contraceptives may also have a role in the increased risk on VTE. In 1995 and 1996
it was reported that women who used third generation OC (containing desogestrel or
gestodene) had a thrombotic risk two to three times that of women using second
generation OC containing levonorgestrel." ^ The outcome of these studies was,
however, questioned in later publications." ™ This controversy resulted in several
critical reviews in which the effects of progestagen on the occurrence of VTE were
discussed."""
So far, there is no good biological explanation for the thrombotic effect of oral
contraceptives. These preparations affect the concentrations of many proteins
involved in blood coagulation/" ^ but since changes are small and because
concentrations of coagulation factors usually stay within normal range during oral
contraceptive use, most investigators agreed that the effect of such preparations on
haemostatic variables could not explain the incresaed risk of venous
thromboembolism.
Earlier we have reported that oral contraceptive use is associated with
acquired resistance to activated protein C (APC), and that the plasma of women who
use third generation OC is more resistant to the anticoagulant action of APC than the
plasma of users of second generation OC.^ Since hereditary APC resistance,®"
which is due to a mutation in factor V (factor Vi.eiden) at an APC cleavage site,^ is
associated with an increased risk of venous thrombosis,^ several investigators^ ®°
®^  have postulated that acquired APC resistance (measured as the effect of APC on
thrombin generation) may explain the thrombotic effect of oral contraceptives and the
further risk associated with the use of third generation preparations.
Since our previous study was cross sectional and did not control for menstrual-cycle
effects, selection-bias or uncontrolled effects may have contributed to the observed
differences between the different kinds of oral contraceptive." " ®®'®° We now report
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the effects of a second generation OC containing levonorgestrel and a third
generation OC containing desogestrel on the anticoagulant action of APC and other
proteins involved in the anticoagulant pathways in the plasma of women who took
part in a cycle controlled randomised cross-over study.
Des/gn
Thirty three healthy female volunteers between the ages of 18 and 40 years,
with no history of venous thromboembolism, no previous pregnancy, and who had
not used oral contraceptives for at least 12 months before the start of the study, were
assigned in random order two oral contraceptive preparations: a levonorgestrel-
containing monophasic oral contraceptive preparation (30ug ethinylestradiol and
150ug levonorgestrel) and a desogestrel-containing monophasic oral contraceptive
preparation (30ug ethinylestradiol and 150ug desogestrel). Randomisation was done
in blocks of ten, by use of a central facility (Academic Medical Center).
33 women
randomised
_L
17 received levonorgestrel
than desogestrel
(group 1)
2 withdrew consent::
1 moved during the trial
1 because of long-lasting
gastroenteritis
_L
16 received desogestrel
than levonorgestrel
(group 2)
1 withdrew consent
1 no sample during the use
of levonorgestrel
15 completed trial
1 excluded because
samples were mislabeled
14 completed trial
14 qualified for analysis 14 qualified for analysis
Figure 5.1 Trial profile
The first OC was used for two consecutive cycles and after a washout of two
menstrual periods the volunteer was switched to the other preparation for two more
cycles. Blood samples were obtained between day 18 and 21 of six menstrual cycles.
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That is at baseline (before starting on the OC), during the two cycles of the first
period, in the second menstrual cycle of the washout period and during the two
cycles of the second period (see Figure 5.1). All volunteers gave written informed
consent. The study was approved by the Institutional Review Board of the Academic
Medical Center, Amsterdam, The Netherlands.
All blood samples (nine parts blood in one part 0.13M sodium citrate, pH 7.8) were
drawn under standard conditions, i.e. at 9.00 a.m., after a period of 15 minutes rest,
and after abstinence of caffeine, alcohol or nicotine for 12h. Cell free, citrated plasma
was prepared and centrally stored at -70°C. Control normal plasma was from 90
healthy volunteers (40 women not using OC and 50 men, mean age 35 years).
Plasma samples were analyzed after all volunteers had completed the study protocol.
Measurements were performed in duplicate and without knowledge of the OC
preparations used.
Laboratory mef/jods
The chromogenic substrates D-Phe-(pipecolyl)-Arg-pNA (S2238) and L-
pyroGlu-Pro-Arg-pNA (S2366) were supplied by Chromogenix, Mölndal, Sweden.
Phospholipids were from Avanti Polar Lipids, Alabaster, Alabama, USA. Small
unilamellar phospholipid vesicles, composed of a mixture of 1,2-dioleoyl-sn-glycero-
3-phosphoserine (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine
(DOPE) and/or 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (20/20/60,
M/M/M), were prepared as described before "' ^ . Phospholipid concentrations were
determined by phosphate analysis ^ .
Quanf/faf/on of p/asma prote/n /eve/s The plasma levels of the proteins
determined (antigen or activity) were expressed as percentage of that present in
normal pooled plasma determined in the same experiment.
All commercially available assays were carried out according the manufacturer's
instructions. ci2-Macroglubulin and cd-antitrypsin were determined via their ability to
inhibit trypsin added to diluted plasma samples using the Coaset ci2-
macroglubulin/ai-antitrypsin kit from Chromogenix (Mölndal, Sweden). Antithrombin
activity was determined with the Coamatic antithrombin kit (Chromogenix). Antigen
levels of protein C inhibitor (PCI) were determined by ELISA using a monoclonal
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antibody against PCI (API-93) as capturing antibody and rabbit polyclonal anti-PCI
serum as secondary antibody ^. This assay will be described in detail elsewhere.
Protein C was determined using the kits from Chromogenix (Coamatic protein C
activity) and from Boehringer/Stago (protein C antigen). Protein S (total and free
antigen) was determined using the protein S antigen kit from Reaads Medical
Products Inc, USA. At the time of measurement of protein S, some plasmas were no
longer available for analysis. This resulted in incomplete sets (samples from start,
first phase, washout and second phase) and in smaller groups (total protein S
antigen: n = 13 starting with levonorgestrel- and n = 8 starting with desogestrel-
containing OC; free protein S antigen: n = 13 starting with levonorgestrel- and n = 10
starting with desogestrel-containing OC). Coefficients of variation (%CV =
100*SD/mean) were estimated from repeated measurements (on various days) of
reference samples and were similar to those given by the manufacturer for the
commercially available assays. The %CV for the PCI antigen determination and for
the nAPC-sr determined with the ETP-based assay (see below) were 11.6 and 6.9%,
respectively.
APC-res/sfance assays Normalized APC-sensitivity ratios (nAPCsr) in the
ETP-based assay were determined by comparing the effect of 5 nM human APC
(Enzyme Research Laboratories purchased from Kordia Laboratory Supplies, Leiden,
The Netherlands) on thrombin generation initiated in subject plasma and in normal
pooled plasma with 0.4 ug/L tissue factor (Dade, USA), 15 nM phospholipid and 16
mM added CaCb (final concentrations in plasma) as described previously '®. APC
was quantitated as described by Sala et al. ^ and tissue factor was determined with
an antigen assay (American Diagnostics). To 80 ul defibrinated plasma incubated at
37°C was added 45 ul starting solution containing tissue factor, CaCb and
phospholipid vesicles, with or without APC to result in the abovementioned final
concentrations. After 20 min incubation at 37°C amidolytic activity of 012-
macroglobulin-thrombin (ci2M-lla) complexes was determined in diluted aliquots using
S2238 by measurement of the rate of change in absorbance determined at 405
minus 492 nm at 37°C in a microtiter plate reader (SLT Labinstruments, Salzburg,
Austria) set in the kinetic mode The normalized APC sensitivity ratio (nAPCsr) was
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defined as the ratio of the amounts of a2-macroglobulin-thrombin complex (ct2M-lla)
determined in the presence and absence of APC divided by the ratio determined in
the normal plasma pool (cf. De Ronde ^ ) :
nAPCsr = (a2M-lla+Apc/a2M-lla.Apc)piasmasampie/(a2M-lla+APC/a2M-Ma.APC)nofmaipiasma
The aPTT-based APC resistance test (Coatest ® APC™) was performed in undiluted
plasma as described by the supplier (Chromogenix, Mölndal, Sweden). Clotting times
were determined on an ACL 300R coagulation analyser (Instrumentation Laboratory,
Milan, Italy). The normalized APC sensitivity ratio (nAPCsr) was defined as the ratio
of the clotting times (aPTT) determined in the presence and absence of APC
normalized by division through the same ratio determined in the normal plasma pool:
nAPCsr = (aPTT+Apc/aPTT_APC)plasma sample/(aPTT+Apc/aPTT_Apc)normal Plasma
The presence of the factor V|_eiden mutation was determined by DNA analysis.
Sfaf/sf/ca/ ana/ys/s Analysis was limited to subjects, of whom both baseline
samples and at least one sample during each OC exposure were available. For each
parameter determined, all samples of an individual were assayed in duplicate in a
single experiment and compared to normal plasma determined in the same
experiment. Values obtained during the two cycles on a given OC preparation were
averaged and the change in parameter was calculated relative to the value
determined immediately prior to the start of OC use (/.e. relative to baseline in phase
1 or washout in phase 2). Graphs of this treatment effect were inspected for
interaction. In the absence of interaction (protein C antigen, protein C inhibitor
antigen, total and free protein S antigen, antithrombin, ai-antitrypsin and nAPC-sr in
the aPTT-based assay) the changes in parameter in the first and second phase of
treatment were combined for each oral contraceptive and the statistical significance
of the change relative to baseline/washout was assessed with a paired t-test. The
difference between the values of the parameters during the use of levonorgestrel and
desogestrel was also assessed using a paired t-test.
Since there was an indication for a modest treatment by phase interaction for ot2-
macroglobulin, protein C activity and the ETP-based APC-resistance assay the
phase difference (phase 1 minus phase 2) as a result of changing OC was calculated
for the individuals in each separate group^. The statistical significance of the phase
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difference between the two treatment groups (desogestrel -> levonorgestrel and
levonorgestrel -> desogestrel) was assessed with a t-test assuming non-equal
variances**. It was calculated that the inclusion of 30 volunteers would allow
detection of differences of changes between desogestrel and levonorgestrel use
which are 60% or more of the standard deviation.
Associations between parameters were searched for by calculation of the Pearson
correlation coefficient before and during OC use and for the change occurring as a
result of OC use (relative to baseline or washout).
Resu/rs
Five of the 33 eligible volunteers were excluded from analysis. One because
blood samples were only obtained during use of one OC type, one due to
mislabelling of samples and three because they withdrew consent. None of the
volunteers developed clinical signs or symptoms of venous thromboembolism. Thus,
Table 5.1 Effect of oral contraceptives on anticoagulant plasma parameters
Levonorgesfre/
before OC during OC
mean (SD) mean (SD)
increase*
mean (SD)
before OC
mean (SD)
Desogesfre/
during OC
mean (SD)
increase*
mean (SD)
/nd/wdua/ p/asma componenfs fexpressed as % of nomia/ poo/ed p/asmaj
Antithrombin 111(9) 110(8) -1.3(8.0)"*
ec2-macroglobulin 119(32) 128(34) 8.9(14.9)
a1-antitrypsin 94(22) 125(29) 31.8(13.8)
PC antigen 84(14) 93(19) 9.1(13.2)
PC activity 89(15) 97(18) 7.6(10.3)
PC Inhibitor antigen 83(18) 84(17) 0.(11.4)"*
PS total antigen (n=21) 99(13) 104(16) 5.0(20.4)"®
PS free antigen (n=23) 94(14) 99(15) 4.3(17.9)"*
4PC res/sfance assays
nAPCsr (ETP-based) 1.39(0.49)2.17(0.58) 0.77(0.33)
nAPCsr (aPTT-based) 0.83(0.11)0.84(0.12) 0.00(0.10)"*
112(11)
114(31)
92 (20)
85(17)
89(16)
82(13)
99(10)
94(12)
109(10)
128(31)
128(27)
95(1)
100(18)
89(18)
88(13)
82(12)
-3.1 (7.8)
14.1 (14.6)
36.1 (11.0)
9.8(12.1)
11.0(9.6)
6.6(12.0)
-11.4(9.7)$
-12.1 (9.3)$
1.40(0.55) 2.69(0.76) 1.29 (0.44)¥
0.83(0.11) 0.80 (0.09) -0.04 (0.08)$
PC= protein C, PS=protein S, nAPCsr=normalized APC sensitivity ratioDifferences before and during
OC use were statistically significant (P<0.05) unless indicated with NS (NS=non-significant) using a
paired t-test $ Significant difference between levonorgestrel and desogestrel OC preparations
assessed with a paired t-test. ¥ Significant difference between OC preparations assessed with a t-test
(assuming non-equal variances)
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plasma samples of 28 subjects were available for analysis, group 1 starting with
levonorgestrel (n=14) and group 2 starting with desogestrel (n=14).
Effecfs of OC on fhe p/asma /eve/s of anf/coagu/anf prote/ns. Table 5.1
summarizes the plasma levels of protein C, protein S, antithrombin, a2-macro-
globulin, ai-antitrypsin and protein C inhibitor determined at the start of each OC
regime (baseline or washout), during OC treatment and the calculated change
observed as a result of OC use. One woman was found to have a combined
heterozygosity for the factor vYeiden mutation and protein C deficiency (antigen and
activity levels 40% of normal). With the exception of this woman, plasma levels of the
various anticoagulant proteins at the start of the study were similar for both treatment
groups.
During treatment with levonorgestrel-containing OC, the plasma levels of protein C
(both antigen and activity), a2-macroglobulin and ai-antitrypsin significantly
increased, while the changes in antithrombin, protein C inhibitor and total and free
protein S did not reach statistical significance. The use of desogestrel-containing OC
had a more pronounced effect on the levels of the anticoagulant proteins and
resulted in statistically significant increases of a2-macroglobulin, ai-antitrypsin,
protein C inhibitor and protein C and in significant decreases in antithrombin and total
and free protein S. (Table 5.1). Differences between the
two OC preparations, however, only reached significance for the decrease in both the
total and free antigen levels of protein S.
The individual values determined for protein S (total and free antigen) are
shown in Fig. 5.2. Both total protein S and free protein S antigen showed a small
increase (4-5%, p>0.25) with levonorgestrel, whereas with desogestrel-containing
OC a significant decrease was observed (11-12%, p<0.005). The overall difference
between desogestrel- and levonorgestrel-containing OC was estimated to be
approximately 16% for both total protein S (p<0.005) and free protein S (p<0.0001,
Table 5.1). The individual with the factor VLeiden mutation, who was also deficient in
protein C had relatively high protein S levels (Fig. 5.2, open circles), but the changes
in protein S during OC use were similar as for the other volunteers.
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APC-res/sfance measurements
Two functional assays were used to evaluate the effect of OC's on the ability of
APC to down-regulate in vitro coagulation /.e. the classical aPTT-based APC
resistance test, which quantifies the effect of APC on the clotting time of plasma in
which coagulation is initiated via the intrinsic pathway and an assay which
determines the effect of APC on the time integral of thrombin formation (the
endogenous thrombin potential, ETP) initiated in plasma via the extrinsic coagulation
pathway. It should be noted that due to the calculation procedure APC-sensitivity
ratios (APCsr) show opposite trends in the two assays /.e. compared with normal
plasma, APC resistant plasmas will give a lower APC-sr in the aPTT-based assay
and higher APC-sr in the ETP-based assay (see also Fig. 5.3).
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Figure 5.2 Protein S antigen levels at different time intervals in the cross-over. (A) Total protein S
antigen (B) Free protein S antigen. Lev= levonorgestrel containing OC Dsg= desogestrel containing
OC. The open symbol represents the individual combined heterozygous for FV-Leiden and protein C
deficient.
Normalised APC sensitivity ratios were calculated for each treatment group at
each sampling time during the study (Fig 5.3). With the exception of one women with
a factor V|.e,den mutation (baseline ratio 3.13), the APCsr before OC use were similar
in the two groups and within the normal range. Fig. 5.3A shows the results obtained
with the aPTT-based APC resistance test. Levonorgestrel-containing OC caused a
minimal increase of the nAPC-sr whereas the use of desogestrel-containing OC
resulted in a slight decrease of the nAPC-sr (Fig. 5.3A, Table 5.1).
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Figure 5.3 nAPCsr values determined in the (A) classical undiluted aPTT-based assay and the (B)
ETP-based assay. The open symbol represents the individual combined heterozygous for FV-Leiden
and protein C deficient.
Figure 5.4 Change in normalised APC
sensitivity ratio during cross-over.
Difference between average increases in
ratios in phase 1 and phase 2, relative to
baseline or wash-out, respectively. Open
symbol represents heterozygous factor
Vuiden carrier.
o
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Thus, compared to levonorgestrel, exposure to desogestrel-containing OC was
associated with an increased resistance to APC in the aPTT-based APC-resistance
assay (p = 0.02, Table 5.1).
In both groups (including the FV|_eiden individual), the APCsr's increased
substantially during OC treatment (Fig. 5.3B). Also, the difference between the two
OC preparations was more pronounced in the ETP-based test (Fig 5.4) than
observed in the aPTT based APC resistance test. The use of desogestrel-containing
OC caused significantly higher resistance to APC than the use of levonorgestrel-
containing OC (p<0.0001, Table 5.1, Fig. 5.2), the mean difference being 0.51 (95%
Cl 0.37-0.66, Fig 5.4).
The average nAPCsr for the two cycles of either contraceptive (irrespective of the
treatment period) were plotted against the values calculated before the start of the
respective treatments (Fig 5.4). For both regimens, a highly significant correlation
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was observed between the ratio before and during OC therapy (r=0.81 (0.64-0.91) for
levonorgestrel and 0.83 (0.66-0.92) for desogestrel). The correlation remained when
the FV-Leiden individual was omitted from the regression analysis (0.69 (0.42-0.84)
and 0.75 (0.52-0.88) respectively).
0.5 1.0 1.5 2.0 2.5 3.0 3.5
nAPC-sr (before levonorgestrel)
0.5 1.0 1.5 2.0 2.5 3.0 3.5
nAPC-sr (before desogestrel)
Figure 5.5 Correlation plots of normalised APC sensitivity ratios before and during OC use. The open
symbol represents the FV-Leiden carrier.
Table 5.2 illustrates that the APCsr obtained with both APC-resistance assays
showed a rather weak correlation both before using OC and during levonorgestrel
treatment and a somewhat stronger association during the use of desogestrel-
containing OC. However, no association was observed between the changes of the
APCsr determined with both tests occurring as a result of OC-use.
Table 5.2 Correlations between ETP-based APC resistance mesurements and the aPTT-based APC
resistance measurements, total protein S and free protein S.
Correlation p-value Correlation p-value Correlation p-value
.r,-"" - « " ' - — Total Protein S Free Protein S
Ö~Öi
aPTT nAPCsr
Before OC use -0.43 0.02 -0.32 0.16 -0.54
During OC use
Levonorgestrel -0.49
Change with levonorgestrel-0.31
Desogestrel -0.61
Change with desogestrel -0.23
0.01
0.11
0.001
0.25
-0.52
-0.53
-0.51
-0.45
0.01
0.02
0.02
0.05
-0.49
-0.60
-0.66
-0.44
0.02
0.003
0.001
0.04
Pearson correlations (excluding the combined heterozygous FV-Leiden en Protein C deficient
individual) for the association between nAPC-sr determined in the ETP-based assay and the nAPCsr
determined in the aPTT and plasma protein S levels before and during OC use and for the change in
parameters as a result of OC treatment (relative to baseline or washout).
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ÄPC-res/sfance and profe/n S /eve/s. Since protein S is a cofactor for APC in
the inactivation of factors V(a) and Vlll(a) and hence may modulate the response to
APC in APC resistance tests, the data obtained with both assays were analysed with
respect to a possible association with protein S levels. In this analysis the individual
who was combined factor V|_eiden positive and protein C deficient was excluded. The
aPTT-based nAPC-sr values did not show an association with the protein S levels
determined (not shown). Table 5.2 shows the Pearson correlations observed for the
ETP-based assay. The nAPC-sr obtained with the ETP-based APC resistance test
showed association with protein S levels and also the change of the nAPC-sr
observed during treatment with both OC preparations correlated with the change in
protein S levels (Table 5.2). Free protein S values showed somewhat stronger
correlations than total protein S (Table 5.2).
D/scuss/on
In order to obtain more information on possible differential effects of second and
third generation OC on the anticoagulant pathways we have performed a randomized
cross-over study in which we compared the effects of levonorgestrel- and
desogestrel-containing OC on anticoagulant parameters known to be associated with
an increased risk for venous thromboembolic disease. These include protein C,
protein S and antithrombin as well as two APC-resistance assays, which assess the
ability of added APC to down-regulate coagulation. In addition, we determined the
plasma levels of protease inhibitors that may be involved in the regulation of the
activity of APC /.e. protein C inhibitor, a2-macroglobulin and ai-antitrypsin.
With regard to the trends of the changes of the anticoagulant proteins induced by
OC, the data presented here are in good agreement with earlier reports (for recent
reviews see.™ ®^  Both OC preparations caused some 10% increase in protein C
(both antigen and activity) and a2-macroglobulin and a marked increase (30-35%) in
ai-antitrypsin. The latter inhibitors have been implicated in the control of APC /n wfro
^"^ and /n v/vo ^ and their increase may, therefore, attenuate the effect of the raised
protein C level. With levonorgestrel, changes in the other proteins were not significant
but the use of desogestrel-containing OC resulted in significant changes of the
plasma levels of antithrombin, protein C inhibitor and protein S (cf. Table 5.1).
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A highly significant difference between the two OC preparations was observed
with respect to the effect of OC on protein S levels (cf. Table 5.1, Fig. 5.1). In
agreement with earlier reports we observed that total protein S ™°"™^  as well as free
protein S levels ^ ' ' " " decreased during the use of desogestrel-containing OC. In
contrast, treatment with levonorgestrel-containing OC resulted in a slight, but not
significant increase of the protein S level. This finding differs from an early report in
which lower protein S levels were found to be associated with the use of a
levonorgestrel-containing OC/°® but it is in agreement with a later study in which 11
women were followed during the first cycle of levonorgestrel-containing OC use™^
and in which a decrease in total protein S was observed during the second week of
hormone administration but no significant change was observed at the end of the pill
cycle. Thus, the increased protein C levels observed with both OC preparations will
be counteracted by decreased protein S levels during the use of desogestrel-
containing OC but not during the use of levonorgestrel-containing OC. Hence, the
anticoagulant potential of plasma of desogestrel-users will likely be less than that of
levonorgestrel users.
This assumption was corroborated by the overall APC-resistance measurements. In
agreement with others^ ™®"^  we observed that the nAPC-sr as determined with the
aPTT-based APC resistance test was marginally influenced by OC use (Table 5.1,
Fig. 5.2). APTT-based nAPC-sr values were not affected by levonorgestrel-containing
OC whereas treatment with desogestrel-containing OC caused a small increase in
APC-resistance (p<0.05, Table 1). Compared with second generation OC, the use of
third generation OC resulted in a small overall increased resistance to added APC in
the aPTT-based assay (p=0.02). Resistance to APC as determined in the ETP-based
assay was strongly increased on both OC, with desogestrel-containing OC causing
more pronounced APC resistance than levonorgestrel-containing OC (p<0.001, Table
5.1, cf. also Fig. 5.2), the latter result is in concordance with previous publications.
The mechanistic basis of the occurrence of acquired APC resistance during OC use
and of the different extents by which second and third generation OC affect the
anticoagulant action of APC remains to be established. Since neither the protein C
antigen and activity assays, nor the level of protein C inhibitor did show a significant
change it is tempting to speculate that other plasma components that regulate the
protein C pathway are involved in the increased resistance to APC. Rotteveel et a l . ^
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reported that the time integral of thrombin formation (ETP) in plasma of OC users
increased some 20%. Consistent with this, we observed that the ETP in the absence
of added APC (as reflected in the measurement of c^-maeroglobulin-thrombln
complexes, azM-ila) increased about 24% with levonorgestrel and 30% with
desogestrel-containing OC (data not shown). This increase is well explained by the
increased levels of prothrombin ^ (13% and 16%, respectively) and a2-
macrogiobuiin and the small decrease in antithrombin (Table 5.1). Since the ETP.^ pc
(ot2M-lia-APc) is in the denominator of the APCsr, a sole increase of thrombin
generation in the absence of APC during OC use would result in a decrease of the
APCsr rather than in the observed increase. Thus, the increase of the APCsr during
OC therapy observed with the ETP-based APC resistance test must be caused by a
profound increase of thrombin generation in the presence of APC. Since the
anticoagulant action of APC quantified in the aPTT-based assay is hardly affected by
OC, this indicates that the use of OC impairs the efficacy by which thrombin
formation, initiated via the extrinsic coagulation pathway is down-regulated by the
protein C system.
Although both APC-resistance assays are equally sensitive for the presence of the
factor VLeiden mutation,™® the correlation between APCsr determined with both assays
is surprisingly weak ™® (Table 5.2). On the basis of these observations we proposed
that both assays are differentially modulated by other plasma components ™°. One
such a component appears to be protein S. The classical aPTT-based APC-sr is
rather insensitive to variations in protein S " * ^ . The results obtained in the present
study confirm that protein S levels (both total and free antigen) do not correlate with
the aPTT-based nAPC-sr. The ETP-based assay, however, appears to be influenced
to some extent by protein S levels, particularly by free protein S (Table 5.2). It should
be noted that the observed changes in protein S levels cannot fully account for the
increased nAPC-sr values during OC use since in the period of treatment with
levonorgestrel-containing OC the average protein S levels did not significantly
change, while the nAPC-sr determined with the ETP-based assay significantly
increased (Table 5.1). It appears, therefore, that the overall increase in nAPC-sr
observed in the ETP-based assay during OC use is modulated by changes in protein
S, but that these changes can only partially explain the OC-induced increase of the
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APCsr. However, the data presented here clearly point to an important role for
protein S in determining the APC-resistant plasma phenotype observed with the ETP-
based assay and in the different extents of acquired APC resistance occurring during
the use of levonorgestrel- and desogestrel-containing OC preparations.
Hereditary APC resistance caused by the FV-Leiden mutation is associated with an
increased risk for venous thrombosis. Moreover, there seems to be a correlation
between normalised APC sensitivity ratios calculated by quantification of the effect of
APC on thrombin generation and the risk increase of venous thrombosis in OC users
and in carriers of the FV-Leiden mutation (PART I, Chapter 4).Taken together these
findings suggest that acquired APC resistance may explain the increased thrombotic
risk for OC users, and the suggested further risk reported for users of desogestrel-
containing preparations. One report, however, concluded that acquired APC
resistance, established via a tissue-factor-initiated test, had no association with
venous thromboembolism. Analysis of the plasma collection of the Leiden
Thrombophilia Study showed that APC sensitivity ratios calculated with the same
APC resistance test as that used in our study predict the risk for venous thrombosis
in both carriers and non-carriers of FV-Leiden. In addition, there are several other
indications that acquired APC resistance may have clinical implications and that APC
resistance in the absence of the FV-Leiden mutation is a risk factor for venous
thrombosis.
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Chapter 6
Changes in
APC Resistance
during IVF-treatment
Based on.
Effecfs of /n WYro Fert///zaton Treafmenf and subseguenf pregnancy on fne Prote/n C pafnvvay. J.
Cun/ers, /A. W. A/ap, M.C.L.G.D. Tnomassen, S. J. A//en/7U/s, K. Hamu/yäfc, J. L H. Evers, G. Tans and
J Ros/ng. Accepted for publication
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Summary
Subfertile women who were planned for an In Vitro Fertilization (IVF) cycle
donated blood at four time points during treatment; at baseline and after down
regulation, hyperstimulation and luteal support. Levels of progesterone, 17ß-estradiol
and indicators of the protein C pathway, ;.e. APC sensitivity ratios (APCsr), protein C,
protein C inhibitor and protein S, were measured.
Compared to baseline, estradiol decreased 2-fold at down-regulation and
increased 40-fold at hyperstimulation. Progesterone was elevated 2.5 fold at
hyperstimulation and 40-fold at luteal support. The APCsr slightly increased at down
regulation, significantly increased during hyperstimulation and remained high during
luteal support. The plasma levels of the anticoagulant proteins did not or moderately
change during treatment. During down regulation, progesterone correlated negatively
with APCsr (r= - 0.398, p=0.024). At hyperstimulation estradiol correlated with the
APCsr (r=0.615, p<0.0005). Moreover, there was a significant correlation (r=0.599,
p<0.0005) between the difference in baseline and hyperstimulation values of
estradiol (AE2 = 6.6 nmol/L) and the APCsr (AAPCsr = 0.30). Six women who
participated in this study became pregnant. Compared to baseline the APCsr was
increased 1.9-fold (AAPCsr = 1.48) and free protein S free level decreased 30% at 7
weeks of pregnancy.
This study demonstrates that despite the considerable changes of
endogenous estradiol and progesterone during an IVF cycle, changes in plasma
levels of anticoagulant proteins are moderate. The significant increase of the APCsr
during hyperstimulation indicates that acquired APC resistance observed during sex
steroid hormone changes in women is at least partially caused by high estrogen
levels. Our findings demonstrate that IVF treatment is accompanied by the
development of a mild prothrombotic condition.
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/nfrocfucf/on
Hormonal changes in women occurring during pregnancy, the use of oral
contraceptives (OC) or hormone replacement therapy (HRT), have been associated
with an increased risk for venous thromboembolism (VTE)^ ^ ^ ^ Many
investigators have studied the effect of hormonal changes on haemostatic
parameters in an attempt to explain the increased risk of VTE. Both during
pregnancy^' ^ ^ and OC use™ ^ ^ "*•"® marked changes in the proteins involved
in coagulation, anticoagulation and fibrinolysis were observed. The use of OC is
associated with changes in the procoagulant (increased prothrombin, factor VII and
factor X) and anticoagulant pathways (decreased protein S and increased APC
resistance) that result in a prothrombotic state which might be responsible for the
increase in VTE. Particularly the occurrence of APC resistance, which is a risk factor
for VTE both in the presence®® "® and absence of the factor V|.eiden mutation,""• ^
was suggested to contribute to the thrombotic risk during OC use^ ®° ^ and
pregnancy.'"
The mechanistic basis for the hormone-induced changes of haemostatic
parameters is still unclear. In vitro fertilisation (IVF) treatment is a unique model to
study effects of hormones on the coagulation system since during the IVF cycle
endogenous estradiol and progesterone levels change considerably within a short
period of time. Yet, thrombosis as a consequence of IVF treatment is a rare evenf"
^ which mainly occurs during ovarian hyperstimulation syndrome.^" The fact that
changes of coagulation parameters during IVF treatment are modest^'^® is in line
with the low risk for venous thrombosis. Recently, however, two case reports were
published of APC resistant women who suffered a thrombotic event during IVF
treatment.^ ^° According to the literature IVF treatment itself does not cause APC
resistance^ ^ but in these studies an APC resistance test was used which
quantifies the effect of APC on the intrinsic coagulation pathway and which is much
less sensitive to changes of sex steroids than the tissue factor-based APC resistance
test used in investigations of OC.™®
To obtain insight in the biological basis and the extent of hormone-induced changes
of coagulation parameters, especially of APC resistance determined via the extrinsic
coagulation pathway, we have investigated the effect of estrogen and progesterone
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changes on the protein C system in women undergoing IVF treatment and in the
subgroup of women who became pregnant during the IVF cycle.
Mafer/a/s and methods
Des/gn This study was approved by the Medical Ethics Committee of the
Academic Hospital in Maastricht. At intake for IVF treatment, women were asked to
participate in this study and were included after written informed consent was given.
The women who agreed to participate donated blood at four time points (cf. Fig. 1)
during IVF treatment: (1) at baseline on menstrual cycle day 2, 3 or 4 before starting
with an OC preparation containing 30ug ethinylestradiol and 150ug levonorgestrel
(Microgynon 30, Schering), (2) at maximal down regulation after approximately 14
days of treatment with nasal spray containing the gonadotropin releasing hormone
(GnRH-) analogon, Synarel (Nafarelin, Searle), (3) at maximal stimulation after
treatment (average 15 days) with follicle stimulating hormone (FSH, Puregon, 100 to
250 IU follitropin, Organon, Oss, The Netherlands) and before a human chorionic
gonadotropin (hCG) injection (5000 IU Pregnyl, Organon) was given and (4) one
week after the embryo transfer during the luteal support (3x200 M9 Progestan,
Organon) period. From the women who became pregnant additional blood samples
were taken 2 and 4 weeks after embryo transfer which means at 5 and 7 weeks
pregnancy.
Co//ecf/on and hand/ing of b/ood samp/es Women were asked to abstain
from food overnight. The next morning, after 15 minutes rest, they were punctured in
the anticubical vein of the fore-arm. Blood was collected in EDTA (Vacutainer, Becton
Dickinson), in thrombin-coated tubes (Vacutainer) and in 0.129 M sodium citrate
(Greiner, Germany). Blood collected in citrate was centrifuged 5 min at 3,000xg at
room temperature. The cell free plasma was subsequently centrifuged for 10 min. at
11,000xg at 4°C. Plasma was frozen at -80°C in small aliquots until use.
Deferm/naf/on of b/ood and p/asma variab/es. Haemoglobin, haematocrit,
platelet count, mean platelet volume and mean cell volume were determined using a
Coulter® Gen S system in whole blood collected in EDTA that was left for 2 hours at
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Figure 6.1 Design of the study. Arrows indicate the time of blood sampling. M+S = Microgynon 30 + Synarel.
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room temperature. Hormone levels of progesterone and 17ß-estradiol were
determined in serum by a fluorescence-enzyme immunoassay (AutoDELFIA TM,
Wallac Oy, Turku, Finland) at the Department of Clinical Chemistry of the Academic
Hospital Maastricht.
The ETP (endogenous thrombin potential)-based APC resistance assay, the
principle of which was described before ^ ^ , quantifies the effect of 5 nM human
APC (Enzyme Research Laboratories, Kordia Laboratory Supplies, Leiden, The
Netherlands) on thrombin generation initiated in plasma with 0.4 ng/L recombinant
tissue factor (DADE®lnnovin®), 16 mM CaCb and 15 (.iM phospholipid vesicles
containing 20 mole% i^-dioleoyl-sn-glycero-ß-phosphoserine, 20 mole% 1,2-
dioleoyl-sn-glycero-3-phosphatidylethanolamine and 60 mole% 1,2-dioleoyl-sn-
glycero-3-phosphatidylcholine (Avanti Polar Lipids, Alabaster, Alabama, USA). The
concentrations given are final concentrations present in plasma during thrombin
generation. The amount of thrombin captured by a2-macroglobulin, ;.e. the amidolytic
activity of the a2-macroglobulin-thrombin complex (ct2M-lla) was used as an end-point
marker to quantify thrombin generation ^ . The APC sensitivity ratio (APCsr) was
defined as the ratio of the amounts c^M-lla determined in the presence and absence
of APC: APCsr = (c^M-lla+APC^M-lla.APcWma sample
which was normalised through division by the same ratio determined in the normal
plasma pool (cf. ^ ) . Since APC inhibits thrombin generation and prolongs the
activated partial thromboplastin time (aPTT), APC-sr determined with the ETP-based
assay exhibit trends that are the reverse of APC-sr determined with aPTT-based
APC resistance tests (APC-sr = aPTT+APc/aPTT.APc) ^- Compared to normal pooled
plasma, samples of APC resistant individuals yield higher APC-sr in the ETP-based
assay and lower APC-sr in aPTT-based assays.
The presence of the factor V|_eiden phenotype was determined with a functional
assay that measures the sensitivity for APC of factor Va present in a highly diluted
plasma ^. Since this assay is performed with more than 1000-fold diluted plasma it is
100% sensitive for the factor V|_eiden mutation. Thus far no individuals were found who
were APC resistant in this assay and who were not carrying the factor VLe.den
mutation. Total and free protein S were measured by enzyme-linked immunosorbent
assay (ELISA) using a polyclonal antibody against total protein S or a monoclonal
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antibody against free protein S, respectively (REAADS purchased from Nodia,
Amsterdam, The Netherlands). Protein C activity was determined after activation of
protein C in diluted plasma to which 0.05 U/ml Protac (Kordia Laboratory Supplies,
Leiden, The Netherlands) was added. Activated protein C was quantified with S2366
(Chromogenix, Mölndahl, Sweden). Protein C antigen was measured with an ELISA
using a polyclonal anti-human protein C as capturing antibody (DAKO) and a
horseradish peroxidase conjugated rabbit-anti-human protein C (DAKO) as
secondary antibody. Protein C inhibitor (PCI) levels were also determined by ELISA,
using a monoclonal against PCI (API-93) as capturing antibody and a horseradish
peroxidase conjugated polyclonal rabbit anti-PCI as secondary antibody ^ .
Values determined for total and free protein S, activity and antigen levels of
protein C and protein C inhibitor are expressed as percentage of that determined in
pooled normal plasma prepared from plasma of 49 men and 25 women (pregnant
women and OC users were excluded) with a mean age of 37 years.
Sfat/sf/cs All samples of one woman were determined in duplicate in a single
experiment and compared to normal pooled plasma determined in the same run.
Differences between visit 1 (baseline) and the following visits were compared using a
paired t-test. Correlations between variables were calculated on the basis of non-
parametric Spearman rank correlation coefficients.
Resu/fs
C/iaracfer/sf/cs of part/c/panfs
The schedule of IVF treatment and the time points at which blood samples were
taken are indicated in Fig 6.1. Baseline characteristics of the women who participated
in this study are summarised in Table 6.1. Of the 41 women who had given informed
consent and who started IVF treatment, 33 completed the cycle. One woman was
excluded since embryo transfer was not possible due to unsuccessful fertilisation of
the oocytes. Two women, responded poorly to FSH and treatment was stopped. Five
women discontinued treatment because of signs of threatening of ovarian
hyperstimulation syndrome. The coagulation parameters of these women at visit 1
and 2 did not significantly differ from those of the women who completed the IVF
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Table 6.1 Baseline characteristics of the women who were
included in the study and completed the IVF treatment
Variable
Indication for assisted
reproduction
IVF-cycle
number of women (%)
tuba obstruction
unexplained
male factor
1
2
3
>3
Amount of Puregon (FSH) 100
Nr of oocytes retrieved
150
200
250
<5
5-10
>10
Nr of fertilised oocytes (2PN)* <5
5-10
>10
1 (3%)
12 (37%)
20 (59%)
15(46%))
11 (33%)
5(15%)
2 (6%)
1 (3%)
2 (6%)
13(39%)
17(52%)
10(30%)
12(37%)
11 (33%)
16(49%)
15(46%)
2 (6%)
' Of one women the oocytes could not succesfully be fertilized.
cycle. From the women with threatening ovarian hyperstimulation syndrome no blood
samples of visit 3 and 4 were available. The average age of the 33 women who
completed IVF treatment was 33 years. The mean body mass index was 24.2 (95%
Cl 23.8-25.1) and six women were smokers who on the average smoked 10
cigarettes per day.
None of the volunteers experienced clinical symptoms of venous thrombosis
during treatment. In 33 women oocytes were successfully retrieved and fertilised.
One woman exhibited the factor V|_eiden phenotype. She is indicated by the half filled
circles in Fig 2 and her APCsr values during IVF treatment are separately given in
Table II. Six women became pregnant and donated additional blood samples at 5
weeks and 7 weeks of pregnancy /.e. 2 and 4 weeks after embryo transfer.
Effects of/VF treatment on who/e b/ood measurements
Of the whole blood measurements (Table 6.2), haemoglobin, the haematocrit
and the mean cell volume significantly increased from baseline values after down-
regulation (p<0.05). At hyperstimulation these variables returned to base-line and at
luteal they dropped to values below base-line. The changes of haematocrit during
Chapter 6 Changes in APC during IVF treatment 117
IVF treatment were relatively minor. Hence, the effects of haemoconcentration or
haemodilution on the haemostatic variables reported below were negligible.
Effecfs of /VF freaf/nenf on /»or/none /eve/s
Progesterone and 17ß-estradiol changed as expected (Table 6.2). Compared
to the baseline level (0.15 nmol/L), 17ß-estradiol was significantly decreased in the
down-regulated phase (0.08 nmol/L) and rose during hyperstimulation to 6.76 nmol/L
(95% Cl 5.10-8.42). During luteal support 17ß-estradiol levels decreased to 0.38
nmol/L, which was still higher than the baseline level. Progesterone did not
significantly change during down-regulation, but became significantly elevated during
hyperstimulation (from 1.16 to 2.86 nmol/L) and increased considerably during luteal
support (46.2 nmol/L, 95% Cl 39.6-52.8 nmol/L).
Table 6.2 Effects of IVF treatment on hormones, erythrocytes, platelets and the protein C system in 33
women who completed IVF treatment
Variable
Baseline
(visit 1)
mean (95% C.I.)
Downregulation
(visit 2)
mean (95% C.I.)
Hyperstimulation
(visit 3)
mean (95% C.I.)
Luteal support
(visit 4)
mean (95% C.I.)
17-ß-Estradiol 0.15(0.13-0.17) 0.08* (0.06-0.10) 6.76* (5.10-8.42) 0.38* (0.23-0.53)
Progesterone 1.16 (1.00-1.32) 1.13(0.88-1.38) 2.86* (2.44-3.29) 46.2* (39.6-52.8)
Haemoglobin 8.3(8.1-8.4)
Haematocrit 0.40(0.39-0.41)
Mean cell volume 91.1 (90.2-92.0)
Platelet count (x10^/L) 271 (250-291)
Mean platelet volume 8.2 (8.0-8.4)
Protein S total (%) 91.5 (85.2-97.8)
Protein S free (%) 87.7 (80.5-94.9)
Protein C activity (%) 101.4 (95.9-106.9)
Protein C antigen (%) 105.3 (99.6-111.1)
Protein C inhibitor (%) 83.5 (78.4-88.6)
APCsr* 1.73(1.49-1.97)
APCsr Of FVLeiden 4.41
8.5* (8.4-8.7)
0.41* (0.41-0.42)
91.6* (90.7-92.5)
276 (255-296)
8.3 (8.0-8.5)
95.4* (89.1-101.8)
92.8* (84.9-100.7)
105.7" (99.1-112.3)
105.1 (98.2-112.0)
84.0 (79.2-88.7)
1.79(1.54-2.04)
5.50
8.2 (8.0-8.3)
0.40 (0.39-0.40)
91.2(90.2-92.1)
247* (230-264)
8.4(8.1-8.6)
88.4* (82.0-94.9)
87.1 (81.0-93.2)
104.2(98.0-110.4)
105.6(99.2-112.0)
84.7 (80.0-89.5)
2.03* (1.72-2.35)
6.37
8.1* (8.0-8.3)
0.39* (0.38-0.40)
90.9(90.0-91.8)
276 (255-298)
8.4* (8.1-8.6)
90.3 (84 5-96.2)
87.8(81.9-93.6)
102.3(96.0-108.6)
104.8(97.4-112.2)
82.2 (77.0-87.5)
1.93* (1.71-2.15)
5.29
* mean and 95% Cl are given excluding the women with heterozygous factor V|_e,den phenotype
significantly different from baseline *(p<0.05) or *(p<0.005)
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E/fecf of /VF freafmenf on anf/coagu/anf parameters
Table 6.2 also summarizes the effects of IVF treatment on the anticoagulant
parameters. Compared to the baseline value (91.5%), the total protein S levels
increased slightly at down-regulation (95.4%), decreased during hyperstimulation
(88.4%) and did not differ from baseline levels during luteal support (90.3%). Free
protein S only increased at down-regulation (92.8%) and returned to baseline values
during hyperstimulation (87.1%) and during luteal support (87.8%). Protein C antigen
did not substantially change during IVF treatment. A modest increase of the protein C
activity was observed at down-regulation and during the other phases of treatment
(Table 6.2). Protein C activity levels correlated with the antigen measurements
(r=0.848, p<0.0001). Protein C inhibitor levels did not change during the in vitro
fertilisation cycle.
Table 6.2 and Fig. 6.2 show that the APCsr values slightly increased from 1.73 at
baseline to 1.79 during down-regulation. At hyperstimulation the APCsr reached a
maximum (2.03) and decreased slightly during luteal support (1.93). The subject with
the factor VLeiden phenotype, who was excluded from the analysis of the mean APCsr
values, had a baseline APCsr of 4.41. During down-regulation her APCsr increased
to 5.50, increased further to 6.37 at hyperstimulation and decreased again during
luteal support (APCsr = 5.29).
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Figure 6.2 Effect of IVF treatment on the APCsr. Visit 1 refers to baseline,
Visit 2 refers to downregulation after treatment with GnRH analogon, visit 3
is at maximum stimulation and visit 4 is during luteal support. Visit 5 and
visit 6 refer to plasma samples taken at 5 and 7 weeks of pregnancy
following IVF treatment. The half filled circle represents a woman with
heterozygous Fv i^den phenotype. The closed circles at visit 4, 5 and 6
represent the six women who became pregnant after OVF treatment. APC
sensitivity ratios were determined as described in the materials and
methods section. Horizontal bars represent the mean APCsr value.
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Effecfs of ear/y pregnancy on anftcoagu/ant parameters
Six women who participated in this study became pregnant. The plasma levels
of anticoagulant proteins (Table 6.3) and the APCsr of these women (Fig 6.2, Table
6.3) did not differ from the women who did not become pregnant. Analysis of
additional blood samples showed that protein C antigen and activity did not change
during the first weeks of pregnancy (Table 6.3). Protein C inhibitor levels increased in
5 out of 6 women at week 5 and returned to normal levels after 7 weeks of
pregnancy. The plasma protein S level and APC resistance measurements revealed
no changes at week 5. However, after 7 weeks of pregnancy the APCsr was
increased from 1.93 at the end of IVF treatment (luteal support) to 3.20 (mean
change 1.27, 95%CI 0.54-2.01). Total protein S decreased 12% (95%CI 4-21%) and
the decrease of free protein S was even more pronounced (mean change 27%,
95%CI 17-38%).
Table 6.3 Effects of IVF treatment on hormones, erythrocytes, platelets and the protein C system in 6
women who became pregnant
Baseline Luteal support 5 week pregnant 7 week pregnant
(visit 1) (visit 4) (visit 5) (visit 6)
mean (95% C.I.) mean (95% C.I.) mean (95% C.I.) mean (95% C.I.)Variable
17-ß-Estradiol
Progesterone
Haemoglobin
Haematocrit
Mean cell volume
Platelet count (x1f//L)
Mean platelet volume
Protein S total (%)
Protein S free (%)
Protein C activity (%)
Protein C antigen (%)
Protein C inhibitor (%)
APCsr
0.17(0.13-0.21) 0.51(0.17-0.85) 2.31(0.29-4.32) 6.44(0 76-12.13)
0.95(0.61-1.29) 56.0(22 4-89.6) 258(30 7-486) 210(0-492)
8.1 (7.7-8.5)
0.39(0.37-0.41)
90.5 (88.7-92.4)
278 (228-328)
8.1 (7.8-8.3)
87(81-93)
88(75-102)
98(80-116)
110(86-134)
86 (79-93)
8.1(7.7-8.4) 8.2(7 7-8.6) 7.6(7.1-8 0)
0.39 (0.37-0.41) 0.39 (0.37-0.42) 0.36 (0.34-0.39)
90 3(87 8-92.7) 90.3(88.2-92.3) 89.1(85.4-92.7)
287(255-318) 324(288-370) 289(274-305)
8.4(7.7-9.1) 8.3(7.7-8.9) 8.0(7.2-8.8)
97(84-111)
87 (79-95)
105(74-136)
110(75-144)
91 (76-105)
96(83-108)
81 (69-93)
103(85-121)
104(81-127)
98(87-110)
85 (77-93)
60 (46-74)
100(81-120)
102 (77-127)
87 (77-98)
1.72(1.07-2.37) 1.93(1.42-2.43) 1.79(1.29-2.29) 3.20(2.02-4.39)
Corre/af/ons berween nor/none /eve/s and coagu/af/on parameters
During down regulation ;.e. at low estradiol levels the plasma progesterone
concentration correlated negatively with the APCsr (r=- 0.398, p=0.024, Fig 3A).
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During hyperstimulation there was a correlation between 17ß-estradiol and the APCsr
(r=0.615, p<0.0005, Fig 3B). Total protein S correlated slightly with 17ß-estradiol at
hyperstimulation (r=-0.386, p=0.029). The change in 17ß-estradiol from baseline to
hyperstimulation correlated with the change in APCsr, r=0.599, p<0.0005 (Fig 3C).
No other significant correlations were observed between the levels or the changes of
hormones and coagulation parameters.
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Figure 6.3 Correlation plots between
progesterone, 17ß-estradiol and APCsr values.
Correlations between (A) APCsr and
progesterone at the down-regulated state, visit
2; (B) APCsr and 17ß-estradiol at
hyperstimulation, visit 3; (C) the change of the
APCsr and 17ß-estradiol from visit 1 to visit 3
(hyperstimulation minus baseline). The half-
filled circle represent a women with a
heterozygous factor V^den, phenotype (omitted
from the correlation analysis). The lines given
in these plots were obtained by linear
regression. Correlation coefficients and p-
values presented in the results section were
calculated using Spearman's rho
inu
Q.
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At baseline the APCsr correlated with total protein S levels (r= - 0.43,
p=0.013), a correlation that was maintained at down-regulation (r= - 0.624,
p<0.0001), hyperstimulation (r= - 0.483, p=0.005) and during luteal support (r= -
0.534, p=0.002). A similar correlation was observed between the APCsr and free
protein S levels during the first three visits (r= - 0.511, p=0.003; r= - 0.483 p=0.005
and r= - 0.390, p=0.02, respectively), but not during luteal support. Although the
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absolute values of the APCsr and protein S correlated with each other during the
different phases of IVF treatment there appeared to be no correlation between the
changes of the APCsr and protein S. However, a strong correlation was observed
between the decrease of free protein S and the increase of the APCsr in the women
who became pregnant after IVF treatment (r = - 0.657, baseline minus 7 weeks
pregnancy). This correlation did not reach significance (p = 0.156) which is
presumably due to the fact that only a low number of pregnant women (n = 6) were
available for statistical analysis.
D/scuss/on
We have investigated the effects of the changes in endogenous estradiol and
progesterone during IVF treatment and subsequent pregnancy on haemoglobin,
haematocrit, platelets and on a number of haemostatic parameters that probe the
activity of the protein C pathway. Despite considerable changes in the plasma
concentrations of estradiol and progesterone, IVF treatment had modest effects on
haemoglobin, haematocrit, platelets and on the plasma levels of the proteins involved
in the protein C pathway. With respect to the anticoagulant proteins our observations
confirm earlier studies which indicated that hyperstimulation induced only marginal
changes of coagulation parameters.^ 5-127 Q ^ g ^ y also shows that during down-
regulation and luteal support the changes of the plasma levels of anticoagulant
proteins are virtually negligible.
The only coagulation parameter that changed considerably during IVF
treatment was the APCsr. In this study we observed that hyperstimulation ;.e. high
estrogen levels induce APC resistance and that under these conditions both the
absolute values and the changes of the APCsr and the estrogen levels
(hyperstimulation - baseline) correlate significantly. Previously, it was reported that
high estrogen levels are not associated with APC resistance ^ ' " \ However, the
APC resistance test used in these studies, which is based on quantification of the
effect of APC on the clotting of plasma initiated via the intrinsic coagulation pathway,
is not very sensitive to changes of sex hormones.™® In the present study an assay
was used that quantifies down-regulation of extrinsic coagulation by APC and that is
particularly sensitive to hormonal changes in women.^ ^ "" ' " The fact that
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according to this test the large increase of estrogen during ovarian stimulation is
accompanied by APC resistance indicates that acquired APC resistance occurring
during OC use^' ^ and pregnancy^ "^  is at least partially due to elevated levels of
estrogen. However, second and third generation OC have different effects on
coagulation parameters^ ^ while they contain the same amount of ethinylestradiol
which suggests that the progestagens (levonorgestrel or desogestrel/gestodene) also
influence the coagulation system. The present study shows that profound changes in
natural progestagen (40-fold) have modest effects on the APCsr. Only during down-
regulation of estradiol a significant negative correlation was found between the
progesterone level and the APCsr. This suggests that under certain conditions
progesterone can counteract the response of the coagulation system to estradiol, a
phenomenon that was also observed by Kluft et a l . ^
In OC users a decrease of the plasma level of protein S partially explains
acquired APC resistance.^ However, in all phases of IVF treatment the changes in
the levels of proteins involved in the protein C pathway (including protein S) were
minimal and did not correlate with the changes in APCsr. Thus, it is likely that
changes in plasma proteins other than protein S are responsible for the acquired
APC resistance induced by hyperstimulation.
It is well established that pronounced APC resistance develops during
pregnancy.^ "^  Six women who participated in the present study became pregnant.
At 7 weeks of pregnancy they had APCsr that were two times higher than the
baseline value (AAPCsr = 1.48) and their plasma level of free protein S decreased
-30%. It is interesting note that in these women the estrogen levels at 7 weeks of
pregnancy were similar to those observed after hyperstimulation. Therefore, the large
increase of the APCsr and the decrease of the plasma level of free protein S in early
pregnancy are likely caused by other changes occurring in the first weeks of
pregnancy. These changes primarily cause a decrease in protein S which for a large
part is responsible for the increase in APC resistance. This is concluded from the fact
that the differences between the protein S levels at baseline and during early
pregnancy correlated with the increase of the APCsr. A change of the APCsr and
plasma protein S levels that early in pregnancy has not been shown before. Kjellberg
et al^ reported that protein S decreases to 40% after 10 weeks of pregnancy. The
decrease in free protein S and the increase in APC resistance observed here
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indicates that a hypercoagulable state already develops within the first 7 weeks of
gestation.
Although estradiol and progestagen levels increase considerably during in
vitro fertilization, clinical complications such as venous thrombosis are very rare. The
synthetic hormones present in OC are far more potent than the natural/endogenous
17ß-estradiol and progesterone."^ This might explain why, compared to OC, high
concentrations of natural hormones have only marginal effects on haemostatic
parameters. The change of the APCsr caused by hyperstimulation (AAPCsr = 0.30)
was less than that occurring during the use of second generation (AAPCsr = 0.77) or
third generation (AAPCsr = 1.29) oral contraceptives^ ^ or early pregnancy
(AAPCsr = 1.48, this paper). It should be emphasized, however, that the effect of
hyperstimulation concerns a mean change. In some women (n = 5) the increase in
APCsr was > 0.80. When such a change occurs in women with a hereditary risk
factor of venous thrombosis this results in a temporary aggravation of an existing
prothrombotic condition and in a further increased risk of venous thrombosis.^® " °
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Sum/nary
Compared with second generation oral contraceptives, the use of third
generation oral contraceptives has been associated with a higher risk of venous
thrombosis, particularly in women with the factor VLeiden mutation. To find an
explanation for these risk differences we investigated the effects of second and third
generation oral contraceptives and of the progestagens used in these pills on the
anticoagulant pathway in women with and without factor VLeiden-
In a single center, double blind trial, 51 women without and 35 women with
factor VLeiden were randomized to either a second generation (30|.ig ethinylestradiol /
150(.ig levonorgestrel) or a third generation (30(.ig ethinylestradiol / 150|.ig
desogestrel) oral contraceptive. After two cycles of use and a wash-out of 2 cycles,
the participants received the corresponding progestagen-only preparation containing
150|.ig levonorgestrel or 150|ag desogestrel. In plasma of the participating women
hemostatic variables that probe the activity of the anticoagulant protein C system
were determined.
Both combined preparations induced APC resistance, increased plasma levels
of protein C and protein C inhibitor and caused a decrease of protein S, C4b-binding
protein and the APC independent anticoagulant activity of protein S. Compared with
levonorgestrel, desogestrel-containing oral contraceptives significantly decreased
protein S and increased APC resistance in both study populations. Oral
contraceptives with desogestrel had more pronounced effects in carriers than in non-
carriers of factor VLeiden, a trend which reached statistical significance for APC
resistance and C4b-binding protein. Progestagen-only preparations caused changes
of anticoagulant parameters opposite to those of combined oral contraceptives and
which in a number of cases were more pronounced with levonorgestrel.
Progestagens in combined oral contraceptives counteract the thrombotic effect
of the estrogen component. The observation that of desogestrel is less antithrombotic
than levonorgestrel, can explain the different thrombotic risks associated with the use
of second and third generation oral contraceptives, especially in women with factor
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/nfroducf/on
In 1995 and 1996 four studies reported that women who used so-called third
generation oral contraceptives containing desogestrel or gestodene were at higher
risk of venous thromboembolism than users of oral contraceptives with the second
generation progestagen, levonorgestrel." ^ The absolute risk of venous thrombosis
associated with the use of particularly third generation oral contraceptives is further
elevated among carriers of the factor Vi_eiden mutation," ^ a hereditary disorder in
which activated factor V is inactivated by activated protein C (APC) at a lower rate
than normal factor V a . ^ " ^ This hereditary defect, also called APC resistance, is a
common risk factor for venous thrombosis which is associated with a three- to seven-
fold increased risk in heterozygous individuals.^"^
A plausible biological mechanism for the thrombotic effects of second- and third-
generation oral contraceptives is still lacking. Rosing et a l " ^ reported that oral
contraceptive use leads to acquired APC resistance. Women using third generation
oral contraceptives were more resistant to the anticoagulant action of APC than users
of second generation oral contraceptives and that the effects of oral contraceptives
and factor V|_eiden on the APC sensitivity ratio (APC-sr) were additive.'® A recent
cross-over study indicated that second and third generation oral contraceptives not
only cause differences in acquired APC resistance, but also have different effects on
a large number of other procoagulant, anticoagulant and fibrinolytic parameters.^ " ^
^ Particularly the differential changes of the proteins involved in the protein C
system may contribute to the thrombotic effects of oral contraceptives.^ The protein
C system, which comprises the plasma proteins protein C and protein S, down-
regulates /n wVo blood coagulation^® via proteolytic inactivation of coagulation
factors Va and Villa. Protein S, which acts as cofactor of APC, also exhibits
anticoagulant activity independent of APC by directly inhibiting thrombin formation.'^
The anticoagulant activity of protein S is modulated by C4b- binding protein, which
binds some 60% of plasma protein S.'*° "" The physiological importance of the
protein C system is illustrated by the fact that defects in this pathway are associated
with an increased risk of venous thromboembolism.^ 1^9.1920 j ^ g thrombotic risk of
women with hereditary defects in the protein C pathway is enhanced by oral
contraceptive / *
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For a long time, the increased thrombotic risk associated with oral
contraceptive use was attributed to the estrogen component. Because low dose
second and third generation oral contraceptives contain the same estrogen dose, the
differences may reflect a progestagen-specific effect. Although it has been proposed
that progestagens have estrogen-like effects,^ among others on hemostasis,^ there
is as yet no data on the influence of levonorgestrel or desogestrel in the absence of
the estrogen component on the protein C pathway.
To gain more insight in the biological basis of an enhanced risk of venous thrombosis
in oral contraceptive users, particularly in carriers of factor VLeiden, we performed a
double blind, randomized trial in which we determined the effects of second and third
generation progestagens, alone or in combination with estrogens, on the protein C
pathway in the absence or presence of the factor VLeiden mutation.
Methods
Study des/gn and part/c/panfs Figure 1 illustrates the design of the trial in
which 51 women without and 35 with factor VLeiden were randomly assigned to one of
two different combination pills containing either 30 |ig ethinylestradiol and 150 pg
levonorgestrel or 30 (.ig ethinylestradiol and 150 ng desogestrel. These formulations
are identical to those commercially marketed. The oral contraceptives were used for
a period of 2 menstruation cycles (phase 1). After a wash-out of two menstrual
periods, the participants were treated with a corresponding progestagen-only
preparation containing either 150 ^g levonorgestrel or 150 ng desogestrel. These
progestagens were used for a period of 2 menstruation cycles without a stopweek to
provide full contraceptive safety (phase 2). Randomization was done in blocks of ten.
Blood samples were taken at the end of phase 1 (days 47±2 and 49±2), at the end of
the wash-out period (days 101 ±2 and 105±2), and at the end of phase 2 (days 152±2
and 154±2). For reasons of safety, ultrasound examination of the veins of both legs
was performed before the start of the study, after the wash-out period and at the end
of phase 2, to exclude venous thrombosis.
Exclusion criteria were a history of any malignant disorder, cardiovascular,
cerebrovascular, hepatic or renal diseases, venous thrombosis, epilepsy or classical
migraine, vaginal bleeding of unknown etiology, pregnancy, rheumatoid arthritis,
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diabetes mellitus, psychiatric disorders, alcohol abuse or drug abuse within the last
12 months, heavy smoking, excessive obesity, chronic infectious diseases and
suffering from any other serious disease. Moreover, volunteers with a contra-
indication to estrogens and/or progestagens were excluded.
FVLeiden
negative (n=51)
FVLeiden
positive (n=35)
Desogestrel
containing OC*
Levonorgestrel
containing OC*
Desogestrel
containing OC*
Levonorgestrel
containing OC*
Stop
Week
No use
No use
No use
No use
Desogestrel only*
Levonorgestrel
only*
Desogestrel only*
Levonorgestrel
only*
J I ' '**
' 0 f J h a s f e l 7'
' xx
14' phase 2
' xx
2 f
Duration of the study in weeks ->
* Desogestrel containing OC: 30/jg ef/?/ny/ esfrad/o/ + 750/jg desogesfre/. Levonorgestrel
containing OC: 30pg ef/7/ny/ esfrad/o/ + 750/vg fevonorgesfre/. Desogestrel only: ^50/L/g
desogesfre/. Levonorgestrel only: 750/jg/evonorgesfre/.
x Time of blood sampling
Figure 7.1 Trial profile.
To include women who carry factor VYeiden, a screening was arranged among
students and employees of Utrecht University. We screened 1083 women aged 18-
40 years. Sixty (5.5%) were heterozygous carrier of the factor vleiden mutation; 36
agreed to participate of whom one did not meet the inclusion criteria (psychiatric
disorder). From the women without factor V|_eiden, 111 were approached for the trial
and 51 agreed to participate; all fulfilled the inclusion criteria. One participant was
excluded from phase 2 because the wrong medication was supplied. Another woman
withdrew consent in phase 2 because of side effects of the progestagen-only-pill
(symptoms of depression). Both were factor V|_eiden negative.
All participants gave written informed consent. The study was approved by the Ethics
Committee of the University Medical Center Utrecht.
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Laboratory metfiods All blood samples were drawn in the morning after an
overnight abstinence from intake of food, caffeine, alcohol or nicotine. Cell-free,
citrated plasma was prepared and centrally stored at -80°C. Anticoagulant
parameters were determined after all participants had completed the treatment
regimen and were done in duplicate.
All commercially available assays were carried out according to the
manufacturer's instructions. Protein C was determined using the Coamatic protein C
activity kit from Chromogenix (Mölndal, Sweden). Total protein S antigen was
assayed by an enzyme-linked immunosorbent assay using antibodies from DAKO
(Glostrup, Denmark). Free protein S was measured by precipitating the C4b-binding
protein-bound fraction with polyethylene glycol 8000 and measuring the
concentration of free protein S in the supernatant. C4b-binding protein antigen levels
were determined by enzyme-linked immunosorbent assay using a combination of
monoclonal antibodies against C4b-binding protein (8C11 and horse-radish
peroxidase-labelled 9H10). The APC independent anticoagulant activity of protein S
(PSAPcind) was determined as described by van Wijnen et a F with two modifications.
To avoid contamination with endogenous phospholipids all plasma samples were
centrifuged for 10 min at 13,000 g at 20°C. Plasma aliquots taken from the bottom of
the tube were used for the assay. Recombinant human tissue (Innovin, Dade
Behring, Germany) diluted 100 fold was used to initiate coagulation. Antigen levels of
protein C inhibitor (PCI) were determined by ELISA using a monoclonal antibody
against PCI (API-93) as capturing antibody and rabbit polydonal anti-PCI serum as
secondary antibody^. APC sensitivity ratios (APC-sr) were determined by quantifying
the effect of APC on thrombin generation as described before ^. The plasma levels
of the proteins determined (antigen or activity) were expressed as percentage of that
present in normal pooled plasma determined in the same experiment. The presence
of the factor Vi_eiden mutation was assessed by DNA analysis ^*. All tests were
performed without knowledge of the carrier status of the individual and the oral
contraceptive preparation used.
Sfaf/sf/ca/ ana/ys/s To increase the precision of the measurements, the
results of the two visits at the end of phase 1, at the end of the wash-out period, and
at the end of phase 2 were averaged. If only one sample was available, the values
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obtained for that sample were used in the analysis. According to the design of the
trial (Figure 1) three comparisons were made in the data analysis and represented in
the corresponding tables. To assess the effect of progestagens in combined oral
contraceptives, mean differences in anticoagulant parameters between the two
treatment groups relative to values when no oral contraceptives were used, were
tested with unpaired t-tests for non-carriers and carriers of factor Vteiden separately.
The effect of combined oral contraceptives (progestagens plus estrogen) versus
progestagen-only preparations was calculated by testing differences in means
between phase 1 and phase 2 using paired t-tests. Again, these analyses were
performed separately for non-carriers and carriers of factor V|_e,den-
Differential effects of a hormone preparation between women with and without the
factor Vi_e,den mutation were assessed from the mean change in anticoagulant
parameters in the period of oral contraceptive use relative to no use using unpaired t-
tests. For all estimates 95% confidence intervals were calculated.
Resu/fs
Characfer/sf/cs of fhe Vo/unfeers Parf;c/paf/ng /n ffte Sfudy No differences
in general characteristics were present between the study groups (Table 7.1). The
values of the anticoagulant parameters determined at the various stages in the trial
are summarized in Table 7.2. During the study none of the volunteers showed clinical
signs or symptoms of venous thromboembolism or abnormalities on ultrasound
examination of the leg veins.
Table 7.1. Baseline characteristics according to factor V^en arid type of oral contraceptive (OC)
Age (years)
Body weight (kg)
Height (cm)
BMI (kg/m')
Previous OC use (%)
Second generation
Third generation
Others
Factor Vte«j«i negaf/ve
Levonorgestrel
containing OC
(n=24)
22.9 ±3.4
67.6110.6
168.6 ±5.5
23.4 ± 3.4
19(79)
5(26)
13(68)
1(5)
Desogestrel
containing OC
(n=27)
24.1 +5.9
67.619.5
170.9 ±6.5
23.2 1 3.4
20 (74)
9(45)
5(25)
6(30)
Factor ^oid«> pos/ftVe
Levonorgestrel
containing OC
(n=19)
23.3 ± 2.7
64.0 ±7.9
169.2 ±6.4
22 3 ±2.5
15(79)
6(40)
9(60)
0
Desogestrel
containing OC
(n=16)
22.6 ±2.8
65.9 ±10.6
171.5 ±6.7
22.4 ± 3.5
15(94)
3(20)
5(33)
7(47)
Values are means ± SD or numbers with percentage in parentheses
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Table 7.2a Effects of combined oral contraceptives on anticoagulant parameters in the absence and
presence of the factor V|_e,aen mutation.
Factor l^,
Protein C
Protein S
Protein S
C4BP"
PSAPCind**
PCI"
APC-sr"
Factor Vi.<
Protein C
Protein S
Protein S
C4BP"
PSAPCind**
PCI "
APC-sr"
Levonorgesfre/ confa/n/ng OC
No use
Mean ± SD
,«»„ negaf/Ve
96.0 ±18.3
total 88.5 ±13.2
free 39.9 + 7.0
89.9 + 20.1
1.32 + 0.12
90.6 ±16.6
1.92 ±0.61
„(te„ pos/f/Ve
92.1 ±12.3
total 88.2 ±11.4
free 42.2 ± 9.4
80.5 ±11.2
1.24 ±0.10
86.0+ 14.9
4.60 ±1.02
OCuse
Mean ± SD
108.8 ±21.7
83.4 ±13.6
43.9 + 8.0
77.1 ± 17.3
1.19 + 0.08
101.0 ±15.0
3.26 ± 0.72
102.5+ 16.3
85.9 ±12.9
45.9 ±9.9
72.3 ±9.8
1.16 ± 0.10
92.2 ± 16.3
5.95 ± 1.38
Desogesfre/ confa/n/ng OC
No use
Mean ± SD
92.0 ±14.0
85.9 ±9.9
38.9 ±5.8
88.8 ±15.8
1.34±0.13
90.5 ±13.7
2.04 ± 0.63
106.6 ± 15.9
96.9 ±10.9
42.1 ±8.1
101.5 ±12.7
1.33±0.12
92.5 ±17.0
4.29 ±1.00
OC use
Mean ± SD
103.7 ± 17.8
71.7 ±10.2
33.8 ±7.5
79.1 ±15.1
1.14 ±0.07
99.5 ±18.1
3.76 ± 0.77
122.7 + 22.2
77.6 ±11.1
35.3 + 8.4
85.4 ±16.6
1.14 ±0.05
106.9 ±17.6
7.06 ±1.40
Mean difference
in change (95% Cl)
-1.1 (-7.2-5.0)
-9.1 (-13.4--4.7)
-9.2 (-12.0--6.4)
2.6 (-1.5-6.6)
-0.08 (-0.13--0.02)
-1.4 (-8.4-5.6)
0.38 (0.08 - 0.67)
5.7 (-1.8-13.3)
-16.9 (-23.8--10.1)
-10.5 (-15.0--5.9)
-8.0 (-13.9- -2.1)
-0.10 (-0.15--0.05)
8.2(2.2-14.1)
1.41 (0.76-2.07)
A/ote fne /nd/V/dua/p/asma componenfs are expressed as % ofnorma/poo/edp/asma
* For rn/s ana/ys/s, one woman was exc/uded due to protoco/ wb/afon /n phase 2
" PCI, Protein C inhibitor; APC-sr, activated protein C sensitivity ratio; C4BP, C4b-binding protein,
d. APC-independent anticoagulant activity of protein S
01
O)
cn
C4BP PSAPCind PCI
D-FVUIev l-FVUdsg a+FVL/lev • +FVUdsg
Figure 7.2a Changes of anticoagulant parameters during the use of combined oral
contraceptives, according to pill type and presence of the factor V Leiden mutation.
PS = protein S, C4BP = C4b-binding protein, PSAPCHKI = APC-independent anticoagulant
activity of protein S, PCI = protein C inhibitor, APC-sr = activated protein C sensitivity ratio
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Table 7.2b Effects of progestagen only preparations on anticoagulant parameters in the absence and
presence of the factor NA^ den mutation.
Levonorgesfre/ conra/n/ng OC
No use
Mean ± SD
Factor V<.e«to> negaf/Ve
Protein C
Protein S
Protein S
C4BP"
PSAPCmd**
PCI"
APC-sr"
Factor V,.,
Protein C
Protein S
Protein S
C4BP"
PSAPCmd"
PCI"
APC-sr"
96.7 ± 18.3
total 88.6 ±13.4
free 40.0 ±7.1
89.2 ± 20.3
1.32 ±0.12
88.9 ± 14.6
1.93 ±0.63
9«te„ pos/f/Ve
92.1 ±12.3
total 88.2 ±11.4
free 42.2 ± 9.4
80.5 ±11.2
1.24 ±0.10
86.0 + 14.9
4.60 ±1.02
OC use
Mean ± SD
92.7 ± 18.6
94.9 ± 13.4
47.9 ±8.4
82.0 ± 15.8
1.46 ±0.23
90.4 + 17.7
1.58 ±0.61
86.2 ±11.1
95.2 ±10.5
48.9 ±7.8
75.1 ±9.7
1.33 ±0.16
85.7 ±18.3
4.09 ±0.97
Desogesfre/ conte/n/ng OC
No use
Mean ± SD
92.0 ±14.0
85.9 ±9.9
38.9 ±5.8
88.8 ± 15.8
1.34 ±0.13
90.5 ±13.7
2.04 ±0.63
106.6 ±15.9
96.9 ± 10.9
42.1 ±8.1
101.5 ±12.7
1.33 ±0.12
92.5 ±17.0
4.29 ±1.00
OC use
Mean±SD
84.9 ±11.5
92.5 ±13.2
42.7 ±7.1
87.5 ±17.8
1.35±0.13
90.0 + 14.4
1.80 ±0.52
96.5 ±14.9
100.6 ± 11.2
45.9 ±6.8
95.3 ±12.1
1.33 ±0.10
91.0 ±20.8
4.10 ±1.04
Mean difference
in change (95% Cl)
-3.1 (-6.8 - 0.6)
0.3 (-4.2 - 4.7)
-4.0 (-6.4--1.7)
6.0(0.03-12.0)
-0.13 (-0.20--0.06)
-2.0 (-7.8 - 3.9)
0.11 (-0.09-0.30)
-4.2 (-9.0-0.7)
-3.2 (-8.1 -1.6)
-2.9 (-5.9-0.1)
-0.8 (-6.4-4.9)
-0.09 (-0.14--0.03)
-0.6 (-8.0-6.8)
0.32 (-0.05 - 0.68)
/Vote. f/?e /r/d/V/di/a/p/asma compor/enfs are expressed as % ofr/orma/poo/edp/asma
* For fh/s ar/a/ys/s, one woman was exc/uded doe to protoco/ wo/afon /n phase 2
** PCI, Protein C inhibitor; APC-sr, activated protein C sensitivity ratio; C4BP, C4b-binding protein;
PSAPCmd. APC-independent anticoagulant activity of protein S
Protein C PS-total PS-free C4BP PSAPCind PCI
O-FVL/lev l-FVUdsg D+FVUIev l+FVUdsg
Figure 7.2b Changes of anticoagulant parameters during the use of progestagen only
preparations, according to pill type and presence of the factor V Leiden mutation.
PS = protein S, C4BP = C4b-binding protein, PSAPCIFKI = APC-independent anticoagulant
activity of protein S, PCI = protein C inhibitor, APC-sr = activated protein C sensitivity ratio
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Effecf of Comö/ned Ora/ Confracepf/Ves The use of combined oral
contraceptives caused considerable changes in anticoagulant parameters (Table 7.2
and Figure 7.2A). With the exception of free protein S, the direction of these changes
were similar for the two kinds of contraceptives. However, in non-carriers as well as
in carriers of factor VLeiden clear differences were observed between the magnitude of
the effects of levonorgestrel- and desogestrel-containing oral contraceptives.
Table 7.3 Differential effects of combined oral contraceptives and progestagen-only preparations on
anticoagulant plasma parameters in the absence or presence of the factor Vuiden mutation
Levonorgestrel containing OC Desogestrel-containing OC
vs. Levonorgestrel-only vs Desogestrel-only
Mean difference (95%CI) Mean difference (95%CI)
Factor We«/«, negative
ProteinC 17.0 (12.8 to 21.3) 18.8 (14.7 to 23.0)
Total Protein S -11.3 (-15.2 to -7.3) -20.8 (-26.0 to-15.6)
Free proteinS -3.7 (-5.9 to-1.5) -8.9 (-11.6 t o - 6 . 2 )
C4BP* -5.7 (-11.2 to-0.2) -9.0 (-12 9 t o - 5 . 2 )
PSAPCnd* -0.27 (-0.35 to -0.19) -0.22 (-0.26 to-0.17)
Protein C inhibitor 9.7 (5.2 to 14.2) 9.5 (3.4 to 15.6)
APC-sr* 1.66 (1.39 to 1.93) 1.96 (1.72 to 2.19)
Factor V(.„«*>n pos/Y/ve
ProteinC 16.3 (12.4 to 20.2) 26.2 (18.2 to 34.3)
Total Protein S -9.3 (-14.1 to -4.5) -23.0 (-28.9 to -17.1)
Free prote inS -3.0 (-6 3 to 0.3) -10.6 (-13.3 to-7.8)
C4BP* -2.8 (-6.4 to 0.8) -10.0 (-17.6 to-2.3)
PSAPCmd* -0.17 (-0.23 to-0.11) -0.19 (-0.23 to-0.15)
Protein C inhibitor 7.1 (4.2 to 10.1) 15.9 (9.6 to 22.2)
APC-sr* 1.86(1.41 to 2.31) 2.96 (2.46 to 3.46)
Note: the individual plasma components are expressed as % of normal pooled plasma
* C4BP, C4b-binding protein; PSAPCmd. APC-independent anticoagulant activity of protein S; APC-sr,
activated protein C sensitivity ratio
Women without factor V|_eiden who used desogestrel-containing oral contraceptives
became significantly more resistant to APC (as indicated by the increase of the APC-
sr) than users of levonorgestrel-containing oral contraceptives (Figure 7.3). Total and
free protein S significantly decreased in women using desogestrel-containing oral
contraceptives, whereas in users of levonorgestrel-containing oral contraceptives
there was a minor decrease of total protein S and even an increase of free protein S.
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In addition, protein SAPdnd was significantly more decreased on desogestrel than on
levonorgestrel-containing oral contraceptives. No differential changes were observed
for protein C, C4b-binding protein and protein C inhibitor.
In carriers of factor Vi_eiden, the largest changes were observed with desogestrel-
containing contraceptives (Table 7.2 and Figure 7.3).
o
Q.
Fig 7.3 nAPC-sr levels (95% Cl) on combined oral contraceptives (COC),
progestagen-only (POP) or during no oral contraceptive use according to the
absence (A) or presence (B) of the factor VLeiden mutation.
Effecf of Progesfagens-On/y Preparations Relative to the period of no use,
the progestagen-only preparations caused changes in anticoagulant parameters that,
with the exception of C4b-binding protein, were opposite to those observed during
the use of combined oral contraceptives (Table 7.2 and Figure 7.2B). The effects of
progestagen-only preparations were in general more pronounced with levonorgestrel.
The increase in free protein S and PSAPCmd and the decrease in C4b-binding protein
in women without factor VLeiden were significantly more pronounced on levonorgestrel
than on desogestrel. In carriers of factor VLeiden the only significant differential effect
between levonorgestrel and desogestrel was observed for PSAPCmd-
The effects of the combination of estrogens and progestagens versus progestagen-
only were estimated from the difference between the anticoagulant parameters in
phase 1 and phase 2 (Table 7.3). Almost all anticoagulant parameters differed
significantly between the periods that combined oral contraceptives and progestagen-
only preparations were used.
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Compar/son of women vv/f/j and w/fhouf fhe factor VLwden mufaf/on The
magnitude of the changes induced by levonorgestrel-containing contraceptives was
not materially different in carriers compared to non-carriers of the factor Vielen
mutation (Table 7.4). In contrast, the changes observed during the use of
desogestrel-containing oral contraceptives were more pronounced in carriers than in
non-carriers of factor V|_eiden which was statistically significant for the increase in the
APC-sr (Figure 7.3) and the decrease in the plasma level of C4b-binding protein.
Table 7.4 Differences between the effect of combined oral contraceptives and progestagen only
preparations on anticoagulant plasma parameters in the absence or presence of the factor
vleiden mutation
Factor Vle^n positive vs. factor V^den negative
Mean difference (95%CI)
Levonorgesfre/ confa/n/ng OC Levonorgesfre/-on/y
Protein C -2.4 (-8.7 to 3.9) -1.9 (-6.3 to 2.5)
Total Protein S 2.8 (-2.8 to 8.3) 0.6 (-3.5 to 4.8)
FreeproteinS -0.3 (-4.0 to 3.5) -1.1 (-3.6 to 1.4)
C4BP* 4.7 (0.5 to 8.8) 1.8 (-4.8 to 8.5)
PSAPCnd* 0.05 (0.01 to 0.09) -0.05 (-0.13 to 0.03)
Protein C inhibitor -4.2 (-9.7 to 1.4) -2.4 (-8.6 to 3.9)
APC-sr* 0.01 (-0.44 to 0.47) -0.16 (-0.42 to 0.10)
Desogesfre/ confa/n/ng OC Desogesfre/-on/y
ProteinC 4.4 (-2.9 to 11.8) -3.0 (-7.0 to 1.1)
Total Protein S -5.1 (-10.5 to 0.2) -2.8 (-8.1 to 2.4)
FreeproteinS -1.6 (-5.0 to 1.8) 0.07 (-2.7 to 2.9)
C4BP* -5.9 (-11.4 to-0.3) -4.9 (-10.3 to 0.4)
PSAPCHO* 0.03 (-0.04 to 0.09) 0.00 (-0.05 to 0.05)
Protein C inhibitor 5.4 (-2.7 to 13.5) -1.0 (-8.0 to 5.9)
APC-sr' 1.05 (0.48 to 1.62) 0.05 (-0.27 to 0.37)
Note: the individual plasma components are expressed as % of normal pooled plasma
* C4BP, C4b-binding protein; PSAPCnd. APC-independent anticoagulant activity of protein S; APC-sr,
activated protein C sensitivity ratio
D/scuss/on
We found that third generation oral contraceptives have a stronger effect on
anticoagulant parameters than preparations of the second generation. These
differential effects disappear or go in an opposite direction with the progestagen
components of these pills only. The contrasts are similar, but more outspoken among
13?
women with the faster V{.«3*n mutation than among Ron-earners. Our tsrvdtngs
sug§ests that, compared to tevonorgestref« desogestret is tess effective in
counteracting the thromhotie effects induced by the estrogen component In combined
oral contraceptives. - a
Oral contraceptive use has repeatedly been associated with ar> increased risk
of venous thrombosis ^ **\ ^ Particularly, the differentia! changes of the protttot
involved in the protein C system may contribute to the thrombötfe effects of oral
contraceptives. This study was designed to investigate the effect of second and third
generation oral contraceptives and their respective progestagens fievonorgestrel or
desogestrel) on the protein C pathway in carriers and non-carriers of the factor Vie**»,
mutation. We showed that earlier reported changes in anticoagulant parameters
induced by oral contraceptives in healthy women" ^ ' '** also occurred in women
with factor Vt«den"' ^ In carriers as well as in non-carriers of the factor Visa«a
mutation both oral contraceptives induced APC resistance, increased the plasm®
levels of protein C and protein C inhibitor and decreased the APC-independent
anticoagulant activity of protein S and the plasma levels of total protein S and C-4b-
binding protein. In both study populations free protein S increased on levonorgestrel-
and decreased on desogestrel-containing oral contraceptives. This increase of free
protein S on combined pills with levonorgestrel is explained by the fact that on this
contraceptive total protein S hardly changes which together with the decrease of
C4b-binding protein (which complexes protein S) results in an elevation of the plasma
level of free protein S. In both carriers and non-carriers of factor V|_eiden the changes
in anticoagulant parameters were most pronounced in the women using desogestrel-
containing oral contraceptives. Since hereditary defects of the protein C pathway are
associated with an increased risk of venous thromboembolism,^^ the differential
effects of levonorgestrel- and desogestrel-containing oral contraceptives particularly
on the plasma levels of protein S and on the degree of acquired APC resistance may
well explain the differences in thrombotic risk associated with these preparations^' ^
^ ^ . The pronounced increase in APC resistance in women with factor Vleiden who
use desogestrel-containing oral contraceptives may account for the reported elevated
risk of venous thrombosis in carriers of this mutation taking third generation oral
contraceptives "*.
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•:- To determine to what extent the progestagens levonorgestrel and desogestrel
are responsible for the changes of anticoagulant parameters induced by combined
oral contraceptives, we also investigated the effect of progestagens-only on the
protein C pathway. Some years ago, Winkler et al ™® compared two progestagen-
only pills containing either 30 pg levonorgestrel or 75 ng desogestrel. They reported
increased protein S levels for desogestrel compared to levonorgestrel. However, the
doses of progestagen used in these pills differed from those normally used in oral
contraceptives. In our study we compared progestagen-only preparations that
contained the same dose of progestagen as present in oral contraceptives (150 (.ig
levonorgestrel or desogestrel). Almost all effects of combined oral contraceptives on
anticoagulant parameters disappeared or even went in an opposite direction when
the participants used progestagen-only preparations. Our observations are supported
by reports indicating that the changes of several other hemostatic parameters on
progestagen-only pills and implants are the inverse of those induced by combined
oral contraceptives ™® ™^ , which may indicate a net antithrombotic effect.
Progestagen-only-pills may thus be a safer method of contraception. However, during
the study many women complained about irregular bleedings when these
preparations were used (65% compared to 15% during the use of combined oral
contraceptives).
The present study may provide an explanation for the observation that combined oral
contraceptives with desogestrel cause more marked changes of the anticoagulant
protein C system than levonorgestrel-containing oral contraceptives. We hypothesize
that estrogens such as ethinylestradiol cause changes of anticoagulant parameters
that are in the same direction, but more profound than observed with combined oral
contraceptives. Due to their androgenic properties, progestagens induce changes in
the anticoagulant system that are opposite to those of estrogen, and which, due to
the higher androgenicity^* ^ are more pronounced with levonorgestrel than with
desogestrel. Hence, we propose that combined oral contraceptives with desogestrel
induce more profound changes of the anticoagulant system than levonorgestrel-
containing oral contraceptives because the effects of ethinylestradiol on
anticoagulant parameters are less well compensated by desogestrel than by
levonorgestrel. This view is supported by the observation that APC resistance
correlates inversely with the dose of levonorgestrel present in five different combined
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oral contraceptives"* suggesting that high concentrations of levonorgestrel
counteract the increase in APC resistance.
In conclusion, our findings indicate that desogestrel-containing oral contraceptives
have a more pronounced effect on the anticoagulant protein C system than
levonorgestrel-containing oral contraceptives, especially in women with factor Vi^en.
Particularly the decrease in protein S and the profoundly increased resistance to APC
might contribute to the elevated risk of venous thrombosis in carriers of factor VLeiden
who use third generation oral contraceptives. The differential effects of second and
third generation oral contraceptives on the anticoagulant pathway can at least be
partially explained by the observation that levonorgestrel is more effective than
desogestrel in counteracting the thrombotic effect of ethinylestradiol.
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General summary
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Venous thrombosis is recognized to be a multicausal disease. In recent years
more and more genetic and acquired risk factors have been identified that play a role
in the development of venous thrombosis. One major risk factor that was discovered
in 1993 is activated protein C (APC) resistance. Hereditary APC resistance results
from a single point mutation in coagulation factor V. The mutated molecule, often
called FVLeiden, lacks an APC cleavage site and therefore, its procoagulant activity
cannot be efficiently down-regulated by APC. As a consequence, the plasma of
carriers of the FVLeiden mutation is APC resistant. However, 10% of the APC resistant
individuals are not carrying the FVLeiden mutation and hence have a different, as yet
unknown cause for APC resistance'. Moreover, APC resistance without the FVLeiden
mutation has also been established as a risk factor for venous thrombosis^
Theoretically, APC resistance not caused by FV-Leiden could be induced by altered
levels in haemostatic factors that enhance thrombin generation or that hamper the
action of the anticoagulant protein C pathway, i.e. 1) high concentrations of
procoagulant proteins (e.g. prothrombin, factor VIII), 2) low concentrations of
inhibitors of coagulation (e.g. tissue factor pathway inhibitor), 3) low concentrations of
anticoagulant proteins (e.g. protein S) or 4) high concentrations of inhibitors of
anticoagulant proteins (e.g. protein C inhibitor). It is also possible that combinations
of these occur and act in concert to render an individual's plasma APC resistant.
Rather than trying to identify single contributing risk factors by a combination
of individual measurements, it is useful to assess a possible prothrombotic condition
via a single overall assay. The APC resistance test used throughout the
investigations described in this thesis, is such a measurement. This assay quantifies
the effect of APC on thrombin generation initiated in plasma via the extrinsic
pathway. The first results obtained with this test, revealed that women using oral
contraceptives (OC) were more resistant to APC than women not using OC.
Moreover, users of so-called third generation OC exhibited responses to APC equal
to that of individuals with the FVLeiden mutation^. Since the observed APCsr's
correlated with earlier reported risks of venous thrombosis for carriers of FV-Leiden
and of users of different types of OC (i.e. second and third generation), it was
proposed that acquired APC resistance could provide a biological explanation for the
increased risk of thrombosis associated with the use of OC.
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In Chapters 2, 3 and 4 of this thesis the use of this assay for the assessment of APC
resistance is described. In Chapters 5, 6 and 7, the effects of changes of female sex
hormones on the anticoagulant pathway are reported. In this discussion a summary
will be given of the different investigations described in this thesis.
Characteristics of f/ie APC res/stance tesf
In Chapter 2 we have described the effects of analytical and pre-analytical
variables on APCsr determined with our APC resistance test. The effects of variation
of the concentration of the different reactants used in the test (calcium,
phospholipids, tissue factor and APC) on thrombin formation were determined. We
found that APC inhibits by thrombin formation in a dose-dependent manner. The
inhibition by APC was affected by the concentration of tissue factor, calcium and
phospholipids. In order to obtain reproducible APCsr, the concentrations of these
reactants should therefore, be standardized. We have chosen the conditions of this
assay such, that normal pooled plasma has a residual thrombin formation in the
presence of APC of approximately 10%. Small variations in residual thrombin
formation, due to variations of reactants, will influence the outcome of the assay in
both normal and patient plasma. This may result in a day-to-day variation that can be
minimized by normalisation i.e. by dividing the APCsr of a particular plasma sample
by the APCsr obtained in normal pooled plasma".
The influence of different procedures to process whole blood to plasma, was
also investigated. These included 1) concentration of citrate used to anticoagulate
whole blood, 2) time before processing, 3) time and speed of centrifugation, 4)
storage temperature of plasma and 5) an additional thawing of a frozen plasma
sample. Differences in centrifugation and additional thawing of plasma had no effect
on the APCsr, whereas a minor effect was observed for the time waited before
sample processing as well as for the storage temperature. However, variation in the
concentration of sodium citrate, used to anticoagulate whole blood upon drawing, has
considerable influence on the APCsr. This is likely due to the fact that the
anticoagulant action of APC is critically dependent on the calcium concentration. In
different laboratories the sodium citrate concentration that is used to anticoagulate
whole blood varies between 0.105 and 0.129M. Thus, the citrate concentration
appears to influence the APCsr, an effect that has also been reported for APCsr
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values determined with clotting times in the aPTT*. To at least partially reduce citrate
effects, it is recommended to normalize APCsr against a pooled normal plasma that
is collected on the same concentration of anticoagulant.
Hered/fary and acgu/red APC res/stance
The APC resistance assay described in this thesis is sensitive to both
hereditary and acquired risk factors for venous thrombosis (Chapter 3). Carriers of
the prothrombin mutation (PT G20210A), as well as individuals with protein S
deficiency had higher APCsr than controls. APC resistance in carriers of the
prothrombin mutation, which is associated with high levels of prothrombin, may be
explained by an inhibition of APC-dependent factor Va inactivation". Moreover, high
levels of prothrombin might increase the amount of thrombin formed, leading to
excessive formation factor Va. This poses an increasing demand on APC to down-
regulate thrombin formation, which may lead to an APC resistant state of plasma.
Protein S is a cofactor of APC in the inactivation of factor Va. Hence, at low
levels of protein S down-regulation of thrombin formation is impaired, which results in
APC resistance. Protein S deficiency can be both of hereditary and acquired origin.
Hereditary protein S deficiency can be caused by mutations in the protein S
molecule. Acquired protein S deficiency, on the other hand, is associated with the
use of hormone preparations (OC), and with pregnancy.
In chapter 3 it is also described that co-existence of risk factors for venous
thrombosis that increase the APCsr, cause an even higher APCsr and in some cases
render the plasma of affected individual almost completely resistant to the action of
APC. The finding that more than one risk factor needs to be present to eventually
cause thrombosis, is thus reflected in the APCsr values. This idea is supported in
Fig3.5, which shows that there is a good correlation between the APCsr of individuals
with hereditary and/or acquired risk factors for venous thrombosis and the reported
odds ratios.
C/ott/ng or fhromb/n formaf/on
In chapter 3 it is shown that acquired APC resistance is especially observed in
women who are using OC or who are pregnant. Depending on the APC resistance
test used, there appears to be a variable number of individuals who are acquired
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APC resistant. The molecular basis of this acquired APC resistance is, however,
unclear. With the intention to gain more insight in this, we have assessed the
sensitivity to APC of FVuiden carriers and OC users with two different APC resistance
assays (Chapter 4): 1) the thrombin generation assay, which is very sensitive to
hormonal influences (e.g. OC, HRT and pregnancy) and thus to acquired APC
resistance and with 2) an APC resistance assay that is routinely used in hospital
laboratories and that evaluates the effect of APC on the clotting times of plasma in
which coagulation is initiated via the intrinsic pathway (/.e. the activated partial
thromboplastin time, aPTT).
Both assays were equally sensitive and specific in determining the Fvleiden
mutation. However, the increased APC resistance during OC use is hardly observed
in the classical clotting assay. Thus, apart from the ability to detect the FVt.e.den
mutation, the correlation between the two assays is rather poor. There are at least
two possible explanations for these observed differences:
1) In the two assays coagulation is initiated with activators which activate
different pathways of coagulation (tissue factor versus kaolin). Tissue factor-induced
coagulation mainly proceeds via the extrinsic pathway, whereas kaolin activates the
intrinsic pathway. Plasma proteins of each pathway may be differentially modulated
during OC use and this can lead to different sensitivities of the plasma for APC. For
example, the APCsr measured in the aPTT is influenced by high levels of factor VIII,
whereas the APCsr determined in the ETP-based test is sensitive to changes in
protein S.
2 4 6
Time (min)
Figure 8.1 Already after
formation of the first traces of
thrombin, clotting is achieved,
as indicated by the grey bar.
However, measurement of
thrombin generation represents
the total amount of thrombinthat
has been formed during
coagulation.
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2) The endpoint determination of the two assays is different ;.e. clotting time
versus thrombin formation. Clotting occurs already after the first traces of thrombin
are formed (i.e. in approximately 30 sec), whereas the measurement of the
endogenous thrombin potential reflects the total amount of thrombin that has been
formed over a prolonged time period (Fig 8.1). It can be hypothesized that the first
phase of coagulation (/.e. when the first traces of thrombin are generated and the clot
is formed) is less sensitive to modulation by (anti)coagulation factors than the
endogenous thrombin potential which quantifies the amount of thrombin that has
been formed over a much longer time period. However, further experiments are
needed to test these hypotheses.
APC res/stance during fhe use of ora/ confracepf/Ves
In PART II of this thesis the effects of changes in female sex steroid hormones
on APC resistance protein C system are described. From the very early beginning
on, the use of oral contraceptives has been associated with an increased risk for
venous thrombosis. However a satisfying biological explanation for the observed
increased thrombotic risk was lacking, until 1997 when acquired APC resistance *
was proposed as a possible mechanism to explain the occurrence of venous
thromboembolism in OC-using women.The study published in 1997 concerned a
cross-sectional, non-cycle controlled design the results of which could have been
influenced by uncontrolled pill effects and selection bias. Therefore, a double blind
randomized cross-over trial of two oral contraceptive preparations was performed.
The cross-over study showed that a large number of haemostatic variables changed
during the use of OC (procoagulant, anticoagulant and fibrinolytic). The changes of
most of the coagulation factors were more pronounced during the use of desogestrel-
containing OC than during the use of levonorgestrel-containing OC. Notably, more
pronounced APC resistance was observed during the use of the desogestrel-
containing preparation than on levonorgestrel-containing OC.
Differences between the effects of second and third generation pills on the
level of anticoagulant proteins were only found for protein S. Decreases in protein S
were more pronounced during the use of third generation OC. Moreover, changes of
total and free protein S correlated negatively with the increase of the APCsr
determined with the ETP-based APC resistance assay (r= -0.44 / -0.60), which
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indicates that the decrease in protein S can, at least partially, explain increases in
APCsr. However, other mechanisms leading to acquired APC resistance must also
be involved, since protein S did not significantly change during the use of second
generation OC, whereas the APCsr increased considerably. Particularly, the
combination of higher levels of factor VII, X and prothrombin' will result in an
increased procoagulant pressure that may further contribute to the APC resistant
phenotype found in OC using women.
Considering the discussion about OC use and the risk of venous thrombosis, it
was proposed that the increased thrombin formation and decreased anticoagulant
action could partially be counteracted by an increased fibrinolysis. The cross-over
study confirmed that levels of fibrinolytic proteins increase during the use of OC,
however, no shortened clot lysis time was found in these samples. Meijers et al.®
report a progestagen specific difference for TAFI (thrombin activatable fibrinolysis
inhibitor). TAFI was increased during the use of OC, especially during third
generation OC. The increase in TAFI together with the elevated thrombin formation,
probably yields more activated TAFI that can counterbalance the effects of increased
levels of fibrinolytic proteins by inhibiting fibrinolysis.
Acquired ÄPC resisfance during HA?T, pregnancy and / VF
The synthetic hormones in oral contraceptives cause changes in procoagulant
(e.g. prothrombin, factor VII and factor X), anticoagulant (protein S total and free,
Chapter 5) and fibrinolytic proteins (TAFI). Pregnancy, during which endogenous
estradiol and progesterone are substantially increased, also induces major changes
in the haemostatic system (factor VIM, protein S and antithrombin). Moreover,
pregnancy, the use of OC and hormone replacement therapy lead to acquired protein
C resistance (Chapter 3). Although, the hormones administered during OC therapy
differ from the naturally occurring hormones (such as during pregnancy) the effects
on haemostatic parameters are similar.
In chapter 6 the effect of changes in endogenous estradiol en progesterone on the
protein C pathway are described. In plasma of women who followed an in vitro
fertilisation (IVF) protocol (n=31) and subsequently became pregnant (n=6) the levels
of hormones and anticoagulant proteins were determined. During IVF the levels of
endogenous estradiol and progesterone increase within a short period of time.
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During IVF treatment, no changes in protein S, protein C and protein C
inhibitor, but an increase in APC resistance was observed. The estradiol levels
correlated well with the APC sensitivity ratios. Moreover, the increase in APC
resistance showed a significant correlation with the increase in 17ß-estradiol (r=0.7,
p=0.001). In this study six women became pregnant following IVF. In these pregnant
women a rapid increase in estradiol and progesterone was observed, concurrent with
a rise in APCsr and a decrease in protein S. Although hormone levels during early
pregnancy were similar to those during hyperstimulation (E2) and luteal support (P),
the effects on APCsr and protein S were more pronounced. This might be caused by
an up-regulation of hormone-receptors already early in pregnancy.
Despite considerable changes in estradiol and progesterone, the levels of
hemostatic factors and the APCsr changed only minimally and less than observed
during OC use. A possible explanation for this might be that synthetic hormones
exhibit higher affinity for and have more pronounced effects on hormone receptors
than natural hormones*' ™.
Progesferone may counferba/ance f/ie prof/jromtoof/c effecfs of esfrogen
Since lowering of the estrogen content in (second and third generation) OC led
to an overall decrease in the risk for VTE as compared to first generation
preparations, estrogen was held responsible for thrombosis associated with hormonal
changes in women. However, since second and third generation OC preparations
contain the same amount of ethinyl estradiol (30ug) this suggests that progestagens
are, at least partially, responsible for the increased risk of VTE during use of third
generation OC. Therefore we have compared the effects of desogestrel and
levonorgestrel on the protein C pathway during the use of combined OC, containing
ethinyl estradiol (EE) and progestagen, and progestagen-only preparations in women
with and without the FV|_eiden mutation (Chapter 7). In both populations desogestrel-
containing (DSG) combined preparations had more pronounced effects on the
anticoagulant pathway than levonorgestrel-containing (LEV) OC. Effects of
desogestrel-containing combined OC were more pronounced in carriers than in non-
carriers of the FVLeiden mutation. During the use of progestagen-only preparations
reverse effects on anticoagulant proteins were found, which in general were more
pronounced for levonorgestrel than for desogestrel. The findings presented in this
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chapter can explain the increased risk for desogestrel users, especially in the case of
carriership of the FVi_eiden mutation combined with OC use".
In a small study it was proposed that progestagens had a "compensating"
effect on coagulation, since APC sensitivity ratios declined with increasing
progestagen content in triphasic OC'*. If progestagens indeed compensate the action
of estrogens on hemostasis, it is appealing to reduce the level of ethinyl estradiol in
oral contraceptives (so called sub-30 pills) and at the same time maintain or even
increase the level of progestagen. The results described in this thesis relate to two
different kinds of OC preparations, both containing 150ug progestagen (either
levonorgestrel or desogestrel). It is interesting to investigate the influence on
hemostasis of OC containing norgestimate, a progestagen that is third generation,
but which is metabolised to levonorgestrel. Furthermore, it would be interesting to
investigate the changes in haemostasis during the use of OC that contain the same
amount of progestagen in combination with a lower EE content e.g. Mercilon® (20ug
EE and 150ug DSG). However, also the newest sub-30 pills that contain gestodene
(Meliane®, Minulet®) should be compared to their older counterparts that contain
more EE and the same amount of gestodene (Femodeen® and Harmonet®,
respectively).
In 1997 the Committee for Proprietary Medicinal Products (CPMP) of the
European Medicines Evaluation Agency (EMEA) requested the oral contraceptive
manufacturers to perform a study to evaluate the effects of seven monophasic oral
contraceptives on the haemostatic system. In this study the effect of seven different
combination preparations on a large number of haemostatic variables have been
investigated". Also a comparison of the effect of different progestagens (gestodene,
DSG, LEV and NGM) and different concentrations of EE (20 vs 30 vs 50 ug EE) was
made in this study. Although there are indications that this study has been
completed, the detailed results of this investigation have as yet not been published.
Can changes of haemosfaf/c parameters exp/a/n p/7/ fhrombos/s?
We have shown in all our studies (cross-sectional, cross-over and longitudinal
designs) that the use of combined oral contraceptives is associated with a decreased
anticoagulant potency of the protein C pathway as reflected by an increased APC
resistance. Moreover, the effects of oral contraceptives containing desogestrel are
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more pronounced than levonorgestrel-containing OC. Our studies and other reports
have indicated that the changes during OC use in levels of factor VII, factor V,
prothrombin and protein S represent an important modulatory effect that in part can
explain the observed difference in risk of venous thrombosis between users of
second and third generation OC use. Our studies further indicate that individuals with
FV|_eiden (who already have impaired APC-dependent down regulation of coagulation)
become even more resistant to APC during OC use (especially when they use
desogestrel-containing OC), and this can explain the high risk for venous thrombosis
in carriers of the FV|_eiden mutation who use OC.
Since changes in haemostatic variables during OC use are relatively small and
the plasma levels of coagulation factors in most women stay within normal ranges,
the relevance of changes during OC use has been questioned. For a number of
reasons we would like to challenge this interpretation.
Recent reports have indicated that elevated levels of prothrombin", factor Vlll^ "\
factor IX" factor X I " and TAFI" are independent risk factors for venous thrombosis.
Even when the changes in levels of these proteins are relatively small, the risk of
VTE is significantly increased. The effects of OC on the coagulation system are
generally judged on the basis of mean changes of haemostatic parameters relative to
the mean level of that parameter in the population. However, it is important to realise
that, although a change in population average can stay within the normal range, such
changes result in an increased number of individuals at the extreme of the normal
population distribution.
Figure 8.2 Normal distribution of the
level of prothrombin before and
during the use of OC. Odds ratio's
of venous thrombosis reported for
the level of prothrombin^ are
indicated in the figure along the x-
axis.
- before OC use
-during OC use
0.50 0.65 0.80 0.95 1.10 1.25 1.40 1.55
prothrombin concentration (ILJ/mL)
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Fig 8.2 illustrates this for the level of prothrombin before and during the use of
OC. It has been shown that individuals with prothrombin levels >1.15 ILJ/mL have a
2.1-fold increased risk for developing VTE'*. The normal distribution of levels of
prothrombin, i.e. without OC, are indicated in light-gray. Of the population only 12%
has a prothrombin level above 1.15 ILJ/mL. However, during the use of OC this curve
is shifted to the right and the number of individuals exposed to such high levels is
increased substantially to 42%. It is unfortunate that in the discussion with regard to
the effects of OC use, this phenomenon, which will lead to an increased number of
women at risk, is underscored.
In most women the changes in hemostatic parameters during OC use will
result in a moderate disbalance, however, the few individuals that already have a
mild prothrombotic condition before they use OC (e.g. elevated levels of factor II, VIII,
IX, XI or low levels of protein S, factor V), may be put in extreme danger during the
use of OC, because the concentration of coagulation factors will further change
during use. In these women OC may further impair the coagulation system and
aggrevate the prothrombotic condition, a situation that in a small number of pill users
(7/10000 women years) may culminate in the development of venous thrombosis.
Chapter 8
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Veneuze trombose is een ziekte die door meerdere faktoren wordt
veroorzaakt. In de laatste jaren is een groot aantal genetische en verworven
risicofaktoren, die een rol spelen bij net ontstaan van veneuze trombose,
geidentificeerd. Een van de belangrijkste risicofaktoren voor veneuze trombose is
ontdekt in 1993 en heet APC resistentie. Geaktiveerd protein C (APC) is een enzyme
dat ervoor zorgt, dat stolling van bloed tijdig geremd wordt, zodat er geen trombose
optreedt. Maar in een groot aantal patienten met veneuze trombose blijkt dat APC
minder goed te werken (net plasma is APC resistent). APC resistentie kan op twee
manieren worden veroorzaakt: door een genetische afwijking (erfelijk) en/of door
omgevingsfaktoren die tijdelijk aanwezig zijn (verworven). Erfelijke APC resistentie is
het gevolg van een puntmutatie in stolfaktor V. Het gemuteerde molekuul, FVi_eiden
genaamd, mist een belangrijke knipplaats voor APC, waardoor de
stollingsbevorderende werking van FV niet goed gereguleerd kan worden. Plasma
van FVLeiden-dragers is dus minder gevoelig voor APC (APC resistent). De oorzaken
van verworven APC resistentie zijn minder eenduidig. Theoretisch kan verworven
APC resistentie het gevolg zijn van een verhoogde neiging tot trombinevorming
veroorzaakt door een verandering in niveau van een of meerdere stolfaktoren. Dit
kan een gevolg zijn van 1) een verhoogde concentratie van stollingsbevorderende
eiwitten (bijv. protrombine of faktor VII), 2) een verlaagde concentratie van remmers
van de stolling (bijv. tissue faktor pathway inhibitor), 3) läge concentratie van
antistollingseiwitten (bijv. protein S) en/of 4) een hoge concentratie van remmers van
het antistollingssysteem (bijv. protein C inhibitor).
Het is daarom niet eenvoudig aan te geven welke hemostase testen de
voorkeur verdienen voor het diagnostiseren van verworven APC resistentie. Een
algemene test, waarvan het resultaat een samengestelde meting van pro- en
anticoagulante effecten (een "protrombotische toestand") weergeeft, zou daarom
heel nuttig zijn. De in dit proefschrift beschreven APC resistentie test kan in een
aantal gevallen als zo'n algemene test beschouwd worden. Deze test kwantificeert
het effect van APC op de totale trombinevorming na aktivatie van bloedplasma via
het extrinsieke stolsysteem.
In Deel I van het proefschrift zijn achtereenvolgens beschreven: de
experimentele omstandigheden waaronder de in Maastricht ontwikkelde APC
resistentiemeting dient te worden uitgevoerd (hoofdstuk 2); voor welke veneuze
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trombose risicofaktoren (erfelijk danwel verworven) de meting gevoelig is (hoofdstuk
3); alsmede een vergelijking van de resultaten met de meer algemeen in gebruik
zijnde methode, waarin APC resistentie bepaald wordt door meting van het effect van
APC op de stoltijd (hoofdstuk 4). In deel II (hoofdstukken 5-7) wordt vervolgens nader
ingegaan op de effecten van veranderingen in de vrouwelijke hormoon huishouding
op stollingsparameters, die de werking van het zgn. "protein C pathway" bepalen.
Dee/ / E/genscnappen van de APC res/sfenf/e-tesf
In hoofdstuk 2 wordt de invloed beschreven van variatie in de concentratie
van de verschillende "ingredienten" van de test (calcium, fosfolipiden, tissue faktor en
APC) op de trombinevorming. De remming van de trombinevorming door APC blijkt
afhankelijk te zijn van de concentratie tissue faktor, calcium en fosfolipiden. Om
reproduceerbare getallen te verkrijgen, moeten de concentraties van deze reactanten
daarom worden gestandaardiseerd. De dag tot dag variatie die desondanks
aanwezig blijft, kan worden geminimaliseerd door de APCsr (APC sensitivity ratio)
van een bepaald plasmamonster te delen door de APCsr van normaal plasma. Het
effect van variaties in plasmabereiding uit volbloed is ook bepaald. De geteste
variabelen zijn 1) de concentratie van het antistollingsmiddel citraat, 2) de tijd voordat
begonnen wordt met de opwerking; 3) centrifugatietijd en -temperatuur gebruikt bij
verwijdering van de cellulaire fraktie uit het bloedplasma; 4) opslagtemperatuur van
het plasmamonster en 5) een extra keer ontdooien alvorens te meten. Het blijkt dat
eigenlijk alleen de concentratie van citraat de APCsr waarden bei'nvloedt. Om een
goede vergelijking te waarborgen is het dan ook van belang dat de APC resistentie
meting uitgevoerd wordt met plasmamonsters die in gelijke concentratie citraat
afgenomen zijn.
De resultaten in hoofdstuk 3 maken duidelijk dat de APC resistentietest,
zoals beschreven in dit proefschrift, niet alleen gevoelig is voor de faktor V|_eiden
mutatie, maar ook voor andere risicofaktoren voor veneuze trombose. Dit kunnen
zowel erfelijke (de protrombine G20210A mutatie; protein S deficientie) als
verworven (zwangerschap, pilgebruik, hormoonsubstitutie therapie) risicofaktoren
zijn. Tevens blijken de effecten van de risicofaktoren op APC resistentie in veel
gevallen additief te zijn, zodat bij het gelijktijdig voorkomen van risicofaktoren extra
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hoge APCsr waarden gevonden worden. Het feit dat de gemeten APCsr waarden
correleren met in de literatuur gerapporteerde risico's van trombose suggereert dat
de door ons ontwikkelde meting klinisch relevante uitkomsten oplevert.
In het laatste hoofdstuk van deel I (hoofdstuk 4) zijn de resultaten vergeleken
met een meer algemeen in gebruik zijnde APC resistentie test (de zgn. aPTT),
waarin het effect van APC gemeten wordt op basis van stoltijdmetingen in plasma
gei'nitieerd via de intrinsieke weg . Beide testen zijn even specifiek en gevoelig voor
de aanwezigheid van de FVi_eiden mutatie, maar afgezien hiervan blijken de
uitkomsten van beide testen verder nauwelijks gecorreleerd. Dit wijst erop dat beide
APC resistentie meting via deze testen door verschillende faktoren bemvloedt word
en dat deze verschillende effecten teweeg brengen in de beide APC resistentie
testen.
Dee/ // Hormona/e fce/nv/oed/ng van »PC res/stenf/e
Reeds vanaf de beginjaren '60 is het gebruik van orale contraceptie
geassocieerd met een verhoogd risico op veneuze trombose. Echter, totdat in 1997
APC resistentie als mogelijk mechanisme werd voorgesteld, ontbrak een biologische
verklaring. In dat jaar werd namelijk gerapporteerd, dat de -in Maastricht ontwikkelde-
test liet zien dat pilgebruik niet alleen tot APC resistentie leidt maar ook dat het
gebruik van de zgn. derde generatie (bv desogestrel bevattende) pil tot een duidelijk
hogere resistentie leidt dan het gebruik van tweede generatie (levonorgestrel
bevattende) preparaten. Aangezien deze eerste resultaten sterk bekritiseerd werden
is een tweede Studie opgezet waarin het pileffect gemeten werd in een dubbel-
geblindeerd gerandomiseerd cross-over experiment met twee combinatiepreparaten
(hoofdstuk 5). Deze Studie liet zien dat een groot aantal hemostase variabelen
veranderen tijdens pilgebruik (stollingsbevorderende, antistollende en fibrinolytische
eiwitten). De veranderingen waren in het algemeen sterker tijdens het gebruik van
desogestrel bevattende pillen dan tijdens het gebruik van contraceptiva met
levonorgestrel. Tevens werd aangetoond dat de verworven APC resistentie meer
uitgesproken was bij het gebruik van desogestrel-bevattende (derde generatie)
preparaten dan bij de levonorgestrel-bevattende preparaten. Verschillen in de
effecten van de twee pilpreparaten op de antistollende eiwitten werden alleen
164 | Nederlandse samenvatting
gevonden voor protein S. Protein S niveaus daalden sterker tijdens desogestrel
gebruik. Bovendien correleerde de daling in zowel totaal als vrij protein S negatief
met de stijging in APCsr waarde (r= -0.44 / -0.60). Dit wijst erop, dat de stijging in
APC resistentie voor een deel verklaard kan worden door de daling in protein S.
Maar andere mechanismen moeten ook bijdragen aan de gestegen APC resistentie,
want tijdens het gebruik van de levonorgestrel bevattende pil veranderde de protein
5 concentratie nauwelijks terwijl de APCsr significant steeg.
Niet alleen synthetische hormonen (zoals in de anticonceptiepil) zijn in staat
het hemostatische evenwicht te veranderen. Ook zwangerschap, wat gepaard gaat
met een forse toename van de endogene estradiol- en progesteronspiegels, leidt tot
significante veranderingen in stollingsparameters(zie ook hoofdstuk 3). In hoofdstuk
6 zijn de veranderingen in het protein C systeem als gevolg van de veranderingen in
endogeen estradiol en progesteron beschreven. De concentratie van hormonen en
stollingseiwitten werden bepaald in plasma van vrouwen die een in vitro fertilisatie
(IVF) protocol volgden (n=31) en vervolgens zwanger raakten (n=6). Tijdens een IVF-
cyclus veranderen de spiegeis van endogeen estradiol en progesteron aanzienlijk in
een kort tijdsbestek. In deze Studie vonden we geen of weinig verandering in protein
S, protein C en protein C inhibitor, maar wel een (lichte) verhoging van de APC
resistentie. Estradiol spiegeis bleken te correleren met APCsr waarden en bovendien
was de verandering in 17ß-estradiol gecorreleerd met de verandering in APC
resistentie. Zes vrouwen werden zwanger na de IVF behandeling. In deze vrouwen
werden hoge estradiol en progesteron waarden gevonden gelijktijdig met een stijging
van de APCsr waarden en een verlaging van protein S. De hormoonspiegels
gemeten in de vroege zwangerschap kwamen overeen met die tijdens
hyperstimulatie en luteaal support, maar de effecten op protein S en APC resistentie
waren beduidend sterker. Dit duidt erop dat tijdens zwangerschap nog andere
faktoren bijdragen aan de ontstane APC resistentie.
Gedurende lange tijd werd verondersteld dat estrogeen in belangrijke mate
verantwoordelijk is voor het ontstaan van veneuze trombose (geassocieerd met de
pil). Het feit dat tweede en derde generatie pillen hetzelfde synthetische estrogeen in
dezelfde hoeveelheid (30ug ethinyl estradiol) bevatten, is echter een aanwijzing dat
de progestageen-component tenminste deels verantwoordelijk is voor het verhoogde
tromboserisico tijdens derde generatie pilgebruik. Hoofdstuk 7 schetst de resultaten
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van een Studie waarin de effecten van de progestagenen, desogestrel en
levonorgestrel vergeleken zijn op stollingsparameters in vrouwen zonder en met de
FVLeiden mutatie (hoofdstuk 7). In zowel draagsters als niet-draagsters van de FVLeiden
mutatie had de desogestrel bevattende combinatiepil een duidelijker effect op het
antistollingsysteem dan de levonorgestrel bevattende pil. De effecten van het
desogestrel bevattende combinatiepreparaat waren groter in draagsters van de
FVLeiden mutatie dan in niet-draagsters. Echter de belangwekkendste bevinding was
dat tijdens het gebruik van preparaten met alleen maar progestageen, effecten
gevonden werden die tegengesteld waren aan de effecten waargenomen bij de
combinatiepreparaten. Het lijkt er dus sterk op dat de progestagen-component in het
combinatiepreparaat de (protrombotische) werking van de estrogeen-component
tegengaat. En aangezien het effect van levonorgestrel alleen in het algemeen groter
was dan het effect van desogestrel alleen, kunnen deze waarnemingen de sterkere
protrombotische effecten van de derde generatie (desogestrel-bevattende) pil ten
opzichte van de tweede generatie (levonorgestrel-bevattende) pil mogelijk verklaren.
Kunnen verander/ngen ;'n hef n/Veau van sto/fafctoren p//tro/nbose
verWaren?
Wij hebben in al onze studies (cross-sectionele, cross-over en longitudinale
opzet) laten zien dat het gebruik van combinatiepreparaten geassocieerd is met een
verminderde werking van het antistollende protein C systeem, weerspiegeld in een
verhoogde APC resistentie. Bovendien waren de effecten op de hemostase
duidelijker bij gebruik van desogestrel bevattende pillen dan bij gebruik van
levonorgestrel bevattende pillen. Onze en andere studies hebben laten zien dat het
gebruik van de pil de niveaus van stollingsparameters op een belangrijke manier
beTnvloedt en dat de verschillen in risico voor veneuze trombose tussen tweede en
derde generatie pilgebruik hierdoor, tenminste deels, verklaard kunnen worden.
Tevens hebben we laten zien dat personen met de FVLeiden mutatie (die reeds een
verslechterde remming van de stolling hebben) resistenter tegen APC worden tijdens
pilgebruik (zeker in tijdens gebruik van desogestrel bevattende preparaten), wat het
hoge risico voor veneuze trombose in FVLeiden draagsters die de pil gebruiken kan
verklaren.
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v Omdat de gerapporteerde veranderingen tijdens pilgebruik bij de meeste
vrouwen voor een groot gedeelte binnen het normale gebied blijven, is de relevantie
van deze veranderingen vaak ter discussie gesteld. Echter, het wordt de laatste jaren
meer en meer duidelijk dat ook kleine veranderingen kunnen bijdragen aan het risico
op trombose. Vaak wordt namelijk vergeten dat een kleine gemiddelde verandering
van een reeds ongustige waarde net voldoende kan zijn om tot trombose te leiden.
Maar ook dient er rekening mee gehouden te worden dat niet in alle personen de
gemiddelde verandering optreedt. Wanneer een (uiteraard minder vaak
voorkomende) grote verandering ook nog eens voorkomt bij een persoon met een
ongunstige beginwaarde kan dat dit wel degelijk leiden tot trombose.
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Curriculum Vitae
De auteur van dit proefschrift is geboren op vrijdag 25 mei 1973 in net ziekenhuis te
Boxmeer. Zij doorliep al kwebbelend de basisschool "de Springplank" en iets harder
werkend het VWO op net Kruisheren Kollege te Uden.
In 1991 vertrok zij naar Maastricht alwaar aangevangen werd met de Studie
Gezondheidswetenschappen aan wat toen de Rijksuniversiteit Limburg heette. Na
het kiezen van Biologische Gezondheidskunde (BGK) als afstudeerrichting, deed zij
haar eerste organisatorische vaardigheden op door (met een tal actievelingen) een
studievereniging voor BGK'ers op te richten (BGK-Helix).
De eerste praktische onderzoeksvaardigheden werden opgedaan bij Prof. J. Smits,
Farmacologie (onderzoek naar de aldosteron-ge'induceerde veranderingen in
bloeddruk bij ratten). Haar afstudeerstage over het groei- en sterfgedrag van vetzuur-
gesupplementeerde endotheelcellen voltooide zij bij Dr. C.P.M. Reutelingsperger en
Dr. J.W.M. Heemskerk, Biochemie, Universiteit Maastricht. En na een buitenlandse
stage in het noordelijke Usland bij Prof. Dr. Sigmundur Guöbjamason in Reykjavik
(onderzoek naar de verandering van de vetzuur samenstelling van het rattenhart na
adrenerge stimulatie), ontving zij in augustus 1996 haar diploma.
Vanaf 1 Oktober 1996 was Joyce Curvers werkzaam als assistent in opleiding bij de
(vakgroep of) capaciteitsgroep Biochemie binnen de onderzoeksschool hart- en
vaatziekten (CARIM) aan de Universiteit Maastricht, onder de bezielende leiding van
Prof. Dr. J. Rosing en Dr. G. Tans, hetgeen heeft geleid tot dit proefschrift.
Momenteel profiteert zij van een stimulerende baan als wetenschappelijk
medewerker van de afdeling onderzoek en ontwikkeling bij Sanquin
Bloedvoorzieningen, Bloedbank divisie Limburg te Maastricht.
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Bedankt...
...enalsjedaneen bijna-af versie in je handen hebt, dan besef je eens te meer dat dit
proefschrift tot stand kwam in ruim vier jaar. Vier jaar waarin ik met zoveel mensen heb
samen gewerkt, gedacht, geprikt, geborreld. AI die mensen hebben direct en indirect een
bijdrage geleverd aan dit "kindje" van mij (vruchtbare periode). Ik bedank er een hoop, maar
ben er ongetwijfeld vergeten, ook diegenen bedankt!
Professor Rosing, voor velen Jan, voorzitter en eerste man van deze kernploeg.
Ik mocht voor jou komen werken en van jou leren wetenschappen, maar achteraf bleek dat
vooral leren abstraheren. Het continue hoge niveau wat je nastreeft, de gedachte dat je alles
voor de wetenschap geeft, siert je als wetenschapper. Je optimisme, als ik het niet meer zag
zitten (minder frequent) en je kritiek als ik weer eens als een idealistiese jonge hond te kort
door de bocht vloog. Teamwork, dat is het! De laatste twee jaar heb je het steeds drukker
gekregen, maar het ijs bleef glad en de wakken ontwijkbaar. In Utrecht aten we de maatjes
van Vishandel (piep). Dr. Tans, Guido, trainer/coach, de vruchtbare discussies, je
opmerkingen en opvliegers, krities, maar ook serieus, je luisterend oor en adviezen, daar kon
ik mee door. Jij was de eerste filter voor mijn artikelen, voordat ze bij Jan op zijn bureau
afgedaan konden worden als "vreemde perikelen". Vaak gaf je een verhelderende kijk op
experimenten, maar je wist ook eenieder van zijn stuk te kletsen. Als er een vreemd
onderwerp opdook, wist jij erover te zwetsen.
Stella, mijn dank aan jou is ontzettend groot. Alle technieken en praktische vaardigheden
legde jij voor mij bloot. Vanaf dag 1 pakte je me bij de hand (of Never duwde je me een pipet
in de hand). Op het laatst ging het pipetteren aan de lopende band. Door jou leerde ik dat"
/een aon de weeg /con zeen of hef fand; /ca/< houw", of "daf d/ecn een /c/nd; houw". Achter het
waterbad leerde ik ook over je muziekvoorkeur, ik genoot van de avondjes Jazz (of fusion),
shagjes rollen tijdens tijdschema's, schilderkunst en Belgische gewoonten ("sorry, maar
eigenlijk wilde ik morgen 3 weken met vakantie, kan dat?"), Hollandse gewoonten (regeltjes),
onze gezamenlijke voorkeur voor "het vest", unbeschreiblich weiblich... en ik vergeef je dat
je niet meer wilde prikken! We begonnen vier jaar geleden met 20 samples op een dag en
eindigde met 800 samples in een week.
Ook Jose bedankt. Samen op glad ijs, voor onze komputer (hij deed het zelden) betaalde we
een hoge prijs. Gelukkig was je over te halen voor een door-Jan-gevreesde "vrouwenlunch"
waar we ge-empowerd van terug sjeesden. Gerry, je bent zelf vlug weggegaan toen ik
kwam, maar jij hebt me (mede) weten te overtuigen om meer dan vier jaar in dit lab te staan.
Het zinkende schip heeft koers gehouden en blijkt bestand tegen wat storm en nu ben je
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terug... Tilman, is het al borreltijd? Jou veelzijdigheid heeft mij gestimuleerd; het lot van de
jonge honden is bezweert! Dankzij het rariteiten-kabinet uit de stuffbak heb ik er een paar
leuke kastjes bij (hoezo peptide Synthese!). Kristien, je versterkt het Belgische front, de stille
kracht, Protein S multimeren in plasma, dat staatü! (Als het maar niet te vroeg is 's ochtends,
trouwens, daar heb je aan Gerry ook een goede). Gaan we nog eens naar de film? Rory, als
little drummer boy en smartlapartiest, de NVTH ziet je komen, jij bent degene die altijd voor
eerlijkheid kiest. Lico, als Fries, goede muziek (van vöör de Kast), maar een beetje koppig,
bedankt voor je thesis-komputer. Rob, mensen zijn niet te vervangen door Roboclots, je bent
voor een minder spannende klus binnen gekomen, maar hebt nu het heft bij farmaco in eigen
hand genomen. Wilbert, helaas, al veel te snel trok jij aan de commerciele bei.
ledereen van de vakgroep Biochemie en biomaterialen dank voor jullie eeuwige
vriendelijkheid en interesse. Het lab, als het ging om het inplannen van vrouwen voor het (tot
in den treuren) verzamelen van de nieuwe pilpool en mijn geweldige bereikbaarheid. Het
duurde helaas langer dan gepland en bijna raakten we eraan gewend (of toch niet).
Alle OBP. Aio's, WP, Oio's, stageo's en andere rare afkortingen (BV's?) van de vakgroep:
BEDANKT, snel vergeten zal ik jullie niet! Met plezier heb ik jullie dagjes uit (mee-)
georganiseerd.
Het was verhelderend jullie creativiteit, doorzettingsvermogen en eetlust te aanschouwen om
over de dans en drank mijn kop maar te houden. Ik heb me heerlijk thuis gevoeld bij jullie.
Speciele haemostase; Karly, Rene, Carina, Carol, Mariöl en Dave met raad en daad altijd
paraat, dank. Ik heb geleerd van jullie expertise en hoop nog vaak jullie kennis en handen te
kunnen "leasen".
Gynaecologie en Obstetrie; Hans, Saskia, Annemiek en het IVF-inplanningsteam (Germaine,
Laurence en Cecile) als trouwe achterban voor het enthousiasmeren, van de bijzondere IVF-
vrouwen. Zelfs voor meerdere keren!
Dank ook voor alle coauteurs uit Utrecht, Amsterdam, Groningen, gelukkig is e-mail sneller
dan de trein!
Thanks to the foreign colleagues (Janet Rimmer, Eric Preston, Peter Clark and Isobel
Walker) for the excellent collaborations. We often had problems with planning because of the
amount of samples that kept arriving. But it always was exciting to interpret the results,
although the articles are much delayed. I hope to keep in touch and improve my knowledge
in Scottish (whiskey)!
Dankwoord
The foreign medical students that have gained some lab-skills and helped reducing the
workload, Signe and Lise, I wonder why both of you came from Scandinavia and wanted to
work on FV-Leiden?
Elisabetta, we have never worked together, but I think by this time you are like furniture to
the lab. You are a wonderful person and I regret that we have not yet thought of a joint
experiment (FVII-deficient pill users?).
Natuurlijk verdienen de vele, vele vrouwen (en die enkele man) die ik heb mögen prikken
voor het onderzoek een extra reep chocola of bioscoopbon; bedankt!
Speciale dank voor vrienden (en ook nog collega's) Jacco, Irene, Lavienja, Cyriel, Paul en
Harold voor de late avondjes waarop de gesprekken hun ware diepgang kregen, maar snel
ook weer verloren. Ook voor de niet-biochemie gewijde vriend(inn)en, BGK-vriend(inn)en,
Uden-vriend(inn)en, Noord-Holland (HHW)-vriend(inn)en en natuurlijk familie (zowel warm
als koud) die voor mij heel belangrijk bleven. Het trombotische FVue,den-karakter van de
familie Curfs heeft gezorgd voor een extra-stukje Stimulans. En natuurlijk Dave, wij konden
menig avondje achter meerdere pilsjes de wetenschap virtueel op zijn kop zetten, ons leven
nog spannender maken, zeker in de ogen (of het hoofd) van de biochemisten. Alles is rech
gekomme.
Bedankt dat jij en ook Leon mijn paranimfen willen zijn.
Jose en Cor, dank jullie voor de interesse, de winderige duinwandelingen, het trotse-
oudergevoel en heerlijke discussies.
Pap en mam, dankjulliewel. Jullie vertrouwen, de onaflatende interesse, het trots zijn, me los
laten en jullie wärmte hebben mij altijd gestimuleerd. Helaas pap, hebben wetenschap en
theologie elkaar hier niet kunnen ontmoeten. Thim en Karin, nog steeds ligt Maastricht niet
dichter bij Brabant (ze bouwen richting het zuiden?!), maar voor cW boekje was het, dat ik
voor zo we/n/'g geld, zo verweg, zo ftarcf werken wilde.
Spike, twee wetenschappers op een küssen, daar past nix tussen. Resistance is futile, but
the force is with us. Ik heb je thuis vaak genoeg verveeld met mijn beroepsdeformaties. Jij
wist me, soms vaker dan mij lief leek, af te leiden met kleine klusjes (?!), zodat ik met frisse
moed en nieuwe ideeön -wel weer wat later- aan de slag kon.
Deze is voor jou want mi gustas tu!


